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Abstract
The tegument of herpesvirus particles is an amorphous region between the capsid 
and envelope and consists of a complex array of virus-encoded polypeptides. It has no 
apparent regular structure but, along with the envelope components, the tegument proteins 
of herpes simplex virus type 1 (HSV-1) can assemble to give non-infectious particles 
termed light particles that lack nucleocapsids. Although most of the HSV-1 genes that 
specify tegument proteins have been identified, little is known about the mode of entry of 
the proteins into virus particles. To examine the processes controlling incorporation into 
the tegument, manipulatable experimental systems that would enable the characterisation of 
sequences that direct proteins to the tegument were developed.
Initial studies involved the construction of a fusion gene composed of the sequences 
from a tegum ent gene (UL41, vhs) linked to a non-viral, non-structural gene 
(chloramphenicol acetyltransferase (CAT)). The resultant fusion product, vhs-CAT, had an 
apparent molecular weight of 84KDa and retained CAT activity. By analysis of fractions 
across Ficoll gradients which were used to purify virions and light particles, the fusion 
protein was shown to be present in both types of particle. The protein could be detected by 
both Western blotting and enzymatic assays but was not incorporated in quantities that 
could be measured by staining methods. Subsequently, the commercial antibody which was 
used to detect the CAT component of the fusion protein was found to have poor avidity for 
the CAT protein and gave unreliable data. This necessitated the production of a new CAT 
monoclonal antibody which delayed progress and prevented further use of CAT as a marker 
polypeptide.
To examine the processes controlling incorporation into the tegument, studies were 
initiated on VP22, a major tegument protein encoded by UL49. Using a virus vector called 
1802, a HSV-1 recombinant, vUL49ep, was constructed that expresses two copies of UL49; 
one copy specified the unmodified form of VP22 under the control of the native promoter 
while the second was placed under the control of the human cytomegalovirus (HCMV) 
immediate early (IE) promoter. To distinguish between the two versions of VP22, the 
inserted copy was tagged at the C-terminus with an epitope from the HCMV UL83 gene 
product. In cells infected with the recombinant virus, the overall levels of VP22 
synthesised were about 5-fold higher than for wild type virus and this increase was due to 
the high levels of expression of the tagged protein. Comparison of the polypeptide 
compositions of particles revealed that the amount of VP22 in the tegument was 
approximately 2- to 3-fold higher in recombinant virions and light particles than in particles 
produced by wild-type virus. To demonstrate that the tag sequence did not influence the 
incorporation of VP22 into the tegument, a HSV-1 recombinant virus containing the epitope
linked to CAT was constructed. In this case, the distribution of epitope-tagged CAT across 
Ficoll gradients did not correspond with that of virions and light particles made by the virus 
and therefore epitope-tagged CAT could not be classified as a structural component. The 
high abundance of VP22 in vUL49ep virus particles correlated with a reduction in the 
quantities of VP 13/14 present in virions and light particles and there was a decrease in the 
amount of untagged VP22 that was incorporated. In addition, the recombinant virions and 
light particles had noticeably increased migration on Ficoll gradients. These results 
provided the first evidence that, for certain proteins, the level of polypeptide synthesis could 
act as a positive controlling factor for the amount of protein incorporated into the tegument.
In order to identify a sequence or motif within the polypeptide sequence of UL49 
that might be responsible for directing the protein into the tegument, a set of insertion and 
deletion m utants derived from the epitope-tagged UL49 gene was constructed. 
Oligonucleotides encoding four amino acid sequences were inserted into specific sites along 
the gene, thus making small changes in the coding sequence of the protein. As a result of 
the design of the oligonucleotides, a series of UL49 mutants lacking portions of the coding 
sequence also was derived from the insertion mutants. Viruses expressing these mutant 
forms of UL49 were constructed in an identical manner to vUL49ep. Thus, they expressed 
not only the mutated form of VP22 but also the endogenous version which had not been 
modified. Of the four insertion mutants, three (at amino acid positions 60, 159 and 267) 
displayed identical properties to vUL49ep. Thus, these mutant forms of VP22 incorporated 
efficiently into virus particles. The fourth VP22 mutant which had an insertion at position 
194 showed reduced levels of incorporation of tagged VP22 and there was also a visible 
increase in the abundance of untagged VP22. The insertion at position 194 lies within a 
region of the UL49 ORF which is highly conserved among the homologues of UL49 
encoded by other a-herpesviruses. This conserved region extends from approximately 
amino acids 178 to 257 and, by computer analysis, is the only portion of the VP22 protein 
for which secondary structure can be predicted. Thus, the insertion at position 194 may 
perturb the structural conformation of VP22. These results would suggest that this 
conserved part of VP22 may be more sensitive to mutation as compared to those regions 
that are poorly conserved.
The mutagenesis strategy also allowed the construction of four UL49 deletion 
mutant viruses. Analysis of the particles made by these viruses revealed that removal of the 
C-terminal 34 amino acids from the UL49 ORF had no effect on the ability of VP22 to 
incorporate into the tegument. This suggested therefore that the C-terminal region of VP22, 
which is not highly conserved, was not required for incorporation into tegument* By 
contrast, removal of residues 120-192 did significantly reduce the amount of mutated VP22 
present in virus particles but sufficient protein did incorporate to remain detectable on 
stained gels. To further analyse whether the sequences that permitted incorporation of
VP22dell20-192 resided within either the N- or C-terminal regions of the protein, mutant 
forms of VP22 were constructed that contained exclusively one or other of these regions of 
the polypeptide. A polypeptide that consisted of the N-terminal 120 residues could be 
detected to a very limited extent by Western blotting while the protein that comprised 
residues 192-301 was not found in virus particles. The levels of expression of VP22dell20- 
301 and VP22del 1-192 were somewhat less than that of VP22dell20-192 in infected cells. 
However the data does suggest that the sequences which permit the incorporation of 
VP22del 121-192 do not reside exclusively in either the N- or C-terminal regions of the 
molecule but presumably rely upon cooperation or structural integrity imparted by 
sequences at both ends of the polypeptide.
During the course of this work, data from Dr. P. O’Hare and his group (Marie Curie 
Research Foundation, Oxted, Surrey) had shown that VP22 interacts with VP 16, another 
major component of the tegument. In short-term transfection assays, this interaction is 
manifested by the appearance of novel structures termed tegument bodies which are 
composed of VP22 and VP 16. In a collaborative study using the VP22 constructs described 
above, it was shown that there is a correlation between the ability of VP22 to incorporate 
into tegument and the formation of tegument bodies in the presence of VP 16. Evidence 
obtained following the completion of this study has suggested that VP22 is also capable of 
oligomerisation (J. M cLauchlan, personal communication) and thus tegument body 
formation may require both VP16/VP22 and VP22/VP22 interactions. Since the virus 
recombinants constructed express unmodified versions of both VP 16 and VP22, this 
implies that the mutant versions of VP22 may incorporate into virus particles by interaction 
with either of these proteins.
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Chapter 1; Introduction
The Herpesviruses
Section 1
Host range
Herpesviruses are widely distributed in nature and have been isolated from a wide 
range of vertebrate species. Man is the natural host for at least seven herpesviruses; herpes 
simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella zoster virus 
(VZV), Epstein Barr virus (EBV), human cytomegalovirus (HCMV), human herpesvirus 6 
(HHV-6) and human herpesvirus 7 (HHV-7). Recent evidence also has identified novel 
herpesvirus sequences present in Kaposi's sarcoma tissue, leading to the conclusion that 
there is an eighth human herpesvirus which has been termed Kaposi's sarcoma herpesvirus 
(KSHV) (Chang et a i ,  1994). However, to date, no virus corresponding to KSHV has been 
isolated (Schalling et al., 1995). These viruses are each able to cause diseases of varying 
severity. As a group, herpesviruses display a wide tropism ranging from infections of 
epithelial tissue, internal organs including the central nervous system and white blood cells. 
A common feature of infection by herpesviruses is their ability to latently infect different cell 
types. In latently-infected cells the viral DNA is not integrated and there is limited 
expression of the viral genome. Reactivation from latency results in expression of the viral 
genes and leads to the production of virus progeny which may cause visible signs of 
infection.
In addition to those that infect humans, herpesviruses are causative agents of disease 
in a wide range of animals, many of which are of significant economic importance. These 
include Marek's Disease virus (MDV) which infects chickens, causing lymphocyte 
infiltration of nerves with demyelination and paralysis, as well as lymphoid tumours. 
Infectious virus is present in oral secretions and feather follicles. However, MDV has been 
successfully controlled with a live virus vaccine (reviewed by Hirai, 1988). Pseudorabies 
virus, (PrV), another economically important herpesvirus, is responsible for a severe 
encephalitis in piglets (reviewed by Gustafson, 1981). The equine herpesviruses, in 
particular EHV-1, give rise to a range of debilitating conditions in horses which include 
respiratory disease, abortion, and neurological disorders (Bryans & Allen, 1989). The 
bovine herpesviruses, including BHV-1, cause infectious rhinotracheitis and pustular 
vulvovaginitis often leading to abortion in cattle (Wyler et al., 1989).
Figure 1. Cryo-electron micrograph of a HSV-1 virion.
Chapter 1; Introduction
Section 2 
Characteristics and Classification of the Herpesviruses
All members of the herpesvirus group have a characteristic virion structure 
composed of three morphologically distinct components termed the nucleocapsid, tegument 
and envelope. The nucleocapsid is icosahedral in shape and contains the virus genome. The 
tegument is an amorphous region that surrounds the nucleocapsid and is in turn bounded by 
the envelope which contains lipid and exhibits glycoprotein spikes on the surface (Fig. 1). 
Nucleocapsids contain a simple linear double stranded DNA genome. This ranges in 
different herpesviruses from 80 to 150 xlO6 molecular weight, and there is great variation in 
G + C content and genome arrangements. The most widely used classification is based on 
the biological properties of the viruses and comprises three sub-families, designated a - 
herpesvirinae, p-herpesvirinae and y-herpesvirinae (reviewed by Roizman, 1990).
HSV-1 and HSV-2 are members of the a-herpesvirinae, which as a group are 
characterised by their relatively short reproductive life cycle (usually less than 24 hours), 
cytolytic infection and the ability to establish latent infection in sensory ganglia. Other 
members of this subfamily include VZV, EHV-1, 3 and 4, and PRV
The p-herpesvirinae, such as HCMV and HHV-6, in tissue culture have a restricted 
host range and a relatively long reproductive cycle. Infection often results in the formation 
of enlarged cells and latent infections can be established in various tissues such as secretory 
glands and lymphoreticular cells. Members of the y-herpesvirinae, such as EBV, have a 
very limited host range with a tropism for lymphocytes. The length of the reproductive 
cycle is variable and latent infections are frequently established in lymphoid tissue.
Comparison of genome sequences is being increasingly used to classify 
herpesviruses into groups and also determine the evolutionary relationships among 
members of the herpesviridae. To date, the complete genome sequences of nine 
herpesviruses have been published (summarised in Table 1) while for many other 
herpesviruses, partial sequence data exist. Although the genomes of the sequenced 
mammalian herpesviruses differ widely in gene content from 70 genes up to 200 and in their 
length, G+C content and arrangement, a subset of around 40 genes are conserved in all a , p 
and y-herpesviruses. This implies a common ancestry followed by extensive divergence 
(Davison & Taylor, 1987; McGeoch, 1989; Chee et a l,  1990; McGeoch et a l ., 1993).
Classification of herpesviruses by sequence homology largely confirms the 
assignment of viruses on the basis of their biological properties. Thus, the genomes of a - 
herpesviruses HSV-1, HSV-2, VZV, PRV and EHV-1 are largely co-linear (Davison & 
Wilkie 1983c), while comparison of VZV and the y-herpesvirus EBV reveals regions of
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Table 1. The genomes of Herpesviruses sequenced to date.
Virus Base pair residues Reference
Epstein-Barr virus (EBV) 
Varicella-Zoster virus (VZV) 
Herpes Simplex type 1 (HSV-1) 
Human cytomegalovirus (HCMV) 
Equine herpesvirus type 1 (EHV-1) 
Herpesvirus saimiri (HVS)
Equine herpesvirus type 2 (EHV-2) 
Human herpesvirus type 6 (HHV-6) 
Channel catfish virus (CCV)
172 282bp (Baer et al., 1984)
124 884bp (Davison & Scott, 1986)
152 260bp (McGeoch etal., 1988b)
229 354bp (Chee et a l 1990)
150 223bp (Telford et al., 1992)
112 921bp (Albrecht et al., 1992)
184 427bp (Telford et al., 1995)
159 321 bp (Gompels etal., 1995)
134 226bp (Davison 1992)
HVS EHV-2
EB
HSV-1
HSV-2
EHV-1
PRY
VZV
HHV-6
HCMV
Figure 2. Broadly based phylogenetic tree. The GC2 neighbour-joining distance tree is 
taken from McGeoch et al., (1995). The arrow indicates the approximate root position.
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rearrangements and divergence (Davison & Taylor, 1987). The biological properties of 
EHV-2 and EHV-5 supported their provisional classification as (3-herpesviruses (Plummer 
etal., 1969), however sequence analysis of fragments derived randomly from the genomes 
showed that EHV-2 and EHV-5 are distinct "/-herpesviruses (Telford et al., 1993). In 
addition, using genomic analysis, MDV, originally considered to be a y-herpesvirus 
principally because of its lymphotropism, was shown to be phylogenetically more closely 
related to the neurotrophic a-herpesviruses (Buckmaster et al., 1988). This classification 
has been further supported by Brunovskis & Velicer (1995) who sequenced the entire MDV 
U s sequence and identified seven homologues exclusive to a-herpesvirus S component
genes. Finally, HHV-6, also originally classified as a y-herpesvirus because of its tropism 
for lym phocytes (Downing et al., 1987), has since been shown to possess more 
characteristics in common with P-herpesviruses, sharing both encoded amino acid sequence 
similarities and overall gene organisation with HCMV (Lawrence et al., 1990; Neipel et al., 
1991; Gompels et al., 1992; Nicholas & Martin, 1994).
The recent sequencing of the entire genome of channel catfish virus (CCV), 
previously thought to be an a-herpesvirus, has been shown to have no detectable significant 
homology with any known herpesvirus sequence. This resulted in the suggestion that this 
virus should be assigned to a separate subfamily, or even removed from the family of 
herpesviridae altogether (Davison, 1992).
Sequence information has enabled detailed phyolgenetic analysis of the mammalian 
members of the family herpesviridae. Phylogenetic trees including timescales have been 
inferred from alignments of sets of sequences. In all cases, the three recognised subfamilies 
(a, P & y), and major sublineages in each family were clearly evident. Also multiple gene 
sets were assembled to give a broadly based tree which, assuming there was a constant 
molecular clock, suggested that the three sub-families arose approximately 180-220 million 
years ago, and that major sublineages within subfamilies were probably generated 60-80 
million years ago. Fig. 2 illustrates the broadly based phylogenetic tree constructed by 
McGeoch etal. (1995).
Chapter 1; Introduction
Section 3.
Biological properties of human herpesviruses
Infections in humans are spread by direct contact between infected and uninfected 
individuals, particularly at mucosal tissues, and are characterised by their ability to cause 
latent infection. HSV-1 generally causes lesions to develop at mucosal membranes around 
the mouth or face, including the eyes often resulting in a corneal infection. HSV-2 typically 
infects the genital and anal region. The clinical situation most harmful to humans results 
from infection of the central nervous system (CNS) causing acute necrotising encephalitis 
(Corey & Spear, 1986). Neonatal infection also has a high mortality rate and is usually due 
to a primary HSV-2 infection in the mother, when no maternal antibody is present for 
protection (Timbury, 1978). In addition, HSV-2 has been implicated in the development of 
cervical cancer from evidence obtained from seroepidemiological studies (Nahmias et al., 
1974) and due to the detection of some sequences of HSV-2 DNA in cervical cancer 
specimens (Macnab etal., 1985). However, a direct link between HSV-2 and the induction 
of cervical cancer remains controversial, and the development of malignancy may be due to 
a synergistic effect with other factors such as certain human papilloma viruses (zur Hausen, 
1982).
VZV, also a neurotrophic a-herpesvirus, is the causative agent for chickenpox 
(varicella) in children. Following primary infection, the virus spreads through viraemia and 
ascends to the dorsal root ganglia of sensory nerves supplying the affected skin areas and 
remains in a non-infectious latent state after recovery. The primary site of latency appears to 
be the satellite cells surrounding the neuron, although some neurons may harbour latent 
virus (Gilden e ta l., 1983; Hyman et al., 1983; Coen e ta l., 1989). Unlike HSV, VZV 
reactivation either does not occur in most individuals or is limited to a single recurrence of 
infection (Straus, 1989). Accumulating evidence has implicated a role for cell mediated 
immunity (CMI) in controlling the ability of the virus to reactivate. Weakening of the CMI 
by age or immunosuppression increases the likelihood of reactivation (Weigle & Grose, 
1984; Hayward et al., 1991; Wilson e ta l., 1992). Upon reactivation, virus spreads by lytic 
infection within the ganglion and via axonal transport infects the skin enervated by the 
neurons, giving rise to a crop of vesicles rich in virus (zoster), known as shingles.
HCMV, a lymphotrophic (3-herpesvirus, asymptomatically affects the majority of 
the population. However, in immunocompromised individuals it causes a wide range of 
chronic respiratory infections, frequently affecting immunosuppressed transplant and AIDS 
patients often resulting in viral pneumonia (Meyers et al., 1986). HCMV has also been 
implicated in causing neonatal abnormalities (Microcephaly; Ho, 1991).
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EBV is a y-herpesvirus that infects at least two cell types, B lymphocytes and 
stratified pharyngeal epithelial cells (Lemon et al., 1977; Morgan et al., 1979). It causes 
infectious mononucleosis (glandular fever), and has been associated with two types of 
human tumour, Burkitts Lymphoma (BL) and nasopharyngeal carcinoma (NPC) (reviewed 
by Epstein & Achong, 1979; Klein, 1989). BL predominantly affects young males in Sub- 
Saharan Africa between the ages of 3 and 9, causing severe swelling in the jaw, testes, 
stomach, etc. NPC is found specifically in Asian men over 60 years old living in a distinct 
region of Southern China. The localisation of NPC and BL within 'hot-spots’ suggests the 
requirement of specific cofactors for the development of EBV-associated cancer. The true 
site of latent infection has been the subject of debate over several years but current evidence 
suggests that EBV persists in B-cells. As with all the human herpesviruses the viral 
genome is not integrated and transcription during latency is minimal (Speck & Strominger,
1989).
Although recently identified (Downing eta l., 1987), HHV-6 is now known to affect 
up to 90% of the population. Infection occurs in infants which may be either asymptomatic 
or cause a mild skin rash (exanthem subitum), however the significance of HHV-6 as a 
pathogen is unclear (Yamanishi et al., 1988; Suga et al., 1989). Its tropism for CD4+ 
lymphocytes has led to speculation that it may be involved in the development of AIDS or 
other immunodeficiencies (Levy et al., 1990). At present there is only limited 
understanding of the properties of HHV-6.
HHV-7, recently isolated from prelipheral blood lymphocytes (Frenkel et al., 1990), 
remains unclassified, as HHV-7 DNA did not show any hybridisation with probes derived 
from other herpesviruses, except to a limited degree with HHV-6 (Frenkel et al., 1990). 
HHV-7 does show significant antigenic dissimilarity to HHV-6, sufficient to allow 
seroepidemiological discrimination (Wyatt et al., 1991).
KSHV, the most recently discovered human herpesvirus (Chang et al., 1994), is yet 
to be fully characterised and indeed the virus has not yet been isolated. Kaposi's sarcoma 
(KS) is the most common neoplasm occurring in individuals with AIDS, rarely affecting 
immunocompetent individuals (Beral e ta l.,  1991). Due to the epidemiology of KS 
sufferers it was suspected that the lesions were due to an infectious agent, and samples of 
KS tissues were shown to contain DNA sequences that had homology to a number of 
herpesviruses, including EBV, BHV-4, HHV-6, HCMV, HHV-7 and herpesvirus samiri 
(HVS). The sequence comparisons were sufficiently divergent to suggest the existence of a 
new human herpesvirus (Chang etal., 1994; Schalling etal., 1995).
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Herpes Simplex Virus type 1
HSV-l is the most widely investigated herpesvirus and is the prototype for a -  
herpesviruses. In addition, since it was also the virus used in this study, a more detailed 
overview of its properties is described.
Section 1. Pathogenesis and latency
Following infection, the virus multiplies at the site of entry, where it invades nerve 
endings and is able to travel through sensory nerves via axonal flow to the nucleus of the 
sensory neuron where it establishes latency. Latency is a condition or state by which the 
virus can persist in infected individuals and involves the maintenance of multiple copies of 
circular extrachromosomal viral DNA in the nuclei of infected cells (Mellerick et a l ., 1987). 
The viral DNA in neuronal cells originally was suggested to have a similar structure to that 
of cellular chromatin (Griffith, 1975; Cremisi et al., 1976; Ponder et al., 1978). However, a 
report on the state of HSV-l DNA in the CNS of acutely infected mice indicated that the 
majority of viral DNA was not organised into nucleosomes (Muggeridge & Fraser, 1986).
Reactivation from the latent state involves virus being transported back along the 
nerve axon to the original site of entry where it infects cells and causes lesions. In some 
individuals, periodical successful reactivation is frequent and painful lesions at the site of 
initial infection cause extreme discomfort to the sufferer. The processes involved in 
reactivation are not fully understood but can be triggered by a range of stimuli including 
exposure to UV light, stress, pregnancy, menstruation, etc. (Hill, 1985).
During latent infection, viral genes associated with lytic replication are not expressed 
but in cells such as peripheral sensory neurons, RNAs called latency associated transcripts 
(LATs) are expressed from the long repeat region of the genome (Deatly et al., 1987; 
Stevens et al., 1987; Dobson et al., 1989). The LATs encoded by these regions of the 
genome are antisense to the mRNA of the immediate early (IE) regulatory protein Vmw 110 
(Introduction; Chapter 3, Section 3.3.c); Stevens et al., 1987; Mitchell et al., 1990). 
Annealing of LAT RNA to IE 110 mRNA may lead to inhibition of synthesis of Vmw 110, 
a protein which appears to play a critical role in reactivation of virus from latency (Russell et 
al., 1987; Cai & Schaffer, 1989; Harris e ta l., 1989; Leib et al., 1989a). In addition, the 
prevention of immediate early gene transcription during latency was suggested by Latchman 
and co-workers to be a result of the repression of the formation of the complex assembly 
implicated in the initiation of immediate early gene transcription (complex formation is 
described in detail in Introduction; Chapter 3, Section 3.2.a, IE promoters) (He et al., 1989;
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Kemp et a l, 1990; Lilycrop et a l,  1991).
LAT RNAs of 2.0 and 1.5Kb accumulate in the nuclei of latently-infected cells, and 
are frequently used as markers for cells harbouring latent virus. A number of studies have 
indicated that the LATs are dispensable for the establishment and maintenance of latent 
infection, though their presence may increase the efficiency of these processes (Leib et a l,  
1989b; Steiner e ta l., 1989). The LATs have been implicated in efficient reactivation of the 
virus from its latent state, but the mechanism of activity remains obscure (Hill e ta l ,  1990; 
Trousdale et a l ,  1991; Fraser et al., 1992; Fareed & Spivack, 1994; Perng etal., 1994). 
However recent evidence does not support this function for LATs (Ecob-Prince & Hassan, 
1994). In these elegant studies, reactivation induced by the explantation of latently infected 
dorsal root ganglia into culture rarely occurred in cells still expressing LATs.
The most useful animal model systems in which latent infection is examined are 
mice, guinea pigs and rabbits. In the mouse, following infection of the corneal epithelium, 
lip, footpad or ear, latent infection is established, but the latent virus does not spontaneously 
reactivate (Stevens & Cook, 1971; Blyth et al., 1976; Hill et al., 1978; Blue etal., 1981; Hill 
et a l ,  1982). However, in rabbits and guinea pigs reactivation of latent virus occurs 
spontaneously (Nesbum eta l., 1967). Currently there are a number of in vitro models for 
studying HSV latency and these rely upon the ability to artificially suppress viral replication. 
Several replication-permissive non-neuronal cell lines sustain non-productive infection at 
temperatures not optimal to HSV replication, with reactivation being induced following 
superinfection with temperature sensitive mutants of HSV-l or with HCMV (Russell & 
Preston, 1986). The in vitro models with the most obvious relevance to latency in animals 
and humans utilise fetal neurons from rats or primates (Wigdahl et al., 1983, 1984; Wilcox 
& Johnson, 1987, 1988; Wilcox et al., 1990). However, non-primary tissue culture cells 
including human fetal lung fibroblasts have also been used (Wigdahl et al., 1981, 1982; 
Harris & Preston, 1991).
In cells in culture, approximately half of the 75 known different genes are not 
essential for virus replication. However, the majority of these genes are required for efficient 
viral replication in experimental animal models. Mutations in a small number of virus genes 
have been shown to decrease the ability of the virus to access the CNS or to multiply 
efficiently and these genes play a key role in defining the pathogenic properties of the virus. 
The virulence functions that enable neuronal growth include the viral thymidine kinase (TK) 
gene (Field & Wildy, 1978). TK phosphorylates pyrimidine nucleosides and analogues and 
is essential for the replication of viral DNA. Cellular TK present in dividing cells is able to 
complement TK negative virus in cell culture, but as neuronal cells are non-dividing and lack 
TK function, virus replication in these cells requires TK expression (Tenser, 1991).
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ICP34.5, encoded by gene RL1, influences intra-cerebral virulence (Chou et al.,
1990). The host response to stress caused by viral infection is to shutoff protein synthesis 
inducing cellular apoptosis. ICP34.5 functions to preclude this response enabling viral 
growth. Deletion or mutation of this gene results in variants that grow as well as wild type 
virus in dividing cells of many established cell lines, but show impaired replication in non­
dividing cells (Chou et al., 1990; McGeoch et al., 1991; Bolovan et al., 1994). In mice 
ICP34.5 mutants are incapable of replicating in the CNS and do not cause encephalitis 
(Javier eta l., 1987; Chou etal., 1990; Taha etal., 1990; MacLean etal., 1991). This ability 
of ICP34.5 mutants to grow in dividing cells but not in non-dividing cells has led to studies 
that show that neuroattenuated HSV-l mutant 1716, with a 759-bp deletion in ICP34.5 
(MacLean et al., 1991), was a safe and effective therapeutic agent for intracranial murine 
melanoma (Randazzo et al., 1995).
The lack of virus gene expression in the latent state presumably is one mechanism 
that permits the virus to avoid detection by the immune system. Recent studies have 
implicated certain virus gene products in additional mechanisms following reactivation 
which also may facilitate infected cells avoiding immune surveillance. For example, 
investigation of UL41 negative mutants by Hill et al., (1995) revealed that this gene product, 
which possesses a host shutoff function and is a component of the virion, was responsible 
for the reduction or abolition of the synthesis of HLA class 1 molecules in cells infected with 
HSV-l. More recently, expression of the HSV-l immediate early protein Vmw 12 (ICP47) 
has been shown to block the presentation of viral polypeptides in MHC class I restricted 
cells. Current evidence suggests that Vmw 12 acts by binding to the transporter protein 
associated with antigen processing (TAP) thereby inhibiting peptide transport across the 
endoplasmic reticulum membrane (York et al., 1994; Fruh et al., 1995; Hill et al., 1995).
Another mechanism by which the virus is able to evade the immune system is 
through cell to cell spread of the virus across cell junctions in a manner resistant to 
neutralising antibodies. This mechanism is facilitated by the gE-gl glycoprotein complex 
(Dingwell et al., 1994) that promotes cell to cell spread of the virus which enables the virus
to avoid the extracellular environment and consequently the humoral antibody response.
Figure 3. The structure of the HSV-l genome.
The HSV-l genome is shown, with unique sequences as solid lines (U s & Ul ). The
repeats TRL, IRL, IRS and TRS are illustrated as boxes with their component parts a, 
b, c and a ’, b \  c ’ designated. Below the genome represenation, the isomerisation of the 
HSV-l genome is illustrated. The four isomers are: P (prototype), EL (L inverted with 
respect to P), IS (S inverted with respect to P), and ISL (S and L inverted with respect 
to P).
a b
u l Us
b’ a’ c’ c a
t r l IR l  IRs TRS
I I  . 
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ISL *
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Section 2.Genome structure and gene content
HSV-l DNA is a linear double-stranded molecule that consists of two distinct 
covalently linked sequences, designated the long (L) and the short (S) segments. Both the L 
and S segments consist of a unique region (UL and Us) flanked by a pair of inverted repeat 
sequences (TRL, IRL, TRS and IRS) as shown in Fig 3. The termini of each molecule 
possess a redundancy of some 400 base pairs, termed the a sequence which is also located 
internally at the joint between the L and S segments in the opposite orientation (Sheldrick & 
Berthelot, 1974; Wadsworth et al., 1975; Wagner & Summers, 1978). The a sequence is 
present as one or more copies at the L terminus and the joint but only as a single copy at the 
S terminus and is essential for packaging of replicated DNA into capsids. As a consequence 
of their model, Sheldrick and Berthelot (1974) suggested that recombination events 
occurring between the terminal and internal repeat sequences might give rise to four isomeric 
arrangements of the genome differing in the relative orientations of the unique regions as 
shown in Fig. 3. Partial denaturation studies by electron microscopy, and restriction enzyme 
analyses of HSV-l DNA (Delius and Clements, 1976; Wilkie & Cortini, 1976) confirmed 
this prediction, indicating that all four possible genome arrangements occur with equal 
frequency in the DNA from virions. One isomer, chosen arbitrarily, is designated as the 
prototype for genetic map representations (Fig 3; Roizman, 1979b).
The complete HSV-l genome sequence has been determined (McGeoch et al., 
1988b) and the interpretation of these sequences indicate at least 75 protein coding 
sequences. The HSV-l genes identified to date and their functions are shown in Table 2. 
The genome is arranged in a compact form with tightly packed open reading frames (ORF's) 
for example, 89% of U l  codes for protein. The genes are orientated in both directions, and
there is little overlap between coding sequences.
At least 3 genes are completely contained within the repeat sequences, R s and Rl ,
that flank the unique segments, and there are therefore two copies of each of these genes in 
the genome. Examples of diploid genes include those encoding the transcriptional control 
proteins Vmw 175 and V m wllO(Rixon et al., 1982; Perry etal., 1986).
The transcripts encoding genes are often arranged as nested families of mRNAs 
which share common 3' termini but have unique 5' ends and promoter sequences (Wagner,
1985). This arrangement is exemplified in the U s region of the genome where 11 of the 13
mRNAs (encoding 12 proteins) are arranged into four nested families (Rixon & McGeoch, 
1984, 1985; McGeoch et al., 1986b). In contrast to cellular and most other viral mRNAs, 
the majority of HSV-l transcripts are not spliced. Of the 75 proposed distinct genes, only 
IE1 (Perry et al., 1986), IE4 and IE5 (Watson et al., 1981; Rixon & Clements, 1982),
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UL15 (Costa et al., 1985; McGeoch et al., 1988) and the latency associated transcripts 
(LATs) (Wagner et al., 1988; Weschler et al., 1988) are known to generate mature mRNA 
by splicing.
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Table 2. The HSV genes identified to date
Gene Protein/Function Status
RL1 Neurovirulence factor (ICP34.5) ne
ORF P Encodes a protein of 248 amino-acids, funtion unknown ne
RL2 IE protein; transcriptional regulator (Vmw 110) e/ne
UL1 Glycoprotein L, role in cell entry e?
UL2 Uracil DNA glycosylase ne
UL3 Function unknown ne
UL4 Function unknown ne
UL5 Component of DNA helicase-primase e
UL6 Associated with virion capsid and involved in packaging
of nascent DNA e
UL7 Function unknown
UL8 Component of DNA helicase primase,
necessary for DNA replication e
UL8.5 Encodes a protein of 486 amino-acids (OBPC),
potential role in HSV DNA replication 
UL9 On-binding protein essential for DNA replication e
UL10 Glycoprotein M ne
UL 11 myristylated tegument protein, role in the envelopment
and egress of virions ne
UL 12 Deoxyribonuclease, role in maturation/packaging
of nascent DNA e
UL13 Tegument protein, protein kinase ne
UL14 Function unknown
UL15 Role in the cleavage of concatameric DNA e?
UL16 Function unknown ne
UL17 Function unknown e
UL18 Capsid protein triplexes (VP23) e
UL19 Major capsid protein (VP5); constitutes the hexons and
pentons e
UL20 Integral membrane protein, role in egress of virions e/ne
UL21 Function unknown
UL22 Virion surface glycoprotein H, role in virion entry e
UL23 Thymidine kinase, DNA replication ne
UL24 Function unknown ne
UL25 Virion protein; role in capsid maturation and
DNA packaging e
Proteinase, the N-terminal portion is capsid protein VP24,
C-terminal is VP21, involved in capsid assembly e
UL26.5 Scaffolding protein of B capsids (VP22a), processed
by UL26 proteinase e
UL27 Virion surface glycoprotein B, role in cell entry e
UL28 Role in capsid maturation/DNA packaging e
UL29 ssDNA binding protein (ICP8),
essential for DNA replication e
UL30 Catalytic subunit of replicative DNA polymerase e
UL31 Nuclear phosphoprotein, function unknown
UL32 Role in capsid maturation/DNA packaging
UL33 Role in capsid maturation/DNA packaging e
UL34 Membrane associated phosphoprotein
UL35 Capsid protein (VP26), present on tips of hexons e
UL36 Tegument protein (ICP1/2, VP 1/2, Vmw273) e
UL37 Tegument phosphoprotein, function unknown,
may have DNA binding role, binds to ICP8 
UL38 Capsid protein (VP 19C), component of triplexes e
UL39 Ribonucleotide reductase large subunit (Rl) e/ne
UL40 Ribonucleotide reductase small subunit (R2) e/ne
UL41 Located in the tegument, Virion host shutoff ne
UL42 Subunit of replicative DNA polymerase,
increases processivity e
UL43 Function unknown, probable integral membrane protein ne
UL44 Virion surface glycoprotein C, role in entry ne
UL45 Envelope protein, mediates cell fusion ne
UL46 Tegument protein (VP11/12, Vmw90/92) ne
UL47 Tegument protein (VP13/14, Vmw81/82), modulates
EE gene transactivation by VP 16 ne
UL48 Major tegument protein (VP 16, Vmw65, aTIF),
transactivator of IE genes e
UL49 Tegument protein (VP22)
UL50 Deoxyuridine triphosphatase ne
UL51 Function unknown e/ne
UL52 Component of DNA helicase-primase e
UL53 Glycoprotein K, role in cell fusion e?
UL54 IE protein, post-transcriptional regulator of gene expression
(ICP27, Vmw63) e
UL55 Function unknown ne
UL56 Function unknown, role in intraperitoneal virulence ne
LAT Family of transcripts expressed during latency, function
unknown, protein coding capacity uncertain ne
RSI IE protein (ICP4, Vmw 175), transcriptional regulator e
US1 IE protein (ICP22, Vmw68), transcriptional regulator e/ne
US2 Function unknown ne
US3 Protein kinase ne
US4 Glycoprotein G ne
US5 Glycoprotein J ne
US6 Glycoprotein D, role in entry e
US 7 Glycoprotein I, complex together with gE, role in
cell-to-cell spread and is receptor for Fc of IgG ne
US8 Virion surface glycoprotein E, complex together with gl,
role in cell-to-cell spread and is a receptor for Fc of IgG ne
US8.5 Function unknown ne
US9 Tegument protein ne
US10 Virion protein ne
US11 Virion protein, ribosome associated in infected cells ne
US 12 IE protein, turns off TAP to block the presentation of viral 
polypeptides to MHC class I restricted cells 
(ICP47, Vmw 12)
ne
e: essential for virus growth in culture cells
ne: non-essential
e/ne: necessity depends on the culture conditions or temperature
e?: the data regarding status is not conclusive
absence of information regarding the status
Adapted from:
Addison et al., 1984, 1990; Al-Kobaisi et al., 1991; Baines et al., 1995; Baines and 
Roizman, 1993; Baradaran e ta l, 1994; Barker and Roizman, 1992; Barnett et al., 1992; 
Chang and Roizman, 1993; Goeorgopoulous et al., 1993; Haanes et al., 1994; Hill al., 
1995; Lagunoff and Roizman, 1994; Liu and Roizman, 1991a; McGeoch et al., 1985, 
1986, 1988a, 1993; Overton et al., 1994; Fruh et al., 1995; Patel and MacLean, 1995; 
Purves et al., 1993; Rosen-Wolff and Darai, 1991; Schmitz et al., 1995;
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The Lytic Life Cycle of Herpes Simplex 
Virus Type 1
The lytic life cycle of HSV-l involves a series of complex stages which, although 
interconnected, can be identified as separable topics for descriptive purposes. Therefore, the 
following sections describe the key events which take place during productive infection. 
These are 1) attachment and entry of the virus particle into the infected cell 2) transcription 
and translation of viral mRNA 3) replication of viral DNA 4) the assembly of mature virus 
particles including the packaging of replicated DNA, and finally 5) egress of virus particles 
from the infected cell.
Section 1. Attachment and Entry
(i) Attachment of HSV-l particles to cells
The initial stages of herpesvirus infection involve the attachment of the virus particle 
to the cell surface. Current research has identified many of the viral and cellular 
components that are involved in the attachment and penetration processes but the precise 
molecular mechanisms involved in these processes are still to be determined. The processes 
of attachment for H SV -l, HSV-2,PRV and BHV-1 are similar, however each of these 
herpesviruses uses distinct cell surface receptor molecules (Vahlne et al., 1979; Wahren et 
al., 1984). The attachment of the HSV-l virus particle to the cell involves interactions 
between the virion glycoproteins and the cell surface. Initial attachment is via gC and/or gB 
to the cell surface heparin sulphate (HS) proteoglycans (WuDunn & Spear, 1989; 
Mettenleiter et al., 1990; Shieh e ta l.,  1992; Gruenheid et al., 1993; Herold et al., 1995). 
These glycoproteins form the most prominent envelope spikes on the virus particle 
(Stannard et al., 1987), and therefore are likely to provide the first virus contact with the cell. 
gC, non-essential for virion infectivity, is principally responsible for the initial adsorption of 
HSV-l virions to cell surface HS (Langeland et al., 1990; Herold et al., 1991). The role 
played by gC is suggested to be similar to that of the gC homologue, gill, of PRV in that it 
may help to mediate stable attachment of the virion to the cell surface (Schreurs et al., 1988; 
Zuckermann e ta l., 1989). gB has heparin binding activity independent from gC, and 
mutant virions lacking both gC and gB are practically devoid of the ability to bind to HEp-2 
cells (Herold e ta l.,  1991 & 1994). In addition, in vitro studies allowing the analysis of 
formation of complexes between virion proteins and cell surface components supported 
evidence that gC and gB play roles in viral attachment (Johnson et al., 1984; Fuller & Spear,
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1985; Khun et al., 1990).
Initial attachment is followed by a stable form of attachment which allows close 
association of the virus with the cell in a manner that is more resistant to removal by heparin 
or high ionic strength washes (Fuller & Lee, 1992; McCain & Fuller, 1994). It is believed 
that this stable form of attachment is mediated by gD, interacting with a number of cell 
surface molecules including 275KDa and 46KDa mannose-6-phosphate receptors (Bumetti 
et al., 1994). Evidence for this second form of attachment comes from biochemical analyses 
which show that gD neutralised, or gD null virus binds to cells but does not penetrate 
(Highlander et a l., 1987; Ligas & Johnson, 1988). gD has also been shown by in vitro 
studies to be able to form complexes with cell surface components, suggesting a role in viral 
attachment (Khun et al., 1990).
(ii) Penetration by HSV-l particles
Following stable attachment, HSV -l particles have been shown by electron 
microscopy to enter the cell by fusion with the plasma membrane (Morgan et al., 1968; Para 
et al., 1980). In order for this fusion to occur multiple interactions involving virion 
glycoproteins and cell surface components are required. The study of HSV mutants has 
shown that several virion glycoproteins including gD, gB and gC known to be involved in 
vims attachment to the cell surface, are also necessary for viral entry into the cell. As a result 
of gB and/or gC interacting with HS moieties, conformational changes in the glycoproteins 
or the HS may trigger further events either in the vims particle or the cell surface, that result 
in fusion of the virion envelope with the plasma membrane. With regards to gD, a model of 
HSV-l cellular entry proposed by Fuller and Lee (1992) suggests that gD performs at least 
two functions. Firstly, as described in the previous section, gD interacts with cellular 
components to bring the vims envelope and cell membrane closer together, and secondly, 
this glycoprotein interacts with a viral component which is directly involved in fusion 
initiation. The conformational change of gD following step one would result in a change that 
allows or triggers the second function. Evidence supporting this dual function of gD comes 
from the observation that there are distinct epitopes that can be neutralised by anti-gD 
antibodies, that either block attachment or that block penetration (Eisenberg et al., 1985a; 
Cohen etal., 1986).
In addition, gH and gL are known to be essential for cell fusion and vims entry into 
cells (Gompels & Minson, 1986; Cai et al., 1987; Ligas & Johnson, 1988; Forrester et 
al., 1992; Roop etal., 1993; Bumetti etal., 1994). HSV-l vims mutants that lack any one of 
these glycoproteins are able to bind to cells at normal efficiency but fail to penetrate. The
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involvement of gH in fusion was demonstrated by the inactivation of virus penetration by 
anti-gH neutralising antibodies. gL interacts with gH forming a heterodimer which appears 
to be essential for the proper processing and intracellular transport of both proteins 
(Hutchinson et al., 1992a). gL negative mutants failed to incorporate gH into the virion 
envelope, and were unable to enter cells (Roop et al., 1993). T herefore gH, probably 
complexed with gL, seems to participate in the initiation of fusion but not the subsequent 
steps associated with the entry of the nucleocapsid into the cell (Fuller & Lee, 1992).
More recently, gK has been implicated in the process of viral penetration. Viruses 
lacking functional gK exhibit a syncitial phenotype which resulted in the suggestion that gK 
might play an important role in regulating membrane fusion (Bond & Person, 1984; 
Pougue-Geile & Spear, 1987; Hutchison et al., 1992b; Ramaswamy & Holland, 1992). 
Recent evidence suggests that the fusion of infected cells mediated by gK is indirect as gK 
is not exhibited on the surface of infected cells (Hutchinson et al., 1995).
The potential role of non-glycosylated proteins in viral attachment and fusion have 
been suggested. Previous investigations have shown that virus attachment can occur when 
glycosylation is inhibited, suggesting that other viral proteins are important in binding 
(Svennerholm et al., 1982). The tegument protein encoded by UL25 has been suggested to 
play a role in penetration following the isolation of a temperature sensitive (ts) mutant with a 
defect in gene UL25. The ts mutant at non-permissive temperature binds to cells but is 
impaired in its ability to penetrate (Addison et al., 1984).
Following fusion with the plasma membrane, discernible changes to the tegument 
and envelope can be seen by electron microscopy. These changes include the condensation 
of the virus tegument and envelope and release of the nucleocapsid and some tegument 
proteins from the virion (Fuller & Lee, 1992). The de-enveloped HSV particle is 
transported across the cytoplasm (Batterson & Roizman, 1983), by a mechanism that 
probably involves host cell microtubules (Lycke et al., 1984) to the nuclear membrane, 
where the viral genome is released from the capsid structure. The virus DNA migrates to 
the nucleus of the infected cell, via a nuclear pore (Hummeler et al., 1969), and it quickly 
becomes associated with one or more host cell nuclear proteins in a pronase-phenol-sensitive 
complex. The release of DNA can take place in the presence of nucleic acid and protein 
synthesis inhibitors, indicating that de novo RNA and protein synthesis are not required for 
this process (Rice et al., 1976). In the light of these observations it was proposed that a 
structural component of the virus or a cellular enzyme mediates the DNA release step 
(Hochberg & Becker, 1968). A function essential for this process has been mapped to the 
UL36 gene (Batterson et al., 1983), which encodes the tegument protein VP1 (McNabb & 
Courtney, 1992b). It is possible that other tegument proteins may also be involved in the
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(iii) The effects of HSV-l infection on host cell 
macromolecular synthesis
Following viral infection, synthesis of a 57KDa cellular species, that corresponds to 
a heat shock protein, is induced in HSV-2 infected cells (La Thangue et a l ., 1984). An 
accumulation of this protein was also seen in HSV-l infected cells, however to a lower level 
(Patel et al., 1986). In the majority of cases the viral lytic cycle is not inhibited by the stress 
response. However it is possible that induction of the stress response in some cell types 
may cause the lytic cycle to be aborted, resulting in the establishm ent of cellular 
transformation (Minson, 1984). In addition, HSV-2 has been shown to induce the 
expression of a cellular protein, U90, a tumour-specific polypeptide (Hewitt et al., 1991).
Reduced host cell protein synthesis is brought about by the host shut-off protein 
(vhs), a component of the virion, and Vmw63, one of the polypeptides produced at the onset 
of infection, vhs acts to induce the degradation of host cell mRNAs which abrogates most 
host protein synthesis, while Vmw63 affects snRNP localisation and splicing. Both vhs 
and Vmw63 are described in more detail in Introduction; Chapter 3, Section 4.3.c and 
Introduction; Chapter 3, Section 3.3.e respectively.
Section 2 .
HSV-l Gene Expression
(i) General features of HSV-l gene transcription
HSV-l genes are transcribed by cellular RNA polymerase II, in the nucleus of the 
host cell (Alwine et a l ., 1974; Costanzo et al., 1977). Following transcription, the viral 
mRNAs share common structural features with cellular RNAs; they have a 5' cap structure, 
are polyadenylated at the 3' end, and are internally methylated (Bachenheimer & Roizman, 
1972; Silverstein et al., 1973; Bartoski & Roizman, 1976). The replication of HSV-l is 
coordinated by temporal control of gene expression, in which genes are transcribed and 
proteins are synthesised sequentially and coordinately. The classification of genes are as 
follows: immediate early (IE,a), early (E,(3), and late (L,y) (Honess and Roizman, 1974). 
Five immediate early genes are transcribed at the onset of infection and their expression does
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not require de novo protein synthesis. The IE proteins activate the early genes which are 
predominantly those that encode the proteins necessary for DNA replication. The late genes 
which encode mainly structural proteins can be sub-divided into leaky late (y l) genes that 
are induced shortly after the E genes and true late (y2) genes which are activated only after 
the onset of DNA replication (Honess & Roizman, 1974; Clements et a l., 1977). 
Expression within each class is determined by cfs-acting DNA sequences within the 
promoter sequences of each gene and trans-acting factors within the infected cell, of cellular 
or viral origin, that interact with defined regions within the promoters.
In addition, the temporal control of gene expression appears to be influenced by the 
post-transcriptional processes of mRNA splicing and 3' mRNA processing. Recent studies 
by McGregor et al., (1995) demonstrated in vitro that HSV-l infection induces an activity, 
which requires Vmw63 gene expression that is responsible for an increase in 3' processing 
at the polyA sites of two late genes, UL38 and UL44. Processing efficiencies at these polyA 
sites appear to be inherently low in the absence of Vmw63. In contrast, the polyA sites of 
selected immediate early and early genes were shown to be efficient processing sites and 
were not affected by Vmw63 expression.
A number of reports provide evidence that Vmw63 inhibits host-cell splicing, and 
the repression of expression of genes has been correlated with the presence of introns 
(Sandri-Goldin & Mendoza, 1992). Inhibition of host cell splicing by Vmw63 is associated 
with the redistribution of snRNPs, with the consequent effect of promoting shutoff of host 
protein synthesis (Sandri-Goldin & Mendoza, 1992; Phelan et al. 1993; Hardy & Sandri- 
Goldin, 1994). This effect would be beneficial for HSV-l as very few of its transcripts are 
spliced. However a recent report by Sandri-Goldin et al. (1995) suggests that the 
redistribution of snRNPs is not sufficient to inhibit host cell splicing. They postulate that 
this redistribution might serve to transport newly transcribed viral mRNA to the the 
periphery of the nucleus.
15.
Chapter 3; Introduction
(ii) HSV-l promoter sequences
(a) Immediate early gene promoters
Transcription of the five immediate early genes (IE1 to IE5) is mediated by both 
promoter and enhancer sequences. The promoter component is found within lOObp 
upstream of the transcriptional start site and contains elements, such as a TATA box, that is 
recognised by the transcription factor TFIID, and the GC box which is recognised by the 
transcriptional activator Spl (Jones & Tjian, 1985). The enhancer-like elements of IE 
promoters are situated far upstream from the transcription start site (-140 to -340) and 
include the consensus sequence 5'-TAATGARAT-3\ where R is purine. The consensus 
sequence is present in one or more copies in either orientation and has been shown to be 
essential for trans-induction by the virion component VP 16 (Mackem & Roizman, 1982a, 
1982b; Cordingley eta l., 1983; Kristie & Roizman, 1984; Preston et al., 1984; Gaffney et 
al., 1985; Bzik & Preston, 1986; O'Hare & Hayward, 1987).
Transcription of the five immediate early genes is stimulated 5-10 fold by VP 16 
(Post et al., 1981; Campbell et al., 1984). The trans-inducing effect is mediated by two 
cellular components; OCT-1, a transcription factor implicated in the regulation of a number 
of cellular genes (Pruijn et al., 1986; Staudt et al., 1986; Fletcher et al., 1987; Stern et al., 
1989) and the less well characterised CCF factor (Katan et al., 1990). Current results 
indicate that CCF binds directly to VP 16 in the absence of OCT-1 or DNA. The next step 
in complex assembly is the binding of OCT-1 to the TAATGARAT site, followed by an 
interaction with the VP16-CCF complex (Gerster & Roeder, 1988; O'Hare & Goding, 1988; 
Preston eta l., 1988; Stern et al., 1989; O'Hare, 1993). A GA-rich element, present in close 
proximity to at least one TAATGARAT sequence, also confers a strong independent 
stimulatory response to VP16 (Bzik & Preston, 1986; Triezenberg et al., 1988). The IE- 
regulatory sequence for the IE1 is contained within a full octam er sequence 
(ATGCTAATGATAT). Results have shown that this overlapping octamer site increases 
the activity of the IE1 promoter element by allowing tighter binding of the Oct-1/VP 16 
complex (Douville eta l., 1995).
The promoters of the IE genes 1, 2 and 3 also possess copies of a sequence 
identified as a binding site for Vmw 175 (Faber & Wilcox, 1986, 1988; Kristie & Roizman, 
1986; Muller, 1987). The binding of Vmw 175 to the IE1 and IE3 promoters results in 
repression of the promoter in transfection assays suggesting a mechanism for the observed 
autoregulation of IE proteins (Gelman & Silverstein, 1987a, 1987b; DeLuca & Schaffer, 
1988; Paterson & Everett, 1988a, 1988b; Roberts etal., 1988; ; DiDonato & Muller, 1989; 
Resnick eta l., 1989; Everett & Orr, 1991) However, Everett & Orr (1991) have reported
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that mutation of the Vmw 175 binding sites in both copies of the IE1 promoter in the viral 
genome has no effect on IE1 expression during normal HSV-l infection.
(b) Early gene promoters
HSV-l genes that are expressed early in infection include UL23 and US6 that encode 
TK, and gD respectively. The promoter sequence for the TK gene has been extensively 
studied and is comprised of a control region that extends 135bp upstream of the transcription 
start site and contains five regulatory elements; a TATA box, a CCAAT box, two GC box 
elements and an octamer binding site (McKnight et al., 1981; Zipser et al., 1981; McKnight 
& Kingsbury, 1982; Smiley et al., 1983; Halpem & Smiley, 1984; Cohen et al., 1986; Boni 
& Coen, 1989). The gD promoter requires only 83bp upstream of the transcription start site 
for efficient induction and, like the TK promoter, contains several regulatory elements 
including a TATA box and two GA-rich sequences (Everett, 1983 & 1984a).
The TK and gD promoters also contain binding sites for Vmw 175 (McKnight et al., 
1981; Tedder e ta l., 1989). However, the binding of Vmw 175 to the TK promoter is not a 
prerequisite for transcription (Imbalzano et al., 1990; Shepard & DeLuca, 1991), and the 
removal of the three binding sites in the gD promoter does not affect the efficiency of gD 
expression during a normal HSV-l infection (Smiley et al., 1992).
(c) Late gene promoters
The structure of a true late gene promoter is much simpler than for IE or E 
promoters. The only consensus sequence element identified in these promoters is the TATA 
box. However, several groups have identified additional c/s-acting sequences downstream 
from the TATA box, but these sequences do not form recognisable consensus sequences 
and the specific binding of factors to these regions has not been observed (Mavromara- 
Nazos & Roizman, 1989; Kibler et al., 1991; Steffy & Weir, 1991).
Efficient expression of late gene promoters requires the presence of IE gene products 
(DeLuca & Schaffer, 1985) and is also dependent on DNA replication (Mavromara-Nazos 
& Roizman, 1987), although it is unclear why. The onset of DNA replication may provide a 
factor which is necessary for transcriptional activation, or it may remove a transcriptional 
block.
Negative regulatory elements have been identified in late gene promoters (Costa et 
al., 1985; Blair & Wagner, 1986). For example, upstream of the UL19 (VP5) cap site 
between -75 and -125 base pairs lies a region that suppresses the activity of the UL19 
promoter in transient expression assays (Costa et al., 1985).
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(iii) Polypeptides involved in the expression of HSV genes
The principal viral factors that influence the transcription of HSV-l genes include 
four of the five IE gene products, Vmw 175, Vmw 110, Vmw68 and Vmw63, and the major 
virion protein VP 16. The following sections are an overview of their properties and 
functions:
(a) VP 16
VP 16 is encoded by gene UL48 and has an apparent molecular weight of 65KDa on 
denaturing SDS-polyacrylamide gels. The protein is synthesised during the late phase of 
HSV-l replication and is phosphorylated. It is a structural component of HSV-l virions, 
residing within the tegument of the virus particle. Upon infection, VP 16 is released from the 
virus particle, whereupon it specifically trans-induces the transcription of viral IE genes in 
the nucleus (Post et al., 1981; Batterson & Roizman, 1983; Campbell et al., 1984). VP 16 
does not directly interact with viral DNA, rather it physically interacts with cellular factors 
including CCF (Preston et al., 1988; Katan et al., 1990; Xiao & Capone, 1990) and OCT-1 
to form a complex that binds to the TAATGARAT sequence element (Gerster & Roeder, 
1988; Stem et al., 1989). Mutational analysis of the VP16 protein led to the identification of 
eight amino acids within the N-terminal portion of the protein that are involved in its 
interaction with OCT-1 (Hayes & O'Hare, 1993), whilst the carboxy terminal 80 residues, 
known as the acidic activation domain, function in IE gene transactivation (Ace et al., 1988; 
Triezenberg et al., 1988a; Walker et al., 1993). The acidic activation domain is not a 
requirement for the formation of the OCT-1/CCF/VP16 complex (Greaves & O'Hare, 
1989), instead it appears to promote the assembly of an initiation complex containing the 
TATA box-binding factor, also known as TFHD. The binding of TFIID to the TATA box 
appears to be the critical step in the formation of the pre-initiation complex which is 
necessary for transcription in vitro (Davison et al., 1983; Sawadogo & Roeder, 1985; 
Moncollin et al., 1986). However, the mechanism by which the acidic domain functions 
and stimulates transcription remains to be discovered.
Mutational studies have shown that the transactivating function of VP 16 is separate 
from its requirement in virus particle assembly (Ace et al., 1988). One of the most well 
characterised VP 16 vims mutants is m l814 which contains a 4 amino acid insertion at 
position 379 in the VP 16 protein. This mutated form of VP 16 is able to perform its 
structural role but is deficient in IE transactivation (Ace et al., 1989). m l814 is viable in 
tissue culture but impaired for growth, exhibiting a dramatically increased particle:pfu ratio 
(Ace et al., 1988, 1989; Harris & Preston, 1991). The vims is also avimlent after inoculation
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into mice, and in an in vitro latency tissue culture system, it establishes a latent infection even 
at high multiplicities of infection (Harris & Preston, 1988). Taken together, these results 
suggest that the IE gene transactivating activity of VP 16 is important for the onset of lytic 
infection. However, induced expression of UL48 mRNA in neuronal cells infected with a 
virus recombinant in which the UL48 gene is under the control of the metallothionein 
promoter demonstrated that despite the presence of VP 16, latency was still established in 
these cells (Sears et al. 1991). In addition, OCT-1 expression is not detected in adult 
murine sensory neurons (He et al., 1989), and therefore the importance of the IE 
transactivating activity conveyed by VP 16 in the establishment of lytic infection is difficult to 
assess.
The second function described for VP 16 is its role in the assembly of the virus 
particle. Its influence on this process has been deduced from studies on a VP 16 deletion 
mutant that lacks the entire UL48 ORF (Weinheimer et al., 1992). Propagation of this 
mutant in a VP 16-expressing cell line gave yields of virus comparable to those for a wild- 
type strain. However, the virus did not replicate in non-expressing cells. Following 
infection of non-expressing cells the deletion mutant produced normal levels of viral DNA 
synthesis and capsid proteins, but levels of DNA encapsidation were decreased and the 
further steps of virion maturation were defective. Therefore the absence of VP 16 protein 
synthesis at late times of infection prevents the production of infectious progeny virus and 
correlates with a profound defect in HSV-l particle assembly.
(b) Vmwl75
Belonging to the EE class of polypeptides, Vmw 175 is the product of IE3 which lies 
entirely within R s  and is therefore present as two copies in the genome (Rixon et al., 1982).
The protein is post-translationally modified by phosphorylation, poly-ADP-ribosylation, 
adenylation and guanylation (Wilcox et al., 1980; Preston & Notarianni, 1983; Blaho & 
Roizman, 1991), and differential modification gives rise to three electrophoretically distinct 
forms in extracts of infected cells (Pereira et al., 1977). Phosphorylation of Vmwl75 is 
essential for its interaction with early and late genes, but not for its interaction with IE genes 
(Papavassiliou etal., 1991).
Vmw 175 localises to the nucleus after synthesis (Pereira et al., 1977) and following 
the onset of viral DNA replication, its distribution changes and it becomes localised to large 
globular structures in the nucleus (Randall & Dinwoodie, 1986; Knipe et al., 1987). These 
structures also contain ICP8 (see Chapter 3; Introduction, Section 4.2) and have been called 
'replication compartments' (Quinlan et al., 1984).
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It is a major transactivator of HSV genes, and its expression is essential for early and 
late protein synthesis (Marsden et al., 1976; Courtney et al., 1976; Watson & Clements, 
1978, 1980; Preston, 1979; Dixon & Schaffer, 1980). Analyses of ts mutant viruses, in 
particular taK, (Preston, 1979; Dixon & Schaffer, 1980; DeLuca et al., 1984; DeLuca & 
Schaffer, 1985) and partial deletion mutants (DeLuca et al., 1985; DeLuca & Schaffer,
1988) have shown that impairing the activity of Vmw 175 results in its overproduction and 
that of other IE mRNAs and an inability to induce synthesis of early and late genes 
(Marsden e ta l., 1976; Watson & Clements, 1980).
Vmw 175 binds to DNA non-specifically (Freeman & Powell, 1982), but it also 
shows a significant preference for the consensus ATCGTCNNNNYCGRG, where R= 
purine, Y= pyrimidine, and N= any base (Faber & Wilcox, 1986). Transient transfection 
assays have confirmed that Vmw 175 can transactivate early gene promoters (Gelman & 
Silverstein, 1985; O'Hare & Hayward, 1985a), however extensive studies have failed to 
provide any evidence for the existence of a Vmw 175-specific induction sequence (Eisenberg 
et al., 1985b; Coen et al., 1986; Smiley et al., 1992). Everett (1984b & 1986) has suggested 
that this transactivation activity is the result of synergistic interaction with Vmw 110. 
Evidence for an interaction between Vmw 175 and Vmw 110 in infected cells has come from 
indirect immunoflourescence studies (Mullen et al., 1994), and these results have been 
further supported by in vitro co-immunopreciptiation experiments (Cuifo etal., 1994). In 
addition, Vmw 175 has been shown to form a tripartite complex with components of the 
cellular transcription machinery acting at the TATA box. These include the TATA-binding 
protein (TBP) and TFIIB (Smith et al., 1993). This complex formation correlates with the 
ability of Vmw 175 to initiate transcription at minimal promoters that only contain a TATA 
box.
In addition to its transactivating capabilities, transient transfection assays have 
shown that Vmw 175 is able to repress transcription from both its own and other IE 
promoters (DeLuca & Schaffer, 1985; O'Hare & Hayward, 1985b; Gelman & Silverstein, 
1986). It has been postulated that this phenomenon may occur through binding of 
Vmwl75 to a cfs-acting element across the transcription initiation site of the gene (Roberts et 
al., 1988). Vmw 175 has been shown to bind to the promoters of IE genes 1, 2 and 3 
(Kristie & Roizman, 1986; Muller, 1987; Faber & Wilcox, 1988), early genes UL23 (TK) 
and US6 (gD) (Michael et al., 1988; Michael & Roizman, 1989; Flanagan et al., 1991).
On the basis of functional studies and comparisons with homologues in other a -  
herpesviruses, five domains have been identified within Vmw 175 (McGeoch et al., 1986b; 
DeLuca & Schaffer, 1988; Paterson & Everett, 1988a, 1988b). Each of these domains has 
distinct functions, for example regions 1 and 2 have been implicated in the stimulation of
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transcription of early genes (Dixon & Schaffer, 1980), while region 4 is believed'to be 
involved in DNA synthesis, late gene expression and intranuclear localisation (DeLuca & 
Schaffer, 1988).
Vmw 175 has been identified as a component of virions (Yao & Courtney, 1989), 
however this observation appears to be cell-type dependent. Vmw 175 is readily detectable 
in virions produced in Vero cells and Hep-2 cells (Yang & Courtney, 1995) but studies on 
virus particles produced in BHK cells have indicated that it is absent in virions and only 
present in L-particles (see Chapter 3; Introduction, Section 6, McLauchlan & Rixon, 1992).
(c) V m w llO
Vmw 110 is encoded by three exons from IE gene 1 and is located within R l- 
Therefore in common with IE3, it is present as two copies in the genome (Perry et al.,
1986). As is the case for Vmw 175, Vmwl 10 is a nuclear phosphoprotein (Ackerman et 
al., 1984) and is a minor component of virus particles (Yao & Courtney, 1992). It non- 
specifically activates expression of viral and cellular genes but is not essential for virus 
replication as mutants are viable in tissue culture (O'Hare & Hayward, 1985a, 1985b; 
Everett, 1989; Cai & Schaffer, 1992; Chen & Silverstein, 1992; Stow & Stow, 1986; Sacks 
& Schaffer, 1987). Despite the non-essential nature of VmwllO, mutants give rise to 
stocks with high particle:pfu ratios and grow very poorly at low multiplicities of infection.
Five functional regions of Vmwl 10 have been mapped by Everett, (1988), two of 
which (regions 1 and 5) are of particular interest in the context of transcriptional regulation. 
Region 1 (amino acids 105-222) contains two zinc finger binding motifs, and mutations 
within this region result in either complete elimination or a significant reduction in the ability 
of Vmwl 10 to activate the HSV-l gD promoter in the absence of Vmw 175 (Everett, 1986). 
In the presence of Vmw 175, mutations in region 5 (amino acids 633-775) markedly reduce 
the synergistic activation of the gD promoter by Vmwl 10 (Everett, 1986).
V m w llO  and V m w l75 have been shown to interact physically with each other 
(Mullen et al., 1994, Yao & Schaffer, 1994), and a dimerization domain identified in the C- 
terminus of the protein appears to play an important role in this interaction (Cuifo et al., 
1994). Given the potent non-specific transactivating ability and DNA binding capability of 
V m w llO , it is possible that the interaction of V m w llO  with Vmw 175 facilitates the 
interaction of Vmw 175 with its low affinity DNA binding sites and with factors in the basic 
transcription complex such as TFIIB and either the TATA-binding protein (TBP) or TFIID 
(Smith etal., 1993).
Studies on virus-cell interactions have shown that Vmwl 10 modifies the distribution
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of cellular structures called ND10 domains. These have been identified as distinct nuclear 
structures that are present in low numbers in a variety of cell types. Stress in the form of 
heat shock induces a large increase in the number of ND10 domains present in cells (Ascoli 
& Maul, 1991). However, infection by HSV-l results in the apparent disappearance of 
ND10 antigens from nuclear structures. This effect requires the expression of Vmwl 10, 
which co-localises with these structures (Maul et al., 1993). It has been suggested that 
ND10 domains are specific sites of transcription, and that ND10 proteins may be involved 
in transcriptional regulation (Xie et al., 1993). The function of ND10 domains and the 
significance of the interaction between Vmwl 10 and these structures is unclear, however it 
may be possible that transcriptional regulation modulated by Vmwl 10 is a result of its 
interaction with ND10 domains. One of the components of ND10 structures has been 
identified as PML, a cellular member of the zinc-binding domain family, and Vmwl 10 has 
been shown to be essential for the apparent release of PML from the ND10 domains (Maul 
& Everett, 1994). The zinc finger binding domain of PML is not functionally 
interchangeable with the zinc finger domain of V m w llO , and PML is not a cellular 
functional counterpart of Vmwl 10 (Everett etal., 1995).
Vmwl 10 also plays a major role in enhancing the reactivation of HSV from latency 
in a mouse model system (Leib et al., 1989), and of the five IE proteins, only Vmwl 10 is 
able to induce reactivation of HSV-2 from latency in an in vitro tissue culture system (Harris 
etal., 1989).
(d) Vmw68
Vmw68, encoded by US1, is also known as ICP22 and is involved in the transition 
from early to late gene expression (Poffenberger et al., 1993). Little is known about the 
functions of this protein but a Vmw68 deletion mutant exhibits decreased virulence during 
acute infection in vivo, and a reduced frequency of reactivation from mouse trigeminal 
ganglia when compared to the parental virus (Poffenberger et al., 1994).
Recent studies have suggested one function of Vmw68 which may influence viral 
transcription (Rice et al., 1995). Infection of cells with HSV-l results in the rapid alteration 
of phosphorylation on the large subunit of host cell RNA polymerase II (RNAPII). In vivo 
RNAPII exists in two discrete forms, IIA and IIO, which differ in the extent of 
phosphorylation: IIA is unphosphorylated and IIO is hyperphosphorylated (Cadena & 
Dahmus, 1987; Baskaran etal., 1993; Dahmus, 1993). The different forms are associated 
with different steps in the transcription cycle and it is thought that the phosphorylation of IIA 
to IIO may be coincident with transcriptional initiation (Dahmus, 1993; Zawel et al., 1993). 
Rice et al. (1995) demonstrated that HSV -l infection results in the intermediate
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phosphorylation of RNAPII. The identification of an HSV-1 mutant containing a nonsense 
mutation in US 1 that was unable to modify RNAPII, showed that this effect was required 
for the normal pattern of transcription of viral genes in some cell lines.
(e) Vmw63
Vmw63, encoded by UL54, is also known as ICP27 and is an essential immediate 
early phosphoprotein that acts post-transcriptionally during infection to regulate gene 
expression by promoting the transition from the early to the late phase of infection 
(McCarthy et al., 1989; Rice & Knipe, 1990; Smith et al., 1992). It localises to the infected 
cell nucleus and multiple nuclear and nucleolar localisation signals (NLS, and NuLS 
respectively) have been identified (Mears et al., 1995). These include a strong NLS 
mapping to residues 110-137, as well as one or more weak NLSs which map to a carboxyl 
terminal portion of the protein between residues 140 and 512. In addition, a short sequence 
mapping to residues 110-152 has been shown to function as a NuLS. Mutants with defined 
lesions in gene UL54 over-express IE and E gene products and greatly reduce the 
expression of late genes (McCarthy et al., 1989; Rice & Knipe, 1990).
Functional studies have indicated that Vmw63 acts at the post-transcriptional level 
and influences both polyadenylation and splicing of mRNA (Sandri-Goldin & Mendoza, 
1992). Both in vitro RNA processing analysis and studies with virus recombinants revealed 
that Vmw63 could specifically stimulate processing at polyadenylation sites of late viral 
genes (McLauchlan et al., 1992; McGregor et al., 1995). By contrast the presence of 
Vmw63 reduces splicing efficiency as assessed in an in vitro splicing system and in 
transfection studies (Sandri-Goldin & Mendoza, 1992; Phelan et al., 1993; Hardy & Sandri- 
Goldin, 1994). This impairment in splicing is likely to contribute to the shut-off of host cell 
protein synthesis by decreasing levels of spliced cellular mRNAs available for translation. 
Such alterations in post-transcriptional processes are probably linked to the redistribution of 
small nuclear ribonucleoproteins (snRNPs) observed in HSV-1-infected cells (Martin et al.,
1987). snRNPs are key components of the cellular splicing machinery and, in infected cells, 
they become localised in punctate sites which are associated with RNA synthesis (Martin & 
Okamura, 1981; Fakan et al., 1984). Vmw63 co-localises to these sites and its expression is 
sufficient for snRNP redistribution from a diffuse speckled pattern within the nucleus to a 
highly punctate distribution (Martin et al., 1987; Phelan et al., 1993).
In vitro transfection assays performed using plasmids containing the IE genes 
Vmwl75, Vmwl 10 and Vmw63 demonstrated that in combination with Vmwl75 and/or 
Vmwl 10, Vmw63 exhibited either a marked repression or stimulation of the expression of 
different target genes (Sekulovich et al., 1988). These data suggested that Vmw63 interacts
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with V m w l75 and Vm wl 10 and this interaction results in transcriptional activation or 
repression of HSV-1 genes. Mutational studies by Rice & Lam (1994) have confirmed the 
presence of at least two distinct essential gene regulation functions in Vmw63. They created 
three amino acid substitutions in the C-terminal end of the protein that retained the 
transcriptional repression activity of Vmw63 but were defective at transactivation in 
cotransfection assays. When introduced into the HSV-1 genome, recombinants containing 
these mutations replicated viral DNA like wild type, but showed several defects in gene 
expression including a failure to down-regulate immediate early and early gene expression 
and an inability to induce late gene expression, similar to the results seen previously with 
Vmw63 ts mutants. Vaughan et al. (1992) identified a putative zinc finger metal-binding 
domain in the carboxy terminal 105 amino acids of the protein however the importance of 
this domain is not clear.
Indirect immunoflourescence studies have shown that Vmw63 inhibits the normal 
pattern of nuclear localisation of Vmwl 10 and V m w l75 in infected cells and that the C- 
terminal half of the protein is responsible for the redistribution (Zhu et al., 1994; Zhu & 
Schaffer , 1995). These results suggest that the regulation of HSV-1 gene expression may 
involve intracellular compartmental restraints for example, the inhibition of the formation of 
replication compartments within the nucleus.
Section 3.
Replication of HSV DNA
The replication of viral DNA will be dealt with in two parts: (i) the viral origins of 
replication, and (ii) the proteins required for replication.
(i) Viral origins of replication
In infected cells, viral DNA is detected from 3 hours post infection and continues to 
increase in abundance for at least another 9-12 hours. The viral DNA is synthesised in 
discrete sites located close to the nuclear membrane (Rixon et al., 1983). Replication is 
thought to proceed through a rolling circle mechanism generating concatomers of viral DNA 
(Jacob & Roizman, 1977; Jacob et al., 1979; Roizman, 1979b). Three origins of replication, 
oriL and two copies of oris, were identified following studies of defective viruses generated 
during serial passage of HSV-1 at high multiplicities of infection (Frenkel et al., 1975 & 
1976). The origins of replication have been operationally defined as those HSV-1 DNA 
sequences which are required for amplification of plasmid DNA in cells infected with helper
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virus (Vlanzy & Frenkel, 1981; Mocarski & Roizman, 1982). All three sites are not 
required on a single DNA molecule for efficient replication since studies with mutant viruses 
have shown that deletion of oriL or one copy of oris has little or no effect on virus replication 
in cultured cells (Longnecker & Roizman, 1986; Polvino-Bodnar et al., 1987). The HSV-1 
strain 17 oris was cloned (Stow, 1982) and subsequently precisely defined by Stow and 
McMonagle (1983). Oris, situated within Rs, consists of a 90bp sequence containing a 
45bp palindromic sequence featuring 18 centrally located A or T residues flanked by G + C- 
rich tracts. OriL, larger than oris, contains a 144bp A + T rich almost perfect palindromic 
sequence. Due to the size of this palindrome, plasmids containing oriL are highly unstable in 
E.coli (Weller et al., 1985), thus the functional domains of oriL have not been investigated as 
thoroughly as oris- However, it has been suggested that oris allows DNA synthesis in only 
one direction, while oriL, being larger than oris would allow bi-directional DNA synthesis. 
The existence of or need for bi-directional synthesis has not been established and both oris 
and oriL appear to be functionally identical in transient expression assays (Wu et al., 1988). 
The potential ability of the origins to form cruciform structures containing a stretch of low 
melting point (A + T-rich) DNA probably facilitates strand-separation in these regions of the 
genome (Stow, 1985).
It is interesting that both oris and oriL are situated between divergent transcription 
initiation sites; oris is situated between IE3 and IE4/IE5, and oriL is situated in the middle of 
Ul , between UL29 and UL30, which are both early genes. This perhaps suggests that 
initiation of synthesis might be activated or enhanced by the changes in the local 
environment of the DNA during transcription initiation events.
(ii) Herpesvirus polypeptides associated with viral DNA
replication
The proteins involved in viral DNA replication include proteins that are essential for 
viral origin-dependent amplification of DNA, and also enzymes involved in nucleic acid 
metabolism which are not essential for viral growth in tissue culture. Seven HSV-1 genes 
have been identified as being essential for DNA replication and at least five additional genes 
have been shown to stimulate DNA replication (Keir & Gold, 1963; Kit & Dubbs, 1965; 
Cohen, 1972; Wu et al., 1988).
In order to identify all of the necessary genes required during origin-dependent DNA 
replication, minimal fragments of the HSV-1 genome that were able to support replication of
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plasmid vectors containing HSV-1 origins of replication in transient complementation 
assays were analysed (Challberg, 1986; Wu et al., 1988). These studies identified seven 
genes which were directly required for DNA replication. Two of these genes, which 
encoded the DNA polymerase (UL30) and the major DNA binding protein (MDBP;UL29) 
also known as ICP8, were already known. The 140KDa DNA polymerase exhibits novel 
DNA polymerase activity readily distinguishable from host enzymes. For example, it is 
inhibited by the pyrophosphate analogue phosphonoacetic acid (PAA) (Hay & Subak- 
Sharpe, 1976) which in experimental systems is a useful method of preventing viral DNA 
replication. The enzyme has intrinsic 3' to 5' exonuclease activity serving a proofreading 
function (Knopf, 1979; O'Donnell et al., 1987). It also possesses ribonuclease activity that 
specifically degrades RNA-DNA heteroduplexes as well as DNA duplexes in the 5' to 3' 
direction (Crute & Lehman, 1988), thus enabling removal of the RNA primers that initiate 
synthesis of Okazaki fragments during lagging strand synthesis. The association of ICP8 
with replicating viral DNA is essential (Conoley et al, 1981), although the function of this 
protein is not well defined. It binds to single-stranded DNA and may act to reduce the 
melting temperature at poly(dA).poly(dT) DNA tracts (eg. at origins of DNA replication), 
thereby facilitating strand-separation (Powell et al., 1981). After viral replication 
commences, indirect immunoflourescence studies have demonstrated that both V m w l75 
and ICP8 localise to large globular structures within the nucleus (Randall & Dinwoodie, 
1986; Knipe et al., 1987). In addition, pulse labelled DNA has also been shown to 
accumulate in similar sites (Rixon et al., 1983). These structures are known as replication 
compartments (Quinlan et al., 1984; Kops & Knipe, 1994). The formation of replication 
compartments and the localisation of the HSV-1 DNA polymerase to these sites is 
dependent on the activity of ICP8 (de Bruyn Kops & Knipe, 1988; Bush et al., 1991).
The other genes required for DNA replication were identified as UL5, UL8, UL9, 
UL42 and UL52. Gene UL42 encodes a DNA binding protein (Parris et al., 1988), and has 
been shown to physically interact with the viral DNA polymerase to form a heterodimer, 
which acts to increase the rate of DNA synthesis (Gallo et al., 1988; Gottlieb et al., 1990; 
Hernandez & Lehman, 1990). The double-stranded DNA binding activity conferred by the 
UL42 gene product may act as a clamp, decreasing the probability that the polymerase will 
dissociate from the template after each cycle of catalysis (Gottlieb & Challberg 1994). UL9 
encodes a polypeptide that binds specifically to ori sequences (Olivo et al., 1988) and which 
also has helicase activity (Boehmer et al., 1993). The UL9 gene product catalyses the 
unwinding of DNA in the 3' to 5' direction, and activity is specifically stimulated by ICP8, 
which increases the rate and extent of helicase activity. There is evidence that UL5 also 
encodes a helicase (Zhu & Weller, 13th International Herpesvirus Workshop abstract;
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Irvine, 1988). UL5, UL8 and UL52 gene products have been shown to form a complex in 
which each protein is present in equimolar amounts. The complex formed acts as a primase 
and helicase (Crute et al., 1989).
Enzymes that have accessory functions in replication include: alkaline DNase, TK, 
ribonucleotide reductase (RR), uracil-DNA glycosylase and dUTPase. Alkaline DNase, 
encoded by UL12, differs from host cell nucleases in its high pH optimum and exhibits exo- 
and endonuclease activity (Strobel-Fidler & Francke, 1980; Hoffman, 1981). Alkaline 
DNase activity does not appear to be essential for viral DNA synthesis but may play a role 
in the processing or packaging of viral DNA into infectious virions (Chou & Roizman, 
1989; W eller et al., 1990). TK, encoded by UL23, acts as a deoxypyrimidine kinase 
(Jamieson & Subak-Sharpe, 1974) but also phosphorylates a number of nucleoside 
analogues not phosphorylated efficiently by cellular kinases (Kit & Dubbs, 1965). RR 
functions to reduce ribonucleotides to deoxyribonucleotides, creating a pool of substrates for 
DNA synthesis. It consists of two non-identical subunits, R1 and R2 (Frame et al., 1985), 
that are tightly associated in a a2 p 2  complex and both subunits are required for activity 
(Ingermarson & Lankinen, 1987). R1 and R2 are encoded for by UL39 and UL40 
respectively (McLauchlan & Clements, 1983). R1 possesses a unique N-terminal domain 
which is not directly involved in ribonucleotide reduction (Nikas et al., 1986; Wymer et al., 
1989; Conner et al., 1992). This N-terminal domain contains amino acid sequences which 
are characteristic of a protein kinase (Chung et al., 1989; Paradis et al., 1991), and Cooper et 
al. (1995) have characterised a novel kinase acitvity within the R1 subunit. It has been 
postulated that the kinase activity may play a role during immediate-early times post 
infection, phosphorylating cellular or viral proteins involved in subsequent stages of the 
replication cycle (Conner et al., 1992b; Sze & Herman, 1992). The uracil DNA glycosylase, 
encoded by UL2 (Worrad & Caradonna, 1988), is thought to function in DNA repair and 
proof-reading. It acts to remove uracil residues in DNA caused by the deamination of 
cytosine residues. It is not essential for growth of the virus in tissue culture (Mullaney et al.,
1989). dUTPases act to hydrolyse dUTP to dUMP, providing both a mechanism to prevent 
incorporation of dUTP into DNA and a pool of dUMP for conversion to dTMP by 
thymidylate synthetase. dUTPase is encoded by UL50 (McGeoch et a l., 1988b) and is not 
essential for growth of the virus in tissue culture (Fisher & Preston, 1986).
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Structure, Assembly and Maturation of 
Virus Particles
Section 1.The HSV-1 virion
The complexity of the virion has been highlighted by the fact that of the 75 genes 
present on the virus genome, over half are known to or suspected to encode proteins which 
are present in the virion or involved in virion assembly. This complexity is further 
emphasised by the multifunctional properties of certain structural components, for example 
VP16, the major immediate early transcriptional activator, is also a major structural 
component of the HSV-1 tegument.
The herpesvirus particle can be described as three morphologically distinct 
components; the nucleocapsid (consisting of the capsid containing viral DNA), tegument 
and envelope.
Section 2 .The Capsid
The morphology of the capsid is a characteristic feature of all herpesviruses. It is 
150nm in diameter and is composed of 162 capsomers, of which 150 are hexamers and 12 
are pentamers arranged in the form of an iscoahedron (Wildy et a l , 1960). Three separable 
forms of capsid can be isolated from infected tissue culture cells; empty capsids with no 
internal structure, intermediate capsids which lack viral DNA but possess a core in the form 
of a second proteinaceous layer inside the outer capsid shell, and full capsids which contain 
the viral genome (Gibson & Roizman, 1972; Perdue et al., 1975). By convention, these are 
referred to as A (empty), B (intermediate) and C (full) capsids, respectively.
The polypeptides which are present in HSV-1 capsids have been determined (Gibson 
& Roizman, 1972; Heilman et al., 1979; Cohen et al., 1980, Rixon et al., 1990). In 
addition, the contribution of individual proteins to capsid structure has been analysed by 
localisation studies using monospecific antibodies and immuno- and cryo-electron 
microscopy techniques (Gibson & Roizman, 1972; Heilman et al., 1979; Cohen et al., 1980; 
Davison et al., 1992). A and B capsids have five structural proteins in common: VP5 
(155KDa), VP19C (54KDa), VP23 (33KDa), VP24 (24KDa) and VP26 (12KDa). In 
addition B capsids also contain VP21 (42KDa) and VP22a (38KDa). With the exception of 
the internal scaffolding proteins VP21 and VP22a, the protein compositions of types A and 
C capsids are identical to that of type B capsids (reviewed by Rixon, 1993).
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Table 3. Protein composition of HSV-1 B capsids
Protein Approx. Gene Presence Location
Mr (X10~3) in A capsids in capsid
VP5 155 UL19 + icosahedral shell
VP19C 53 UL38 + icosahedral shell
VP21 42 UL26 - scaffold
VP22a 38 UL26.5 - scaffold
VP23 33 UL18 + icosahedral shell
VP24 25 UL26 + ?
VP26 12 UL35 + icosahedral shell
Figure 4. Organisation of UL26 and UL26.5 genes and the derivation of the capsid proteins 
VP21, VP22a and VP24. Numbers refer to amino acid residues in UL26 and the arrows 
indicate positions o f cleavage sites.
mRNA
UL26 ORF
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VP21
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(i) Capsid proteins
The proteins that make up B capsids are listed in Table 3. VP5, generally referred to 
as the major capsid protein, is the major component of the hexons and pentons (Schrag et 
al., 1989; Newcomb et al., 1993; Zhou et al., 1995), and is essential for capsid assembly 
(Weller et al., 1987; Desai et al., 1994). VP19c and VP23, also are essential for capsid 
assembly (Pertuiset et al., 1989) and are believed to form trivalent connections which link 
adjacent capsomeres (Newcomb et al., 1993; Desai et al., 1994). Braun et al. (1984) have 
also reported DNA binding activity by VP 19c. Evidence from images obtained by cryo- 
electron microscopy of capsids suggests that VP26, the smallest of the capsid proteins, is 
present at the tips of hexons (Booy et al., 1994; Trus et al., 1995; Zhou et al., 1995). 
Therefore, these four proteins make up the outer capsid shell.
More recently, a 75KDa protein encoded by the UL6 open reading frame has also 
been identified as being associated with the capsid (Patel & Maclean, 1994). It is present in 
very low amounts and although its precise location has not been identified, it appears to be 
tightly integrated into the capsid shell. Evidence obtained from a UL6 ts mutant called r^Fl 8 
has suggested that UL6 is required for cleavage and packaging of nascent viral DNA 
(Sherman & Bachenheimer, 1987).
The proteinaceous core in B capsids is composed of processed forms of the UL26 
and UL26.5 gene products (Lui & Roizman, 1991a). These are overlapping genes which are 
arranged such that the translated portion of UL26.5, termed preVP22a, also represents the C- 
terminal 329 residues of the 80KDa polypeptide encoded by UL26. This 80KDa 
polypeptide contains a serine protease activity, located in the N-terminal portion of the 
protein, which is responsible for cleaving itself at 2 sites. This generates 3 products: VP24 
which consists of the N-terminal 247 residues, VP21 which is composed of residues 248- 
610 and a C-terminal fragment of 25 residues (amino acids 611-635). The C-terminal 
cleavage site is also present in preVP22a and cleavage by the UL26 product at this site 
generates VP22a. The organisation of the UL26 and UL26.5 genes and gene products are 
summarised in Fig. 4. The protease activity resident within the UL26 product is essential for 
the maturation of virions. A temperature sensitive mutant tal201, with a lesion in the 
protease, is unable to process preVP22a and makes capsids with a larger internal core which 
are unable to encapsidate DNA (Preston et al., 1983; Preston et al., 1992). However, a 
mutant virus, lacking full length preVP22a, showed that although growth was severely 
impaired for this virus, a small number of mutant progeny were produced (Matusick-Kumar 
et al., 1994). This unexpected observation lead to the suggestion that either the deleted form 
of preVP22a, produced by the mutant, was able to perform to a limited extent the functions 
of full length preVP22a, or more likely that the autoproteolysis of UL26 resulting in V P21
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may have been able to complement to a limited extent the preVP22a deletion (Matusick- 
Kumar et al., 1994).
(ii) B Capsid assembly
Herpesvirus capsids are assembled in the nuclei of virus-infected cells (Morgan et 
al., 1954) and not surprisingly immunoflourescence studies of HSV-1 infected cells have 
found that capsid proteins localise predominantly in the nucleus (Powell & Watson, 1975; 
Cohen et al. 1980). Nicholson et al. (1994) showed however, that the essential proteins 
VP5 and VP23 are not transported to the nucleus in the absence of preVP22a and VP19C, 
suggesting that the formation of complexes between these proteins is an important early 
stage in capsid assembly. Newly synthesised VP5 has been shown to bind to the 
cytoskeleton and then pass from the cytoplasmic to the nuclear framework along these 
filaments (Quinlan & Knipe, 1983; Bibor-Hardy et al. 1985b). Nicholson et al., (1994) 
therefore suggested that preVP22a may mediate the binding of VP5 to the cytoskeleton.
Significant advances in the understanding of capsid morphogenisis have resulted 
from the assembly of HSV-1 capsids in insect cells using a panel of recombinant 
baculoviruses (Tatman et al., 1994; Thomsen et al., 1994). The six capsid protein genes 
encoding the seven proteins that make up the capsid (see Table 3) were each cloned into 
baculovirus expression vectors. Co-expression of these six genes in insect cells resulted in 
the formation of capsids that were indistinguishable in appearance and protein composition 
from those made during HSV-1 infection in mammalian cells. This demonstrated that the 
proteins encoded by the known capsid genes contained all of the structural information 
necessary for capsid assembly and that other virus-encoded proteins are not required for this 
process. In addition, omission of single recombinant baculoviruses from the system 
allowed the role of individual HSV-1 proteins in capsid assembly to be determined. VP23, 
VP5 and VP19C were all shown to be essential for the assembly of capsids, while VP26 
had no apparent effect on capsid formation. Omitting baculovirus recombinants that express 
either the UL26 or UL26.5 gene products did not prevent the formation of capsids. 
Moerover, omission of the UL26 gene product resulted in the appearance of large cored B 
capsids similar to those produced by the virus mutant te l201. Removal of both UL26 and 
UL26.5 products precluded the formation of closed capsid shells. It had been previously 
documented that cleavage of UL26 and UL26.5 is not essential for the assembly of capsids, 
but is essential for the encapsidation of viral DNA (Preston et al., 1983; Gao et al., 1994). 
However, recent work done by Kennard et al., (1995) showed that when cells were multiply 
infected with baculoviruses expressing truncated forms of the UL26.5 gene product
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corresponding to VP22a, and the essential components of the capsid shell, no capsids were 
detected, whereas large numbers of capsids were observed when the full length preVP22a 
was used as a scaffold. These results suggested that the C-terminal 25 amino acids of 
preVP22a may be directly involved in the assembly of capsids. In addition, 
coimmunoprecipitatation of VP5 with preVP22a, requires the C-terminal 25 amino acids of 
the protein (Thomsen et al., 1995).
Studies by Newcomb et al. (1994) showed that HSV-1 capsids could be assembled 
spontaneously in a cell-free system consisting of extracts prepared from insect cells that had 
been infected with recombinant baculoviruses encoding HSV-1 capsid proteins. These 
capsids resembled native HSV-1 capsids in terms of morphology, sedimentation rate on 
sucrose density, and their ability to react with antibodies specific for VP5. However the 
cavity of these capsids appeared to be empty, and there was no evidence for the large mass 
of preVP22a. In common with the capsids produced in insect cells, capsid fromation in 
vitro required the presence of VP5, VP 19, VP23, preVP22a and the mature form of the 
UL26 encoded protease, but not VP26.
(iii) A and C capsids
B capsids are believed to be the precursors of C capsids and probably of A capsids 
(Perdue et al., 1976; Preston et al., 1983). Formation of C capsids is the result of DNA 
packaging which is accompanied by the removal of the internal scaffold and an associated 
loss of the proteins VP21 and VP22a, while the generation of A capsids is believed to be a 
consequence of abortive packaging. Apart from the UL26 and UL26.5 gene products the 
genesis of mature DNA-containing C capsids during infection requires a range of proteins 
involved in the cleavage and encapsidation of viral DNA. These include the gene products 
of UL28 (Addison et a l., 1984, 1990; Tengelsen et al., 1993), UL33 (Al-Kobaisi eta l.,
1991) and UL6 (Sherman & Bachenheimer, 1987; Patel & MacLean, 1994) since ts mutants 
defective in DNA packaging have been identified with lesions in each of these genes. An 
alkaline nuclease deficient mutant virus, generated by inserting a lacZ gene cassette into the 
UL12 gene (W eller et al., 1990) was found to be unable to produce infectious virions 
suggesting that the nuclease may play a role in processing or packaging of viral DNA into 
virions (S haoera/., 1993).
Major advances have recently been made towards understanding the structure of the 
virion core. Due to the preparation techniques of viruses for electron microscopy it was 
thought that the core consisted of a cylindrical protein plug around which the viral DNA was 
wound (Furlong et al., 1972). However, Booy et al., (1991) using cryo-electron 
microscopy in combination with computer filtration to avoid interference from the capsid
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Figure 5. Structure of the HSV-1 a sequence. The a sequence is flanked by the DR1 
repeats and contains an internal series of repeated sequences (DR2). The Ub and Uc regions 
compose the non-repeated regions and contain the pac 1 and pac2 sequences respectively.
Ub Uc
DR1 DR2 DR1
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shell, have since shown that the viral genome is packaged as a uniformly dense ball of 
DNA.
Section 3. Packaging of viral DNA
Following replication of the viral genome, DNA is packaged into preformed capsids 
via a mechanism still not fully understood. Prior to, or during the packaging process, 
cleavage of the concatomeric HSV-1 DNA results in unit length genomes being packaged. 
Although DNA molecules shorter than genome length are packaged, only capsids containing 
full-length genomes are enveloped (Vlazny et a l ., 1982). Sequences responsible for 
packaging and the resolution of monomeric HSV-1 genomes from the concatomeric 
replicative intermediate (Spaete & Frenkel, 1982; Stow & McMonagle, 1983; Stow et al., 
1983) reside in the a sequences at the termini of the genome, and at the junction between the 
L and S segments. Multiple a sequences are usually evident at the L/S junction and at the 
terminus of the L segment, while a single copy is present at the terminus of the S segment 
(Wagner & Summers, 1978). The a sequence (illustrated in Fig. 5) is approximately 250- 
500bp in length, depending on the number of internal repeats (DR2) present (Roizman, 
1979). The direct repeats (DR1) that flank the a sequence are 20bp in length. The regions 
flanking the internal repeats are termed Ub and Uc and contain cis -acting elements (pac 1 
and pac2) that direct cleavage and packaging (Deiss et al., 1986; Varmuza & Smiley, 1985). 
P a d  and pac2 elements are distinct in nucleotide sequence but both direct the cleavage of the 
genome at defined distances within the same positions of the flanking DR1 repeats: 40-47bp 
from p a d  and 30-35bp from the pac2 sequence. The a sequences of different HSV-1 
isolates are not identical except for the p a d  and pac2 elements that are located in similar 
positions relative to the site of cleavage. The m echanism  by which viral DNA is 
cleaved and packaged into capsids is not understood, however the available evidence 
suggests that both processes are intimately linked. The model that has emerged proposes 
that empty capsids scan concatomeric DNA until contact is made in a specific orientation 
with a pac2 sequence or a DNA/protein complex at a pac2 site. In support of the formation 
of a complex, two virus-induced proteins of >250KDa and 140KDa bind in a sequence 
specific manner to pac2 sequences (Chou & Roizman, 1989). The >250KDa species 
corresponds to the tegument protein VP1 but the 140KDa protein has not been identified. 
Following recognition, cleavage within DR1 occurs. Since cleaved DNA is nuclease 
resistant, it is considered that cleavage and the initiation of the packaging processes are 
coincident (Deiss & Frenkel, 1986). DNA is then packaged until a second a sequence in the 
same orientation and one genome length from the first a sequence is encountered. A second 
cleavage event then occurs to produce unit length DNA. Cleavage occurs at staggered sites
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Table 4. HS V tegument proteins and their functions.
protein Gene Function status
VP1
vhs
VP 16
VP22
UL11
UL13
UL36
UL37
UL41
VP11/12 UL46
VP 13/14 UL47
UL48
UL49
US3
US9 
US 11 
Vm wl 75 RSI
Vm wl 10 RL2
2 myristilated protein products found in 
light particles, thought to be tegument proteins 
Protein kinase
Very large tegument protein, responsible for 
the release of viral DNA from capsids at nuclear 
pores
Tegument phosphoprotein, function unknown, 
may have DNA binding role, binds to ICP8 
Virion host shutoff (vhs) limits the expression 
of both viral and host cell genes by destabilising 
mRNAs
major structural component of the tegument, 
fuction unclear
Proteins that act to enhance VP 16 mediated 
transactivation
Major structural tegument protein and immediate-
early gene transactivator
Major structural component, function unknown
Protein kinase that post-translationally modifies
the UL34 gene product
10K protein of unknown function
RNA binding activity
Only found in L-particles. Major transinducer of 
HSV genes. Mutifunctional protein that participates 
in the formation of complexes with the promoter 
regions of many early and late genes 
Transactivator of early and late genes. Found in the 
nucleus of infected cells, strong synergy with 
V m w l75
ne
ne
ne
ne
ne
ne
ne
ne
ne/e
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in the genome and therefore in order to maintain the integrity of the ends of the genome, it is 
suggested that gap repair is performed following cleavage (Deiss & Frenkel, 1986).
The electron-opaque amorphous region surrounding the capsid known as the 
tegument accounts for approximately 65% of the volume of the virion (Schrag et al., 1989). 
Polypeptides assigned to the tegument were traditionally those that could not be designated 
as being present in either the capsid or envelope. Therefore the composition of the tegument 
is less well defined than for the capsid or the envelope. To date there are fourteen genes 
known to encode tegument proteins. Table 4 summarises the polypeptides assigned to the 
tegument, their functions if known and whether or not they are essential components of the 
virus particle.
Unlike the capsid and envelope proteins which have different but widely used 
standard nomenclatures (VP(x), for capsid and g(x) for the envelope), no standard system 
exists for designating tegum ent proteins. M ost workers in the field use the VP 
nomenclature where possible, but many species identified as structural components were not 
described in the original publication (Heine et al., 1974). As a consequence, although the 
major and some minor structural species have been assigned a VP number, some proteins 
have no such assignment and for others the VP designation is obscure. For descriptive 
purposes therefore, the VP nomenclature system will be used wherever possible while for 
those which do not have a well documented VP assignment, the protein will be described 
according to gene number designation. The exception to this is the UL41 gene product 
which will be referred to as the vhs protein. Since there is no accepted systematic method 
for describing the tegument proteins, the following sections classify them according to their 
abundance in the virion. Therefore proteins which have a copy number of greater than 1000 
per virion will be listed as major components while those present at less than 1000 copies 
will be designated minor components.
UL46 encodes two proteins, V P11 and VP 12, and combined there are an estimated 
1300 copies of these proteins per virion (Zhang & McKnight, 1993). V P11 and VP 12 have 
apparent molecular weights, on denaturing polyacrylamide gels, of 93KDa and 87KDa 
respectively. These are thought to be two differently phosphorylated forms of the same
Section 4. The Tegument
(i) Major components of the tegument
(a) VP11 and VP12
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primary translation product since the predicted phosphorylation sites in the translated-DNA 
sequence result in proteins of these sizes (McGeoch et al., 1988b; Bairoch, 1991). The 
abundance of VP 11/12 in the virion would perhaps imply that these proteins had important 
structural roles, however deletion mutants lacking the UL46 gene have shown that VP 11/12 
are not essential for viral growth or assembly in cell culture (Zhang et al., 1991).
From transfection studies, the UL46 gene products were reported to be involved in 
VP16-mediated transcriptional activation, its presence acting to enhance the induction by 
VP 16 of a TK reporter construct 2- to 3-fold in transient expression assays (McKnight et al., 
1987; Zhang et al., 1991). In contrast to these results however, characterisation of a UL46 
deletion mutant virus indicates that the UL46 gene products have no apparent effect on the 
ability of VP 16 to induce a TK reporter gene in cells transformed with a construct which 
expresses TK under the control of an EE promoter (Zhang et al., 1991). Despite the lack of
any apparent effect on IE synthesis, a TK+ variant of this mutant exhibits a 2 hour delay in 
the expression of the viral thymidine kinase gene at early times post-infection (Zhang & 
McKnight, 1993).
(b) VP13 and VP14
UL47 was shown to encode proteins VP 13 and VP 14, which have similar apparent 
molecular weights of 81KDa and 82KDa, using an antisera raised against a synthetic 
oligopeptide corresponding to the predicted protein product of the UL47 gene (McLean et 
al., 1990). There is a combined total of approximately 1800 copies of VP13 and VP 14 per 
vims particle (Heine et al., 1974; Zhang & McKnight, 1993). Similar to V P11/12 the two 
products of UL47 are thought to be a result of post-translational modifications which include 
phosphorylation, glycosylation (McLean et al., 1990; Meredith etal., 1991; Whittaker et al.,
1991) and nucleotidylylation (Blaho et al., 1994). In addition, a second in-frame initiation 
codon, 99bp down-stream from the predicted translational start site of UL47 could 
contribute to the production of the two forms (McKnight et al., 1987; McLean et al., 1990; 
Meredith etal., 1991).
Similar to V P11/12, the high copy number of VP13/14 in the virion may imply that 
these proteins have important structural roles, however UL47 deletion mutant viruses have 
shown that these proteins are not essential for viral growth in cell culture and are not required 
for viral assembly (Zhang et al., 1991). As is the case for V P11/12, a role for VP13/14 in 
modulating the ability of VP 16 to enhance IE transcription has been suggested, however 
conflicting evidence exists as to whether VP13/14 stimulates or represses VP16 activity 
(McKnight et al., 1987; Zhang et al., 1991; Zhang & McKnight, 1993). From transfection
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studies, the UL47 gene product(s) appears to reduce the levels of VP16-mediated induction 
by 2 to 3-fold in transient expression assays, and this effect is seen either in the presence or
the absence of expression of the UL46 gene (Zhang & McKnight 1993). By contrast, TK" 
virus in which UL47 is deleted induces lower levels of TK activity in cells transformed with 
a construct which expresses TK under the control of an IE promoter. In addition, a TK+ 
variant of this mutant exhibits delayed expression (delayed by 2 hours) of viral TK activity 
in infected cells (Zhang & McKnight 1993). At present, the conflict in these data remain 
unresolved and the precise function of VP 13/14 is unclear.
(c) VP 16
VP 16, the product of gene UL48, is one of the most abundant tegument proteins 
with approximately 1647 copies per virus particle (Zhang & McKnight, 1993). It functions 
not only as a major transactivator of EE genes (see Introduction; Chapter 3, Section 3.3.a) 
but is also essential for the assembly of the virus particle (Weinheimer et al., 1992). The 
construction of a number of VP 16 mutants containing oligonucleotide insertions along the 
length of the UL48 ORF showed that the structural requirements of VP 16 for transcription 
activation and virion assembly differ (Ace et al., 1989). For example, a series of seventeen 
mutants each containing a 12bp insertion at sites spanning the UL48 ORF identified regions 
of the protein which were important for virion assembly but not for transinduction. 
Insertions at amino acid positions 79 and 244 disrupted the assembly process of the 
resulting virus mutants and on superinfection the mutants containing these insertions were 
not able to complement the defect exhibited by ts2203, which has a mutation that maps to 
the 5' end of UL48 and is defective in DNA packaging and virus assembly. On the other 
hand, insertions at amino acid positions 172, 177 and 379 disrupted the ability of the protein 
to form the IE initiaton complex, but these mutants were able to complement ts2203 on 
superinfection.
(d) VP22
VP22 is encoded by UL49 (Elliot & Meredith, 1992) and is a major structural 
component, with an estimated average of 1590 copies per virion (Heine et al., 1974). VP22 
is extensively post-translationally modified. It is highly phosphorylated, ADP-ribosylated 
(Preston & Notarianni, 1983), nucleotidylylated (Blaho et al., 1994), and may also be 
glycosylated (M eredith et a l., 1991). The functions of A D P-ribosylation and 
nucleotidylylation in HSV replication are not known but in other cases these modifications
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are often seen in proteins with regulatory functions. For example, ADP-ribosylation is a 
characteristic feature of G proteins involved in intracellular signalling (Goldman etal., 1981; 
Goding et al., 1983). VP22 has been shown via indirect immunoflourescence studies to 
have a perinuclear localisation (Elliot & Meredith, 1992). An association with the nuclear 
matrix during the virus replication cycle in addition to the fact that the protein is able to bind 
to HSV DNA (Blair & Honess, 1983), might suggest that VP22 has a regulatory role in 
gene transcription. Although the function of VP22 and whether it is required for viral 
growth have not been elucidated, it has recently been shown that VP22 exhibits a strong and 
stable interaction with VP 16. In addition, co-expression of these proteins in infected cells 
results in the relocalization of both proteins from their normal sites to a novel structures 
situated at the edge of the nucleus and the interaction was dependant on presence of the 
VP 16 activation domain (Elliot et al., 1995). These results suggest that VP22 may have a 
role in the regulation of VP 16 function, or that the interaction is important for the 
condensation of tegument proteins during the assembly of the virus particle. The major part 
of this thesis investigates the structural properties of VP22.
(ii) Minor components of the tegument
(a) VP1
VP1 is a 270KDa protein encoded by UL36 that is present at levels of less than 150 
copies per virion (Heine et al., 1974). The apparent molecular weight of 270KDa is a 
significant underestimate of the predicted molecular weight which is 336KDa. On the basis 
of reactivity of oligopeptide antisera raised against the N- and C-terminal portions of the 
protein, the cell- and virion-associated 270KDa form of VP1 appears to represent full-length 
UL36 gene product that is synthesised in a mature form and is not N- or C-terminally 
cleaved (McNabb & Courtney, 1992a and 1992b). Studies indicate that VP1 is transcribed 
as a true late protein, its synthesis being dependent on viral DNA replication (McNabb & 
Courtney, 1992a) and it is phosphorylated by a tegument-associated protein kinase 
(Lemaster & Roizman, 1980). Indirect immunoflourescence has shown that VP1 is 
diffusely distributed throughout the infected cell with no specific compartmentalisation of the 
polypeptide (M cNabb & Courtney, 1992a). VP1 appears to interact tightly with 
nucleocapsids (Campadelli-Fiume et al., 1991) and a complex between VP1 and another 
unknown 140KDa protein (Chou & Roizman, 1989) is capable of binding to the a sequence 
of the genome (see Chapter 4; Introduction, Section 5; Chou & Roizman, 1989). Since a 
sequences are required for the cleavage and packaging of viral DNA into capsids VP1 may 
be involved in these processes, as well as the release of DNA from the capsid (Batterson et
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al., 1983). Evidence supporting this comes from a temperature sensitive mutant, tsB7, 
which contains a disruption in UL36. Following infection with this mutant, newly-formed 
capsids accumulate at nuclear pores and fail to release viral DNA at the non-permissive 
temperature (Batterson etal., 1983).
(b) UL37
Studies on the UL37 gene product have shown that it encodes a protein with an 
apparent molecular weight of 120KDa which is phosphorylated soon after translation 
(Shelton et al., 1990; Albright & Jenkins, 1993). UL37 is regulated as a late gene, its 
expression being dependent on the synthesis of viral DNA (Shelton et al., 1990). The 
protein co-elutes from single- and double-stranded DNA columns with the major DNA 
binding protein ICP8, leading to the suggestion that interaction between the UL37 protein 
and ICP8 accounts for the apparent DNA binding ability of the UL37 protein (Albright & 
Jenkins, 1993). Western blot analysis performed on detergent-treated virus particles in order 
to remove the envelope proteins demonstrated that the UL37 protein is a structural 
component of the tegument (McLauchlan e ta l.,  1995; Schmitz et al., 1995). Indirect 
immunoflourescence studies have shown that the UL37 encoded protein is distributed 
throughout the infected cell, with concentrations being greater in the cytoplasm than in the 
nucleus (McLauchlan etal., 1995).
(c) UL41
UL41 encodes a virion host shutoff function commonly referred to as the vhs 
protein. It is present as a minor component of the tegument and its activity within the 
infected cell, like the UL46, UL47 and UL48 gene products, does not require de novo 
synthesis. An HSV-1 mutant, vhsl, selected on the basis of its inability to suppress host 
protein synthesis was subsequently shown to be defective at inducing accelerated turnover of 
host mRNAs (Read & Frenkel, 1983; Kwong & Frenkel, 1987; Strom & Frenkel, 1987). 
Marker rescue experiments mapped the vhsl mutation to gene UL41 (Kwong et al., 1988), 
and the vhs protein encoded by UL41 was subsequently characterised by Smibert et al. 
(1992). vhs accumulates late in infection and is packaged into the tegument as a minor 
component (McLauchlan et al., 1992a; Smibert et al., 1992). It is not essential for virus 
replication in tissue culture (Fenwick & Everett, 1990b; Read & Frenkel, 1983).
vhs acts with little or no specificity and causes the degradation of cellular mRNA as 
well as viral mRNA (Kwong eta l., 1988; Oroskar & Read, 1989; Read etal., 1993). The 
degradation of mRNAs occurs via 3'-5' exonuclease digestion, and cellular polyribosomes
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are also disaggregated (Nishioka & Silverstein, 1977 and 1978; Fenwick & Walker, 1978; 
Fenwick & M cM enamin, 1984). In order to prevent the nonspecific activity of vhs 
inhibiting viral protein synthesis, one or more newly synthesised viral proteins apparently 
reduce the vhs activity of the infecting virion, thereby allowing the accumulation of viral 
mRNA (Fenwick & Owen, 1988; Fenwick & Everett, 1990a and 1990b). ICP8 has been 
suggested to be a mRNA stabilising factor because an ICP8 ts mutant, te l3, accumulated 
significantly less V m w l75 mRNA than wild type virus (Godowski & Knipe, 1983). 
Recent studies which were performed in order to clarify the role of vhs in the shut-off 
process assayed the effect of vhs in the absence of other HSV proteins on the expression of 
LacZ  reporter gene, vhs strongly suppressed the expression of the co-transfected LacZ  
reporter gene and this effect was eliminated by the vhs 1 point mutation that abolishes virion- 
induced host shutoff during HSV infection (Jones et al., 1995). Therefore the vhs protein 
can induce virion host shutoff in the absence of other viral proteins. Further studies by this 
group involved the identification of functional subdomains within the vhs polypeptide 
following the insertion of linker sequences along the length of UL41. These studies 
identified a minimum of three mutationally sensitive regions that corresponded to regions of 
high homology within vhs (Jones et al., 1995).
Two forms of the vhs polypeptide exist in cells infected with wild type HSV-1; a 
58KDa polypeptide and a less abundant 59.5KDa form of the protein (Smibert et al., 1992). 
Both proteins are phosphorylated and the different mobilities in gels are due to the extent of 
phosphorylation. While both forms are found in infected cells only the 58KDa form of the 
protein is incorporated into virus particles (Smibert et al., 1992). The post-translational 
processing of vhs therefore appears to affect the incorporation of the protein into the 
herpesvirus particle (Read etal., 1993).
Smibert et al. (1994) demonstrated that vhs forms a complex with VP 16, and the 
VP 16 acidic domain is not required. A 21 amino acid domain spanning residues 310-330 of 
vhs has recently been identified as being responsible for the interaction (Schmelter et al., 
1996). Using gel retardation assays, vhs was shown to block the ability of VP 16 to enter the 
multi-protein complex on the TAATGARATTC element, indicating that vhs interacts with 
one or more of the regions on Vmw65 required for promoter recognition (Smibert et al. 
1994). One possible functional significance of this interaction could be that VP 16 may be 
involved in the incorporation of vhs into the virion. In support of this, a mutant vhs protein 
lacking residues 149 to 344 that cannot bind to VP 16 is not packaged into virus particles 
(R ead et al., 1993). It is also thought likely that VP16 modulates vhs function by 
sequestering newly synthesised vhs protein into the virion assembly pathway. In support of 
this, a VP 16 null mutant initiates infection normally but the undergoes a dramatic decline in
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viral protein synthesis at intermediate and late times post infection (Weinheimer et al.,
1992).
(d) US3
Protein kinase (PK) activity is present in HSV-1 virions and from analysis of the 
predicted products encoded by HSV-1, US3 and UL13 were proposed to encode protein 
kinases on the basis of amino acid sequence motifs (McGeoch & Davison, 1986; McGeoch 
et al., 1988; Smith & Smith, 1989). The US3 PK has been identified as an enzyme present 
in the cytoplasm of infected cells (Purves et al., 1986; Frame et al., 1987; Zhang et al.,
1990). US3-defective mutants have been isolated, and it is reported that although 
inactivation of the gene has little effect on the growth of the virus in tissue culture, US3- 
defective virus is markedly impaired for growth in murine brain (Longnecker & Roizman, 
1987; Meignier et al., 1988). The US3 PK has been purified, and exists as a dimer 
consisting of two 68KDa subunits, and although its physiological role remains obscure, it 
has been demonstrated to phosphorylate a virion protein encoded by UL34 which may lie in 
the envelope (Purves eta l., 1986 and 1991). This may suggest that the US3 PK is present 
in virus particles, but to date, the protein has not been formally characterised as a structural 
protein.
(e) UL13
Cunningham et al. (1992) identified a 57KDa protein encoded by UL13 as a virion 
component, and correlated it with a novel kinase activity present in the nuclei of infected 
cells. Detergent treatment of purified virions subsequently identified the UL13 encoded 
polypeptide to be a component of the tegument (Coulter et al., 1993). Purves & Roizman 
(1992) reported that the substrate of the UL13 PK is the regulatory protein Vmw68, 
however several other proteins including VP22 are phosphorylated by the kinase in vitro 
(Coulter et al., 1993). Due to the abundance of the UL13-encoded PK, and also the presence 
of homologues in all the genomes of mammalian herpesviruses sequenced to date (van Zijl 
et al., 1990) it is reasonable to suggest that it may play a significant role in herpesvirus 
infection. However, the disruption of the UL13 PK by the insertion of lacZ sequences 
demonstrated that it was not essential for growth of the virus in tissue culure (Coulter et al.,
1993). The growth of the \JL\3~lacZ  mutant virus was only slightly impaired compared to 
wild type HSV-1 and following intracranial inoculation in mice the pathogenicity of the 
mutant was only slightly reduced (Robertson, Coulter & MacLean, unpublished data) 
Recent data also suggests that UL13 may be involved in virion-induced shutoff. A viral
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mutant with an inactivating lesion in UL13 displays a vhs null phenotype, even though the 
mutant contains normal amounts of vhs protein (Overton et al., 1994).
(f) U L ll
UL11 encodes a family of myristylated polypeptides which are located in the 
tegument, the sizes of which range in molecular weight from 13K to 16K (MacLean et al.,
1992). Prelim enary pulse-labelling experiments suggest that these polypeptides are 
expressed at delayed early times in infection, and are phosphorylated in vitro (MacLean et 
al., 1989). Following sub-cellular fractionation of infected cells, they are found 
predominantly associated with membranes. The gene is not essential for growth in cell 
culture, but the growth of the deletion mutant is impaired and plaques are smaller than wild 
type HSV-1, suggesting a requirement for the protein for efficient replication (MacLean et 
al., 1992).
(g) US9
The lOKDa protein encoded by US9 is extensively post-translationally modified by 
phosphorylation, such that at least 12 electrophoretically distinct forms can be detected 
(Frame et al., 1986b). The lower molecular weight forms are thought to be present in the 
tegument, due to their absence in the capsid and envelope. The phosphoprotein is not 
essential, and its function is unknown (Frame et al., 1986b).
■9
(h) US 11
The protein product of US 11 was first identified using hybrid arrest of translation by 
Rixon & McGeoch (1984) and was shown to be a protein of 21KDa that localizes in the 
nucleoli of infected cells (MacLean et al., 1987). Subsequently using an antiserum raised 
against the US 11 polypeptide sequence Johnson et al. (1986) showed that the US 11 protein 
was a doublet of 21 to 22KDa. The protein is a site- and conformation-specific RNA- 
binding protein (Roller & Roizman, 1990), that has been shown to negatively regulate the 
abundance of a viral RNA called A34 in infected cells. US 11 binds in vitro to a specific 
sequence at or near to the 3 ’terminus of A34 RNA (Roller & Roizman, 1991). It is reported 
that virus particles contain 600 to 1000 copies per virion and that the protein associates 
specifically with the 60S subunit of ribosomes (Roller & Roizman, 1992). In addition, a cell 
line expressing U S 1 1 has been shown to be resistant to HSV-1 infection at a step in viral
entry mediated by gD (Roller & Roizman, 1994).
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Figure 6. Proposed pathways for virion egress. In both of the proposed maturation 
pathways (see text for details), the initial step involves the capsid budding through the inner 
nuclear membrane (gaining an envelope in the process) and the final stages involve passage 
through cytoplasmic (Golgi derived) vesicles and release of mature virions from the cell by 
exocytosis. Differences between the models centre on whether the final virion envelope is 
derived from the inner nuclear membrane (b) or from a cytoplasmic membrane (a), and on 
whether tegumentation takes place in the cytoplasm (a) or in the nucleus (b).
(a)
Nucleus Cytoplasm
yJ )  Tegument 
V proteins
(b)
Nucleus Cytoplasm
Tegument
proteins
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(i) Other minor components of the tegument
Other minor components of the tegument include the immediate early regulatory 
proteins V m w l75, Vmwl 10, Vmw68 and Vmw63. The functions of these proteins are 
described in chapter 3, section 2(iii) (a) to (e). It is not known whether these proteins have 
any significant roles in the structure or assembly of the tegument. In addition, the products 
of UL21 (Baines et al., 1994) and UL25 (Wood, 1993), reside in the tegument. UL21 
encodes a protein of unknown function that is not essential for viral replication (Baines et al.,
1994). UL25 encodes an essential gene product of 67KDa. The construction of ts mutants 
with lesions in the UL25 gene, and the tight association of the protein with the capsid 
suggest that it may play a role in DNA packaging and virion maturation (Addison et al., 
1984; Wood, 1993; Ali e t a l 1996).
(iii) Tegument Assembly
Very little is known about the route by which nucleocapsids obtain tegument. Most 
of the information regarding these events has come from electron microscopy of infected 
cells, and the order in which these steps occur is not clear. The first stage involves the 
budding of the capsid through the inner nuclear membrane, which is unusual as under 
normal conditions the passage of materials into and out of the nucleus takes place 
exclusively via nuclear pores (Rixon, 1993). There is no information regarding either the 
mechanism by which the mature DNA-containing capsids induce membrane budding, or the 
trigger which initiates the journey of the capsids through the cell.
Two models have been proposed (Rixon, 1993) for the route taken by virions 
through the perinuclear cistemae (Fig. 6). In the first, the newly acquired envelope, derived 
from the inner membrane, fuses with the outer membrane or with the contiguous 
endoplasmic reticular membrane, releasing the capsid into the cytoplasm. Final 
envelopment then occurs by budding through a cytoplasmic membrane. In the second 
model, the envelope gained at the inner nuclear membrane is retained and virions leave the 
perinuclear cistemae in a vacuole formed from the outer nuclear membrane. Both models 
propose that the Golgi complex is involved in maturation of the virion and that the mature 
virion finally leaves the cell by exocytosis from Golgi-derived vesicles.
Strong evidence for the first pathway, ie. that tegumentation may take place in the 
cytoplasm, comes from studies on HCMV and HHV-6. In both of these viruses, the 
tegument is a dense structure which can be easily seen in electron micrographs. Cells 
infected with HCMV are seen to have capsids, present in the cytoplasm, which appear to be 
surrounded by tegument but which are clearly not enveloped (Duyckinck Smith & de
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Harven 1973). Electron microscopic evidence suggests that these structures become 
enveloped by budding through cytoplasmic membranes. In addition, EM studies on HHV- 
6 have identified specific regions within the infected cells which appear to be invaginations 
of the cytoplasm into the nucleus, termed tegusomes (Roffman et al., 1990). The EM data 
suggest that maturing capsids gain an envelope at the inner nuclear membrane, which is then 
lost during fusion with the outer nuclear membrane, and the naked capsids are released into 
the tegusome where assembly of the tegument surrounding the capsid takes place. Final 
envelopment then occurs by budding into cytoplasmic vacuoles.
Further evidence for a cytoplasmic envelopment step comes from the treatment of 
cells with the metabolic inhibitor, brefeldin A (BFA). BFA disrupts Golgi function and 
leads to the accumulation of unenveloped capsids in the cytoplasm of infected cells (Whealy 
et a l ., 1991). Thus, BFA may block a cytoplasmic envelopm ent step, but other 
interpretations are also possible.
The evidence obtained by electron microscopy for the maturation of HSV-1 particles 
is not dissimilar to that for HHV-6, although a tegusome-like compartment has not been 
implicated. In addition, in HSV-1 the tegument cannot be resolved in micrographs. The 
presence of non-enveloped capsids in the cytoplasm is a consistent feature of infected cells 
and the apparent budding into cytoplasmic vacuoles is frequently observed (Nii et al., 1968). 
These observations suggest a possible cytoplasmic site for tegumentation. An alternative 
explanation, that cytoplasmic capsids represent terminally de-enveloped virions has been 
suggested (Campadelli-Fiume et al., 1991). This is based on the observation that the 
presence of gD in cell membranes appears to inhibit fusion with the virion envelope and thus 
prevents virus from reentering infected cells. The origin of cytoplasmic capsids was 
examined using an HSV-1 mutant with an alteration in gD which allows it to overcome this 
block (Campadelli-Fiume et a l., 1991). The mutant accumulates large numbers of 
unenveloped capsids in the cytoplasm of infected cells and this was interpreted as a result of 
fusion of cellular membranes with the envelopes of exiting virions passing through the 
cytoplasm.
In order to conclusively distinguish between whether tegumentation occcurs in the 
cytoplasm versus the inner nuclear membrane, the location at which one or more of the 
tegument proteins is added to the capsid structure would have to be directly ascertained.
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Section 5.The Envelope
The envelope surrounding the tegument consists of a lipid membrane (Asher et al., 
1969; Ben-Porat & Kaplan, 1971) with glycoprotein spikes of 8-10nm projecting from its 
outer surface (Wildy et al., 1960; Stannard et al., 1987). The envelope is host cell derived 
but modified by the presence of viral proteins. The phospholipid composition of the viral 
envelope is similar to that of the nuclear membrane except that it contains three times the 
concentrations of sphingomyelin and phosphatidylserine, which are lipids that are typically 
enriched in the Golgi apparatus and the plasma membrane (Campadelli-Fiume et al., 1993; 
Van Genderen et al., 1994). The concentrations of these lipids within the viral envelope 
provide evidence that after budding through the innner nuclear membrane, the virus particle 
loses its envelope by fusing with the outer nuclear membrane and obtains a new membrane 
by budding into a compartment late in the endocytic pathway, likely to be the Golgi 
apparatus or membranes derived from it (Van Genderen et al., 1994). The precise number 
of virally encoded glycoproteins present on the envelope of virions is not yet known. To 
date eleven membrane glycoproteins specified by HSV-1 have been identified: gB, gC, gD, 
gE, gG, gH, gl, gJ, gK, gL and gM (Buckmaster et al., 1984; Spear, 1985; Longnecker & 
Roizman, 1987; Roizman & Sears, 1990; Hutchinson et al., 1991 and 1992; Baines & 
Roizman, 1993).
Stannard et al. (1987) provided evidence that the three major HSV-1 glycoproteins 
(gB, gC and gD) are present in three distinct structures projecting from the virion envelope. 
The gC-containing structures are long and slender, while those containing gB or gD are 
shorter. gB seems to be clustered, whereas gC is randomly scattered. gB forms heat stable 
oligomers, and at least some of them are homodimers (Claesson-Welsh & Spear, 1986). 
Two sets of heterodimers have been identified; gE and gl forming the Fc receptor, and also 
gH and gL (see Chapter 3; Introduction, Section 1). The products of genes UL10, UL20,
■
UL34, UL53 and UL49A may also be associated with the virion envelope as they all have 
hydrophobic regions which could be membrane spanning domains (McGeoch et al., 1988; 
Barnett et al., 1992). In addition, UL45 encodes an 18KDa structural protein associated with 
the viral envelope (Visalli & Brandt, 1993) that is not essential for growth of the virus 
(Vissalli & Brandt, 1991).■
There is evidence for both N and O-linked glycosylation on gB, gC, gD and gE 
(Pizer et al., 1980; Serafini-Cessi & Campadelli-Fiume, 1981; Person et al., 1982; Wenske 
et al., 1982), and the differences in electrophoretic mobilities of mature and immature forms 
of each HSV-1 glycoprotein is due primarily to the presence of O-linked oligosaccharides on 
the mature forms (Johnson & Spear, 1983). All of the major H SV -1-induced glycoproteins 
are sulphated, gE being the most heavily labelled, and sulphation only occurs on the mature
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forms of the glycoproteins (Hope et al., 1982; Hope & Marsden, 1983). The biological role 
of sulphation is not clear but it may influence the polarity of the glycoprotein molecule which 
may be important for the orientation of the protein in the membrane. gE is also modified by 
the addition of fatty acids.
Little is known about the organisation and potential interaction of proteins in the 
tegument and envelope. Studies using chemical cross linking reagents were performed by 
Zhu & Courtney (1994) in order to determine the relationship between gB on the viral 
envelope and other virion proteins. Four structural proteins, thought to be tegument proteins 
were seen to be associated with gB, gD and gH, but not with gC. One of these four proteins 
was positively identified as VP 16 and the others were predicted to be V P11/12, VP 13/14 
and VP22 due to their apparent molecular weights.
Section 6.Non-infectious Particles
During productive infection, virus-related particles known as light-particles are 
released form infected cells in addition to virions. These particles were identified as a diffuse 
band of material which migrated above virions in ficoll gradients (Szilagyi & Cunningham,
1991). Electron microscopy of negatively stained preparations revealed that light-particles 
consisted of an outer envelope, with surface projections, enclosing tegument-like material, 
but lacking the nucleocapsid of virions. Comparison of polypeptide profiles confirmed that 
light-particles share most, if not all, membrane and tegument proteins with virions, but lack 
the capsid polypeptides. Moreover, analysis of [3H]thymidine-labelled particles suggested 
that viral DNA was absent from light-particles (Szilagyi & Cunningham, 1991). The lack of 
any nucleocapsid renders light-particles non-infectious. Also, light-particles contain a 
number of phosphopolypeptides with apparent molecular weights of 175KDa, 134KDa, 
92KDa, 60KDa and 55KDa not seen in virions (Szilagyi & Cunningham, 1991). The 
identity of the majority of these proteins are unclear however the 175KDa polypeptide has 
been shown to be the EE regulatory protein Vmwl75 (McLauchlan & Rixon 1992).
The processes which govern the genesis of light-particles during virus replication are 
not known. Studies with a ts mutant ( te l201) which has a lesion in gene UL26 and which 
fails to assemble infectious virions (see Chapter 4; Introduction, Section 2.3, Preston et al., 
1983, 1991), have revealed that light-particle production does not require the formation of 
mature virions (Rixon et al., 1992). These results implied that the signals controlling the 
condensation of tegument and the acquisition of an envelope are intrinsic to components of 
light-particles. In addition, although the tegument has no apparent regular structure, removal 
of the envelope from light-particles by detergent treatment does not disrupt the tegument.
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This suggests that the structural integrity of the tegument is independent of either capsid or 
envelope proteins (McLauchlan & Rixon, 1992).
To determine whether the polypeptides present in light-particles retained their 
function, two proteins, vhs and VP16 which are common to virions and light-particles, were 
assayed for biological activity (McLauchlan etal., 1992a). vhs activity was determined by 
measuring the decrease in host cell polypeptide synthesis following inoculation with a range 
of virions and light-particles in the presence of the RNA synthesis inhibitor, ara C. The data 
revealed that the reduction in protein synthesis brought about by vhs was equivalent for both 
virions and light-particles. To assay the activity of VP 16 in light-particles, a HSV-1 virus 
mutant m l814 which contains an insertion in the UL48 gene and as a consequence is a 
unable to initiate virus infection at low m ultiplicities of infection was used for 
complementation studies. The growth of m l814 in cells infected with the mutant can be 
stimulated by supplying in trans unmodified VP 16. Co-inoculation of cells with in 1814 and 
UV inactivated virions or light-particles showed that both types of particle were equally 
efficient at complementing growth of the mutant. Thus, the vhs and VP 16 proteins had 
comparable activities in virions and light-particles. Since the activities of these proteins were 
assayed in an intracellular environment these data would indicate that the processes of 
binding, fusion and penetration are similar for virions and light particles. Thus, light- 
particles are biologically competent and may be capable of influencing the early stages of 
virus infection.
Recent studies have identified another virus particle that is morphologically similar to 
light-particles but has a slightly altered protein composition (Dargan et al., 1995). These 
particles are produced in the presence of viral DNA replication inhibitors and have been 
termed pre-viral DNA replication enveloped particles (PREPs). They are deficient in gC 
and gD and also have reduced levels of VP1, VP13/14 and V P11/12, while the levels of 
VP22 are increased as compared to light-particles. While these differences are probably due 
to the inhibition of protein synthesis, the polypeptides within PREPs are biologically active 
(Dargan e ta l ,  1995).
Other alphaherpesviruses, including EHV-1 and PrV, also produce light-particles 
during productive infection of BHK cells (McLauchlan & Rixon 1992) The size 
morphology and quantity of light-partices produced by EHV-1 or PRV were largely 
indistinguishable from those produced by HSV-1. The betaherpesvirus HCMV has also 
been shown to generate two types of non-infectious particle known as dense bodies and non- 
infectious enveloped particles (NIEPs). Dense bodies are membrane bound electron dense 
particles which are considerably larger than HCMV virions. 90% of their mass is 
accounted for by the lower matrix protein pp65 which is encoded by gene UL83 (Irmiere &
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Gibson, 1983; Eggers et al., 1992). However, staining techniques have suggested that dense 
bodies contain DNA and RNA (Sevri et al., 1991). NIEPs contain all structural 
components of the HCMV virion, including the capsid, but lack DNA and resemble the 
enveloped empty capsids seen in preparations of HSV-1 virions (Schrag et al., 1989). 
Neither the functions of dense bodies nor of NIEPs are known, and the gene encoding pp65, 
which has no counterpart in HSV-1, is not essential for the growth of HCMV in tissue 
culture (Schmolke et al., 1995).
Section7. Maturation of Virions and Egress
H erpesviruses acquire their envelope by budding through a modified inner 
membrane of the nuclear envelope which forms thick and dense patches at the site of 
budding (Bibor-Hardy e ta l.,  1985a). This suggests that some of the viral envelope 
glycoproteins must be transported to the nuclear envelope in order to be incorporated into the 
virus. Labelling of glycoprotein gB indicated that it was uniformly distributed around the
J
inner and outer membranes of the nuclear envelope, and that nucleocapsids were only 
labelled with gB after association with the nuclear envelope (Gilbert & Gosh, 1993).
Following envelopm ent the virus is transported via the Golgi apparatus to the 
extracellular space. A mutant cell line, gro29, which is defective in protein secretion, is 
unable to release virions when infected with HSV-1, despite normal viral gene expression. 
These studies suggest that the secretory pathway is critical to HSV-1 release and that specific 
host cell factors facilitate viral egress from infected cells (Banfield & Tufaro, 1990). The 
inhibition of glycosylation, following the exposure of cells to monensin (Johnson & Spear, 
1982) or other late glycosylation inhibitors (Kousulas et al., 1983), prevents the maturation 
of glycoproteins and leads to a reduction in virus egress as well as an accumulation of 
virions in the cytoplasm. These results suggest that specific oligosaccharide moieties 
contribute to efficient viral maturation and egress (Campadelli-Fiume et al., 1982; Serafini-
1
Cessi et a l., 1983). For example, BFA which removes Golgi structure from cells and 
blocks the transport of proteins into post Golgi cellular compartments (Misumi et al., 1986), 
blocks the maturation and egress of HSV during infection (Cheung et al., 1991).
Thin section fracture label elelctron microscopy was used to investigate HSV-1 
envelopment and maturation (Torrisi e ta l., 1991). Results showed that the envelope 
acquired at the inner nuclear membrane contained the envelope glycoprotein precursors, and 
that during transit to the extracellular space maturation of the virion glycoproteins occurred. 
Evidence of virions within and associated with the Golgi apparatus suggested that the 
maturation of glycoproteins is facilitated by the Golgi enzymes. In Vero cells the efficient 
transport of HSV-1 to the perinuclear space and plaque formation requires the UL20 gene
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product (Baines et al., 1991). These results suggest that viral transport from the infected 
cell is an active function of the virus particle rather than a passive function where the cells 
export any macromolecules present within the lumen of transport vesicles unless specific 
sequences which cause them to be retained in the cell (Pelham, 1989).
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Section 1. Chemicals and Reagents
Ampicillin sodium B.P. (Penbritin) Beecham Research
Boric acid, Butanol, Acetic acid, 
Chloroform, Isopropanol, 
Methanol
Prolabo Rhone-Poulenc Ltd., 
Manchester, UK.
EDTA, NaCl, SDS, CaCl2, Glycine,
nonidet P40, Acrylamide, 
N,N’-methylenebis-acrylamide,
Sucrose, Formaldehyde, (3-mercaptoethanol
BDH Laboratory Supplies, Poole, UK.
Tris Boehringer Mannheim GmbH, Germany.
Gelatin, Ammonium Persulphate, TEMED, Bio-Rad Laboratories, Richmond,
California, USA.
Glycerol May & Baker Ltd., Dagenham, UK.
Tween 20, Protein A sepharose, Agarose, Sigma Chemicals Co. UK. 
Lysozyme, Ficoll 400
ECL development reagents Amersham International pic., 
Buckinghamshire, UK.
Kit for large scale plasmid preparation Qiagen plasmid kit, Qiagen GmbH,
Germany.
BHK-medium, newborn calf serum, 
Optim em  1
Life Technologies Ltd., Scotland.
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Caesium Chloride Koch Light Ltd. (Suffolk, England)
Section 2 . Solutions
Boiling mix
Denhardt’s buffer (5x) 
Destain
Eagles medium
electroelution buffer
ETC 10
Fix
Gel electrophoresis buffer 
Gel loading buffer 
Gel soak I
50mM Tris-HCl (pH6.7), 2% (w/v) SDS,
5% (w/v) p-mercaptoethanol, 10% (w/v)
Glycerol, 0.004% (w/v) Bromophenol blue
0.1 % (w/v) Ficoll, 0.1 % (w/v) 
polyvynylpyrollidone, 0.1% (w/v) BSA
5% methanol, 7% acetic acid
lOx Glasgows Modified Eagle’s medium 
(GMEM) was diluted to lx GMEM with sterile 
distilled H2O and supplemented with: 4mM L- 
glutamine, 0.26% sodium bicarbonate
20mM Tris-HCl pH 7.4, lOmM ammonium 
acetate, 2mM EDTA
Eagles medium supplemented with: 5% tryptose 
phosphate broth, 100pl/ml penicillin, lOOpl/ml 
streptomycin, 10% newborn calf serum (NBCS)
50% methanol, 7% acetic acid
52mM Tris, 53mM Glycine, 0.1% (w/v) SDS
5x TBE, 50% sucrose and 0.2% bromophenol blue
0.6M NaCl, 0.2M NaOH
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HBS
HEBS
Hybridisation buffer 
L-broth
Lysis solution 1
Lysis solution 2 
Lysis solution 3 
(5x) Ligation buffer
Na-Phosphate buffer
(10x) NT buffer
Phosphate buffered saline
2 x PK
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0.6M NaOH, 1.0M Tris-HCl pH8.0
20mM Hepes-NaOH (pH7.4), 150mM NaCl
137mM NaCl, 5mM KC1, 0.2mM NaH2P 0 4, 
9mM D-glucose, 21mM Hepes pH 7.05
6xSSC, lOx Denhardt’s solution 20mM Tris-HCl 
pH 7.5 ImM EDTA, 0.5p.g/ml denatured calf 
thymus DNA
170mM NaCl, 5g/l yeast extract, 10g/l Difco 
Bactotryptone.
50mM glucose, lOmM EDTA, 25mM Tris-HCl 
pH 8 containing freshly made lOmg/ml 
lysozyme.
0.2M NaOH, 1% SDS
5M potassium acetate pH 4.8
250mM Tris-HCl pH 7.6, 50mM M gCb,
5mM DTT, 5mM ATP, 25% (w/v) PEG 6000
A: Na2H P 04 2.84g/l
B: NaH2P 0 4 3 .12g/l Add A+B until pH=7.0
0.5M Tris-HCl pH 7.8, 0.05M MgCl2, lOmM 
Dithiothreitol (DTT)
(PBS) 170mM NaCl, 3.4mM KC1, lOmM Na2H P04 and 
2mM KH2P 0 4 pH 7.2
lOOmM Tris-HCl pH 8.0, 20mM EDTA,
50.
Pre-hybridisation buffer 
Regeneration Buffer 
Resolving gel buffer (RGB) 
Stop solution 
(lOx) SSC
Stacking gel buffer (SGB) 
STET
(lx) TBS
TTBS
TE
l OxTBE
Tris-saline
Trypsin
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20mM NaCl, 0.4% SDS
6x SSC, 5x Denhardt’s solution, 0.1% SDS, 
20fig/ml denatured calf thymus DNA
2% SDS, 50mM Tris-HCl pH 7.4, lOOmM 
P-mercaptoethanol
0.4M Tris-HCl pH8.9, 0.1% SDS
95% Formamide, 20mM EDTA, 0.05% 
bromophenol blue, 0.05% Xylene Cyanol FF
3M NaCl, 300mM tri-sodium citrate
0.1M Tris-HCl pH 6.7, 0.1% SDS
0.23M Sucrose, 9mM Tris-HCl pH 8.0, 
50mM EDTA, 10% Triton X-100
4mM Tris-HCl pH 7.5, 0 .1M NaCl
1 x TBS, 0.05% Tween 20
lOmM Tris-HCl pH 7.5, ImM EDTA
0.8M Tris, 0.3M boric acid, 0.2M EDTA
140mM NaCl, 30mM KC1, 28mM Na2H P 04, 
1 mg/ml glucose, lOOmg/ml streptomycin.
25mM Tris-HCl pH 7.4
0.25% (w/v) trypsin (Difco) in tris-saline, 
containing 0.002% (w/v) phenol red.
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Versene 0.6mM EDTA dissolved in PBS containing
0.002% (w/v) phenol red.
Western transfer buffer 25mM Tris pH 8.3, 192mM Glycine,
0.0375% SDS, 20% (v/v) methanol
Section 3.Plasmids
pGEM 1 Supplied by Promega, pGEM 1 is a 2.8Kbp plasmid that contains a poly
clonal linker sequence between T7 and SP6 promoter sequences. It also 
contains an ampicillin resistance gene.
pCATl pCATl was made by inserting a 960bp Hindlll fragment from pLW2
(Whitton, 1984) that contained the open reading frame that encodes 
the bacterial chloramphenicol acetyl transferase (CAT) gene into the 
H indlll site of pG EM l.
pFJ3 derived from the commercially available plasmid, pCHl 10 (Pharmacia), 
pFJ3 contains the (3-lactamase (Lac Z) gene linked to the simian virus 40 
(SV40) early promoter in a 4. lKbp sequence flanked by Xbal sites. In 
addition a polylinker was inserted into the BamHI site (Rixon & 
McLauchlan, 1990).
pTKl
pM Fl
pTKl was constructed by inserting the 3.6Kbp BamHI p fragment of 
HSV-1 strain 17 DNA into the BamHI site of pAT153, as described by 
Wilkie et al. (1979). BamHI p contains the HSV-1 thymidine kinase gene.
pMFl was constructed by inserting a SstI fragment containing the HSV-2 
strain G UL41 sequences into the SstI site of pTKl (Fenwick & Everett, 
1990)
pMJ37 pMJ37 was constructed by inserting a 750bp Sau3AI fragment containing
the HCMV immediate early promoter sequence into the BamHI site of 
pUC18 (kindly donated by Dr. C.M. Preston).
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pSAU30 Derived from pSAU3 (McLauchlan et al., 1989) pSAU30 contains an
oligonucleotide linker inserted at the SstI site of pSAU3. Insertion of this 
linker allows the removal of a 260bp DNA fragment containing the HSV-2 
UL38 polyadenylation sequences by digestion with Hindlll and BamHI.
pBluescript II SK(+/-) Supplied by Stratagene cloning systems, pBluescript is a 296lbp 
phagemid derived from pUC19. It contains a multiple cloning site 
between T3 and T7 promoter sequences.
Section 4.Viruses
1802 HSV-1 1802 contains a unique Xbal site located in the intergenic region
between US9 and US 10 (Rixon & McLauchlan, 1990). This site is located 
in BamHI fragment z.
vFJIO vFJIO is derived from HSV-1 1802 and contains the CAT gene within the
Us region of the genome under the control of the HSV-2 EE4/5 promoter and 
the EE5 polyadenylation site sequences (Rixon & McLauchlan, 1990).
vSAU3 vSAU3 is derived from HSV-1 1802 and contains the CAT open reading
frame within the Us region of the genome under the control of the UL40 
gene promoter and the HSV-2 UL38 polyadenylation site sequences 
(McLauchlan et al., 1989).
vl7G41 vl7G41 was constructed by inserting the HSV-2 strain G UL41 gene into
the TK locus of HSV-1 strain 17 (Fenwick & Everett, 1990a).
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All radioisotopes were supplied by Amersham International pic.. They had the following 
specific activities;
~3000Ci/mmol (lOp.Ci/p.1) 
5000Ci/mmol (lOpCi/pl) 
lOOOCi/mmol (10pCi/fil) 
800Ci/mmol (15|iCi/p.l) 
50-62Ci/mmol (25p.Ci/ml)
Section 6. Antibodies
5’[a -32P] dNTPs
5’[y.32p] adenosine triphosphate
[a-35S] deoxyadenosine thiotriphosphate
[a -35S]-L-methionine
t14C]-chloramphenicol
anti mouse IgG (whole molecule) 
peroxidase conjugated, anti mouse IgG 
(whole molecule) FITC conjugated
CAT rabbit polyclonal antibody
CMV monoclonal antibody.
Late nuclear protein (pp65)
LP-1 and CY8 monoclonal antibodies
Sigma Chemicals Co., U.K.
5 Prime 3 Prime Inc.
DuPont (UK) Ltd., Hertfordshire, 
England.
kindly donated by Dr. H.S. Marsden
Protein A, [125I] labelled with Bolton Amersham International,
and Hunter reagent, affinity purified for 
blotting applications (>30mCi/mg)
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Section 7. Other materials
Hybond N Hybridisation transfer 
membranes
Giemsa Stain
Polaroid-667 Film
Plasticware for tissue culture
Restriction enzymes, T4 DNA ligase, 
Enzyme Buffers
Nitrocellulose membrane (BA 85) 
Agarose gel electrophoresis apparatus 
PAGE apparatus
Repelcote 
XS-1 Film
Sequenase Version 2.0
Amersham International
BDH Chemicals
Polaroid (U.K.)
Becton Dickinson Ltd, UK.
Boehringer Mannheim, Lewes,
E. Sussex, UK.
Schleicher & Schuell, Dassel, Germany. 
Hybaid, UK.
Bio-Rad Laboratories, Richmond, 
California, USA.
BDH Cemicals
Kodak
United States Biochemical
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Methods
Section 1. 
Cell and Virus Methodologies 
1.1. Maintenance of Tissue Culture Cells
The BHK cells used were from the BHK-21 clone 13 fibroblastic cell line derived 
from baby hamster kidney cells (McPherson & Stoker 1962). The cells were maintained in 
Glasgow minimal essential medium (GMEM) supplemented with 10% newborn calf serum 
(NCS), 5% tryptose phosphate broth, lOOU/ml penicillin and lOOU/ml streptomycin 
(ETC 10) in an atmosphere of 95% air, 5% C02- To harvest, the confluent monolayers were
washed with 20ml versene, followed by a trypsin wash. The detached cells were 
resuspended in 20ml medium and could be stored at 4°C for up to one week. Cells were 
routinely passaged in 2 litre sterile roller bottles. From 1 roller bottle, up to 8 roller bottles 
could be seeded and would reach confluence following growth at 37°C for 3 to 4 days. For 
long term storage, detached cells were resuspended in 5ml ETC 10 supplemented with 25% 
calf serum and 10% glycerol. Aliquots were stored overnight at -70°C and then transferred 
to liquid nitrogen (-190°C). Cells were recovered from liquid nitrogen by bringing quickly 
to 37°C and incubating in small flasks with ETC 10 medium until confluent.
1.2. Growth of Virus
For growth of virus stocks and preparation of virus particles, 5-20 roller bottles of 
BHK C l3 cells were grown (see Methods, Section 1.1.) until they were confluent (assumed 
to be lx l 08 cells per roller bottle). The medium from the roller bottles was removed and 
each bottle was inoculated with 40ml of ETC 10 medium containing 3x10^ plaque forming 
units (pfu)/bottle. The multiplicity of infection (moi) was therefore 1:300. The infected 
roller bottles were then incubated until all the cells had rounded and detached from the bottle 
which typically took 3 days at 37°C or 4 days at 31°C. The mixture of cells and medium 
was decanted into sterile 250ml centrifuge bottles. The cells were then separated from the 
medium by centrifugation at 3000rpm for 10 minutes at 4°C. Virus in the supernatant was
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pelleted by centrifugation at 12,000rpm (Sorvall GS3 rotor) for 2 hours at 4°C. The pellet 
was resuspended in 1ml of cold 1 x Eagles medium (minus phenol red) and sonicated to 
disperse the virus. This material formed the cell released virus (CRV) and was stored at 
-70°C. Cell associated virus was not routinely prepared from infected cells.
1.3. Titration of Virus Stocks
To obtain the titre of virus, the stock was diluted in PBS + 5% NCS in step-wise 
dilutions up to 10'9. Confluent monolayers of BHK cells on 35mm plates were infected 
with dilutions by removing the medium and applying 100|il of the diluted virus to the centre 
of each plate followed by incubation for 1 hour at 37°C. The inoculum was removed, and 
the plates were overlaid with carboxymethylcellulose medium (ETC 10 medium containing
1.5% ( w/v) carboxymethyl cellulose) and incubated at 37°C for 3-4 days. Plates were then
fixed and stained with Giemsa stain for 30 minutes, after which the plates were rinsed with 
water and dried. Plaques were counted with a stereomicroscope.
1.4. Purification of Virions and Light particles
Purification o f virions and light particles was as described by Szilagyi & 
Cunningham (1991). 5% and 15% ficoll solutions were prepared in lx Eagle’s medium 
minus phenol red. Using these solutions, 5-15% continuous gradients were formed in 1.4 x 
9.5cm tubes (gradient volume was 13ml) using a gradient pouring apparatus. The gradients, 
rotor, centrifuge and buckets were cooled to 4°C prior to use. 1ml of virus prepared as 
described in Methods, Section 1.2. was loaded onto the top of the gradient, and centrifuged at 
12,000rpm for 2 hours at 4°C  in a Tst41 swing-out rotor. Two bands were visible in the 
gradients: a clearly defined narrow band (V, virions) and above this a wider more diffuse 
band (L, light-particles) (Fig. 25). The virion and light particle bands were collected by side 
puncture through a syringe needle, diluted with lx Eagles medium (without phenol red) and 
spun for 18 hours at 12,000rpm at 4°C in aTst41 swing-out rotor. Following centrifugation 
the supernatant was discarded and the pellets were resuspended in lx Eagles medium 
(without phenol red) and stored at -70°C.
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1.5. Particle Counts
Equal volumes of the virus stock, latex beads ( 1.5x 101 particles/m l) and stain (1% 
phosphotungstic acid, pH 7.0) were mixed and absorbed onto a parlodion-coated copper 
grid. Excess liquid was drained off and the number of virus particles and latex beads 
present in the field of view of the electron microscope counted. The concentration of the 
virus particles was calculated by comparison with the number of latex beads.
1.6. Detergent Treatment of Virus Particles
30jil of purified virions or light-particles (typically 2 x l0 8 particles) was added to 
30jll1 PBS + 1% NP40 and incubated on ice for 20 minutes. The samples were then 
centrifuged at 1 l,500g for 15 minutes and the supernatant which contains the envelope 
components was removed to a fresh tube. Pellets were washed with PBS + 2% NP40 and 
resuspended in 60|il of PBS. To all of the samples, 30|ll1 of boiling mix was added and the 
samples were boiled for 4 minutes prior to loading on a polyacrylamide gel.
1.7. Growth Curves
To determine virus yield after one cycle of replication, growth curves were carried 
out at a high multiplicity of infection. The medium was removed from 35mm plates of 
confluent BHK cells and the virus added at a moi of 5 pfu/ml, in a final volume of 200jil. 
The virus was left to absorb at 37°C for 1 hour after which the monolayers were washed 
three times with PBS. 3ml of ETC 10 medium was then added and the plates were returned 
to 37°C. The 0 hour sample was harvested immediately after the washes with further 
samples harvested at 3 hourly intervals. To harvest, the cells were scraped into the medium 
and subjected to ultrasonic disruption. The volume of each sample was measured and the 
samples were then titrated as described in Methods, Section 1.3. The virus yield at each time 
point was calculated as the titre x sample volume.
1.8. BCdR Selection of TK' Virus
The synthetic thymidine analogue 5 ’bromo-deoxycytidine (BCdR) was used as a 
selective agent for the growth of T K ' viruses. Cells transfected with viral and plasmid 
DNAs, as described in Methods, Section 1.9, were harvested into the growth medium once
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cpe was evident, (usually after 3-4 days incubation)and then this progeny virus was titrated 
on BHK cells. The progeny virus was then enriched for TK negative recombinants by two 
serial passages at low moi (0.005 pfu/cell) in the prescence of BCdR (lOOmg/ml) and then 
plaque purified as described in Methods, Section 1.10. Incubations were carried out at 37°C 
throughout.
1.9. Transfection of DNA into BHK Cells
To generate virus recombinanats, plasmid and viral DNAs were transfected into 
BHK cells by either lipofection or calcium phospate precipitation.
a) Lipofection
For transfection into BHK cells, on 35mm Petri dishes, two 15ml Falcon tubes were 
used and labelled A and B. To tube A, 70|al of HBS and 30|il of lipofectin (kindly supplied 
by C. Addison) were added and vortexed. To tube B was added the solution containing 
DNA (usually 5pg) and HBS up to a final volume of 100|il. The contents of tube A were 
added to tube B and the two solutions carefully mixed. This mixture was kept at room 
temperature for 10 minutes and then 2ml Optimem medium was added. The medium from 
each plate was replaced with the transfection mix and then incubated at 37°C for 5 hours. 
After 5 hours, 2ml of ETC10 medium containing 5% NCS was added to each plate and 
incubation at 37°C was continued until the virus had grown.
b) CaP04 Precipitation
This method is a modification of that described by Stow & Wilkie (1976). 1-5fig 
DNA was added to 1ml HEBS containing 5pg/ml calf thymus DNA and 70fil 2M CaCl2* 
Following mixing^, this solution was added to 50mm dishes containing sub-confluent 
monolayers of BHK cells from which medium had been removed. Following incubation at 
37°C for 45-60 minutes, the cells were overlaid with 4ml of ETC 10 medium containing 5% 
NCS. 4-8 hours later the medium was removed from the plates and they were washed twice 
with lx ETC 10 medium without NCS. 1ml of 20% (w/v) DMSO in lx HEBS was added 
to each plate and the cells incubated for exactly 4 minutes at room temperature. The DMSO 
solution was removed by aspiration and the cells were washed twice with lx ETC 10 
medium without NCS. Cells were finally overlaid with 4ml ETC 10 medium and incubated
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at 37°C until complete cpe was apparent.
Following transfection, infected cells were harvested and screened either by Western 
blot analysis or CAT assays in order to determine whether insertion of DNA into the HSV-1 
genome had been successful.
1.10. Selection and Growth of Individual Plaques
Dilutions of virus progeny from transfections were prepared and used to infect cells 
as described in Methods, Section 1.3. After infection, cells were overlaid with agar medium 
(ETC 10 medium containing 0.5% (w/v) agar) and incubated at 37°C for 3-4 days. Plaques 
which were well separated were selected by viewing under a stereomicroscope. Cells were 
withdrawn from the area of the plaque using lOp.1 disposable tips and transferred to a 1ml 
cryotube containing 200 j l l 1 PBS + 5% NCS. To release virus from the cells, samples were 
frozen in dry ice and then thawed at 37°C. This was repeated a further two times. BHK 
cells on 24 well plates were then inoculated with a 50|il aliquot of the plaque isolate and 
incubated at 37°C for 1 hour. Cells were overlaid with ETC10 medium and incubated at 
37°C until virus growth was apparent in all cells. After virus growth, 1ml of medium from 
the infected cells was removed and stored at -70°C. The infected cells were washed 3 times 
with 1ml PBS and then harvested into the appropriate buffer for either Western blot analysis 
or estimation of CAT activity.
Section 2.
Preparation of Plasmid DNA
2.1. Preparation and Transformation of Competent E.coli
JM101 cells.
100ml of L-broth was inoculated with 1ml of an overnight culture of Escherichia coli 
(E.coin JM101 and grown at 37°C to an approximate optical density of 0.3 at 630nm. 
Bacteria were then pelleted at 3000rprn*for 10 minutes at 4°C, resuspended in half their 
original volume with ice cold lOOmM CaCl2, and incubated on ice for at least 2 hours. The 
bacteria were again pelleted and resuspended in 1ml of ice cold lOOmM CaCl2, after which
Sorvall SS34 R otor*  60.
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they were competent and ready for transformation.
For transformation, IOOjliI of competent bacteria were incubated on ice with 0.5-2pg 
DNA, or 4 |il ligation mix for 40 minutes. Prior to plating onto agar plates (containing 
50p,g/ml of ampicillin), the bacteria were heat shocked at 42°C for 2 minutes. Plates were 
incubated overnight at 37°C.
2.2. Glycerol Stocks of Bacteria
50ml of L-broth, containing the appropriate antibiotic, was inoculated with bacteria 
and incubated overnight at 37°C in an orbital shaker. The culture was centrifuged at 
3000rpm for 10 minutes (Sorvall SS34 Rotor) and the bacterial pellet resuspended in 3-4ml 
of 2% Bactopeptone plus an equal volume of 80% glycerol. The stock was aliquoted and 
stored at -20°C.
2.3. Small Scale Preparation of Plasmid DNA
For initial screening of plasmids, DNA was prepared from a 1.5ml bacterial culture 
which had been grown overnight at 37°C. Bacteria were pelleted by spinning at 50Q£ 
for 1 minute and the pellet was resuspended in 100p.l of Lysis solution 1 (50mM glucose, 
lOmM EDTA, 25mM Tris-HCl pH8 containing freshly prepared lOmg/ml lysozyme). 
150jil of Lysis solution 2 (0.2M NaOH, 1% SDS made fresh) was then added, the samples 
were mixed gently by inversion and incubated at room temperature for 5 minutes. 150jil of 
Lysis solution 3 (5M KAc pH4.8) was added and incubated for a further 5 minutes at room 
temperature. After centrifugation at 1 l,500g for 5 minutes the supernatant was removed 
and the DNA was phenol/CHCl3 extracted and ethanol precipitated as described in Methods, 
Section 3.3.
2.4. Large Scale Plasmid Preparation
10ml of L-broth, containing the appropriate antibiotic, was inoculated with a loop of 
bacteria and shaken overnight at 37°C. This culture was added to 600ml of L-broth plus 
antibiotic and shaken at 37°C until the OD630 was 0.8. In some cases, chloramphenicol was
added to a final concentration of 25fig/ml and the incubation was continued overnight.
Plasmid DNA was prepared by the maxi-boiling technique of Holmes & Quigley
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(1981). Cells were pelleted at 7,000rpm for 10 minutes (Sorvall GS3 rotor) and 
resuspended in 20ml of STET buffer. Lysozyme, was added to a final concentration of 
1 mg/ml and the sample was incubated at room temperature for 30 seconds prior to boiling 
for 45 seconds. The lysate was clarified by centrifugation at 18,000rpm at 4°C for 1 hour in 
a Sorvall SS34 rotor. The supernatant was then extracted with phenol/CHCl3 and the DNA
in the upper aqueous layer was precipitated by the addition of 0.7 volumes of isopropanol. 
DNA was pelleted by centrifugation at 3,000rpm for 10 minutes and the pellet washed with 
70% ethanol. Once the pellet was completely dry, it was resuspended in 1ml of TE.
The plasmid DNA was then purified on a CsCl gradient. Gradients were prepared 
by mixing the DNA with CsCl to give a final density of 1.6mg/ml and ethidium bromide 
(EtBr) was added to a final concentration of 0.5mg/ml. This solution was centrifuged at 
ll,5 0 0 g  i for 10 minutes to remove debris and the supernatant was then transferred to a 
TV865 ultracentrifuge tube. Following centrifugation at 100,000rpm for 4 hours the DNA 
was visualised under long wave UV light and the lower of the two bands, representing the 
super coiled plasmid DNA, was removed by side puncture. EtBr was removed by a series 
of extractions with CsCl-saturated isopropanol, and the DNA was ethanol precipitated (see 
Methods, Section 3.3). Following pelleting, DNA was resuspended in a final volume of 
500pl of TE and stored at -20°C. The concentration of DNA was estimated by measuring 
the optical density at 260nm.
Section 3.
DNA Manipulation
3.1. Restriction Enzyme Digestion of DNA
DNA samples (0.5-2 pg) were usually digested in a total volume of 20pl, containing 
the appropriate enzyme buffer and a suitable amount of restriction enzyme (usually 3 
units/pg DNA). Larger quantities of DNA (up to 15pg) were digested in volumes of either 
100pl or 200pl. Digestion was carried out at 37°C, unless otherwise stated, for 1-3 hours. 
For the analysis of small scale plasmid DNA preparations, samples were digested in the 
presence of lOpg/ml RNaseA. For partial digestion of plasmid DNA, 10pg of plasmid 
DNA was digested for 10 minutes with 10 units of enzyme. Following digestion, linearised 
molecules were purified by agarose gel electrophoresis.
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3.2. Agarose Gel Electrophoresis
For analysis of DNA restriction fragments, 0.8% - 1.5% agarose gels containing
0.5mg/ml ethidium bromide were prepared in 0.5 x TBE. Before loading DNA,the 
appropriate volume of 5x gel loading buffer (5x TBE, 50% sucrose and 0.2% bromophenol 
blue) was added to the DNA samples to give a lx  concentrated solution. Gels were 
electrophoresed at 100V for 2-3 hours. DNA bands were visualised under short or long 
wave UV light, and photographed using Polaroid film (type 667).
3.3.Phenol/Chloroform Extraction and DNA Precipitation
To remove the proteins from nucleic acid solutions, phenol/chloroform extractions 
were performed. An equal volume of 2x PK buffer (typically 200fil) and an equal volume 
ofphenol/CHCl3 was added to the nucleic acid solution. This mixture was vortexed and 
centrifuged at ll,5 0 0 g  t for 1 minute. The upper phase which contained the DNA, was 
transferred to a fresh tube and extraction with phenol/CHCl3 was repeated a further twice. 
After phenol/CHCl3 extraction, an equal volume of CHCI3 was added to the upper phase, 
vortexed, and centrifuged for 1 minute. The upper phase was removed to a fresh tube and 2- 
3 volumes of ethanol, and 1/10th of the aqueous volume of 5M ammonium acetate was 
added to precipitate the DNA. The sample was left at -20°C for 30 minutes, after which the 
DNA was pelleted by centrifugation at ll,5 0 0 g  f° r 5 minutes and the supernatant 
removed. The pellet was washed with lOOfil of 70% ethanol to remove salt, dried and 
resuspended in 30|il of distilled water or TE buffer.
3.4. Purification of DNA Fragments
Digested DNA samples were run on an agarose gel as described in section 3.2. To 
visualise the DNA, the gel was viewed under long wave UV light and the appropriate DNA 
fragments were excised from the gel. The DNA was electroeluted from the gel by placing 
the gel slice in dialysis tubing which had been boiled for 10 minutes in the presence of 
EDTA, and rinsed in deionised water. 600jo.1 of electroelution buffer (20mM Tris-HCl pH
7.4. lOmM ammonium acetate, 0.5mM EDTA) was added to the gel slice and the tubing 
was sealed at both ends. The gel slice was then immersed in a shallow layer of buffer and 
electrophoresed at 100V for 10 - 30 minutes. The gel slice was removed and the DNA was
63.
Chapter 6; Methods 
isolated from the buffer by phenol/CHCl3 extraction and ethanol precipitation.
3.5. DNA Cloning
The vector was linearised using the appropriate restriction enzyme, and to prevent 
recircularisation of the vector DNA during subsequent ligations, 1 unit of Calf Intestinal 
Phosphatase was added after completion of digestion and incubated for 30 minutes at 37 °C. 
The DNA was then phenol/CHCl3 extracted and ethanol precipitated.
For the insertion of blunt-ended fragments into sticky ended vectors, the vector was 
incubated for 30 minutes at room temperature with lOOnM dNTPs and 0.5 unit/fig Klenow 
polymerase in the presence of restriction enzyme buffer. The DNA was then phenol/CHCl3
extracted and ethanol precipitated.
Ligations were carried out in a total volume of 2 0 jliI containing 2 units o f  T4 DNA 
ligase in ligation buffer (50mM Tris-HCl pH7.6, lOmM MgCl2, ImM DTT, ImM ATP,
25% (w/v) PEG 6000). Incubation was performed for a minimum of 2 hours at 16°C.
3.6. Labelling of DNA by Nick Translation
Plasmid DNA was labelled as described by Rigby et al., (1977). 500ng of DNA 
was mixed with 20(iCi of each [ a -32P]dNTP, lp l DNase I (10"^units/ml), in the presence 
of lx NT buffer (50mM Tris-HCl pH7.8, 5mM MgCl2, ImM DTT, 5mg/ml BSA) and 2 
units of E.coli DNA polymerase I. The mixture was incubated at room temperature for 1 
hour and 32P-labelled DNA was then separated from unincorporated triphosphates by 
running through a 10ml Sephadex G50 (medium grade) column in a 10ml pipette plugged 
with siliconised glass wool. Columns were loaded with the sample and bromophenol blue 
dye, and the fastest eluting fractions taken as the peak of radio-labelled DNA.
3.7. Preparation of virion DNA
To prepare virion DNA, IOOjlxI of 2x PK buffer and lOfil of proteinase K (20mg/ml) 
was added to 1 OOjllI of virions (approx lx l 0^ particles) which had been purified as described 
in Methods, Section 1.4. After incubation at 37 °C for 30 minutes, 200fil of phenol/CHCl3
was added to each tube and the upper and lower phases gently mixed for 5 minutes. The 
two phases were separated by centrifugation at 11,500g for 1 minute and the upper layer
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was removed to a fresh tube. To prevent shearing of the DNA, the ends of tips were 
removed to handle the solutions containing viral DNA. A total of three phenol/CHCl3
extractions and one CHCI3 extraction were performed and the DNA was precipitated by the
addition of ethanol and ammonium acetate (see Methods, Section 3.3). DNA was recovered 
by centrifugation at 1 l,500g for 5 minutes after which the DNA pellet was washed, dried 
and resuspended as described in Methods, Section 3.3.
3.8. Southern Blot Analysis of Viral DNA
Purified viral DNA was digested with the appropriate restriction endonuclease, and 
run on a 0.8 or 1% agarose gel. After visualisation on a long wave UV transilluminator the 
DNA within the gel was denatured by shaking the gel in Gel Soak I for 30 minutes and this 
solution was neutralised by shaking the gel in Gel Soak II for 30 minutes. Capillary blotting 
overnight was used to transfer the DNA from the gel to nitrocellulose membrane. The 
DNA was fixed onto the membrane using a UV Stratalinker (120 joules), and the 
membrane was then incubated in 100ml prehybridisation mix (6x SSC, 5x Denhardts 
solution, 0.1% SDS, 20|ig/ml denatured calf thymus DNA) at 68°C for 2 hours. This mix 
was discarded and replaced with 10ml of hybridisation mix (6xSSC, lOx Denhardt’s 
solution, 20mM Tris-HCl, pH 7.5, ImM EDTA, 0.5|lg/ml denatured calf thymus DNA) to 
which 0.5ml of [32P]-radiolabelled DNA had been added. For use as a probe in Southern 
blot analysis, 3-5fig of radiolabelled DNA in a total volume of 800(0.1 of TE buffer was 
denatured by the addition of 100(il 1M NaOH followed by incubation at room temperature 
for 10 minutes. Just prior to adding the probe to the hybridisation mix, it was neutralised by 
adding lOOp.1 of 1M HC1. Hybridisation was carried out at 68 °C overnight. The radioactive 
solution was discarded and the blot washed twice in 2x SSC, 0.1% SDS for 1 hour at 68 °C. 
The membrane was then rinsed in water, dried and exposed to Kodak X-Omat XS-1 film.
3.9. DNA Sequencing
Chain termination sequencing was performed using the Sequenase Version 2.0 kit 
(United States Biochemical). All plasmid DNA was PEG precipitated as follows prior to 
sequencing. Plasmid DNA, prepared as in Methods, Section 2.3, in a total volume of 50jil, 
was incubated with RNaseA at a concentration of 10p,g/ml for 30 minutes at 37°C. The 
samples were then mixed well with 30(il of 20% PEG 6000, 2.5M NaCl and kept on ice for 
1 hour. The precipitates were collected by centrifugation at 1 l,500g for 5 minutes and
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washed with 70% ethanol. The pellet was dried and dissolved in 50 pi distilled water. PEG- 
precipitated DNA (1-1.5 Jig in 18pl) was denatured by the addition of 2 pi of 2N NaOH and 
kept at room temperature for 5 minutes. 8jll1 of filter sterilised 5M ammonium acetate (pH 
7.4) was then added, and the denatured DNA was precipitated by addtion of lOOpl ethanol at 
-70°C for 5 minutes. The precipitates were harvested by centrifugation at 1 l,500g for 5 
minutes, washed with 70% ethanol and then dried under vacume. The denatured DNA 
pellet was kept in this form at -20°C until required. The pellet was dissolved in lOpl of 
distilled water immediately prior to use.
For each DNA to be sequenced a single annealing and subsequent labelling reaction 
was performed. To anneal primer to DNA, l|il of primer (0.5-1.0pmol), 2pl of reaction 
buffer consisting of 200mM Tris-HCl pH 7.5, lOOmM MgCl2, 250mM NaCl and
appproximately 3pg of denatured DNA were mixed in a final volume of 10pi. The mixture 
was heated to 65 °C for 2 minutes and allowed to cool slowly (typically over a period of 30 
minutes) to room tempearature for annealing to occur. The annealed primer/template was 
stored on ice, and used within 4 hours. For the labelling reaction, Sequenase T7 DNA 
polymerase, a genetic variant of bacteriophage T7 DNA polymerase (Tabor & Richardson, 
1989) was diluted 1:8 in ice-cold enzyme dilution buffer. Labelling of DNA was performed 
by adding to the annealed template/primer, lp l 0.1M DTT, 2pl of (dATP) labelling mix (5x 
concentrate; 7.5pM  dGTP, 7.5|iM dCTP, 7.5pM dTTP), 50pCi/ml of [a -35S]-dATP and 
lpl of diluted Sequenase enzyme. For reactions in which sequences could be determined 
up to 500 bases from the primer, the labelling mix consisted of lx dATP labelling mix. In 
order to determine sequences from 30 bases from the primer the reaction mix was 
composed of 0.5x (dATP) labelling mix and M nCl2 buffer (15mM sodium isocitrate, 
lOmM M nCl2) was added. In order to terminate the labelling reaction 3.5pi of the reaction
mix was added to 2.5 pi of ddNTP termination mix and incubated at 37°C for a further 3 to 
5 minutes. 4pl of stop solution was then added to each of the termination reactions and the 
samples were boiled for 5 minutes prior to electrophoresis.
Electrophoresis was carried out at 70W through vertical gels 42 x 34 x 0.04 cm. 
Gels consisted of 6% acrylamide cross linked with 5% (w/v) N,N’-methyenelbisacrylamide 
and 9% urea in lx  TBE. Polymerisation was achieved by the addition of 0.05% (w/v) APS 
and 0.1% (w/v) TEMED. Both plates were treated with Repelcote enabling the gel to be 
transferred to Whatman 3mm chromatography paper following electrophoresis and dried 
under vacume. Dried gels were then exposed to Kodak XS-1 film.
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3.10. Oligonucleotide Synthesis
Oligonucleotides were synthesised on a Cruachem PS250 Oligonucleotide 
Synthesiser. Following synthesis, oligonucleotides were removed from solid supports by 
treatment with ammonia (35% pure, specific gravity 0.88), heated to 55°C for 5 hours and 
then lyophilised. Oligonucleotide pellets were resuspended in 20p.l deionised formamide 
and 5jnl of lOx TBE. Purification of oligonucleotides was performed by polyacrylamide gel 
electrophoresis on denaturing polyacrylamide gels (15% acrylamide cross linked with 4% 
(w/v) N,N’-methyenelbisacrylamide in lx TBE, 8M urea). Polymerisation was achieved by 
the addition of 0.05% (w/v) APS and 0.1% (w/v) TEMED. The oligonucleotides were 
visualised by UV shadowing, with short wave UV light, and excised from the gels. The 
oligonucleotides were then eluted from the gel slice by shaking in 1ml H 2O overnight at
37°C. Following phenol/CHCl3 extraction and ethanol precipitation, the oligonucleotides 
were resuspended in 1ml of H2O and their concentrations were estim ated by 
spectrophotometry. The concentrations were usually in the range of 1 to 3m g/|#m l.
Section 4.
Polypeptide Analysis and Detection
4.1. Preparation of 35S-methionine Labelled Extracts
Confluent monolayers of BHK cells in 50 mm plates were infected at a moi of 5 at 
37°C. At 1 hour post infection, the cells were overlaid with 3 ml of ETC 10 medium and 
infection continued for a further 2 to 4 hours. The media was removed and the cells were 
washed twice with 5 ml of Eagles medium containing one fifth the normal concentration of 
methionine supplemented with 2% NCS (low methionine medium). Cells were incubated at 
37°C for 1 hour in low methionine medium before being replaced with fresh low 
methionine medium containing 100|iCi/ml [35S]-methionine per dish. At the required time, 
the infected monolayers were washed twice with PBS and drained well before the addition 
of 500|nl of boiling mix. After 1-2 minutes, the lysed cells were transferred to a microfuge 
tube and boiled for 5 minutes. 15jil of the samples were then TCA precipitated to estimate 
the level of incorporation of 35S-methionine. Samples were stored at -20°C.
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4.2. Denaturing Polyacrylamide Gel Electrophoresis
The concentration of gel used to separate polypeptides depended on the resolution 
required which was determined by the sizes of the proteins being investigated. The ratio of 
acrylamide to the cross-linking agent N,N’-methylene bisacrylamide was 39:1 for single 
concentration gels, and 19:1 for gradient gels. Gel solutions containing the appropriate 
percentage of acrylamide were prepared in buffer of final concentration 375mM Tris-HCl 
pH 8.9 and 0.1% SDS. For gradient gels the (w/v) acrylamide solution at the higher 
concentration also contained 15% glycerol to stabilise the gradient. Polymerisation was 
initiated by the addition of ammonium persulphate and TEMED to final concentrations of
0.06% and 0.04% respectively. The gel solution was poured between 2 glass plates (22 x 
24cm for full size gels or 8 x 6cm for mini-gels), separated by 1.5mm thick spacers, and 
sealed with rubber tubing. The gel was then left to polymerise under a thin layer of butan-2-
01. Following polymerisation a stacking gel consisting of 5% acrylamide solution in 
122mM Tris-HCl pH 6.7, 0.1% SDS was added. Wells were formed by a Teflon comb.
Samples were boiled for 5 minutes in boiling mix prior to electrophoresis. This 
denaturing buffer contained bromophenol blue so as the dye front could be visualised. 
Electrophoresis was carried out in a buffer containing 52mM Tris, 53mM glycine, 0.1% 
SDS at 100V for approximately 3 hours.
4.3. Western Blot Analysis
Proteins were separated on a SDS-polyacrylamide gel (see Methods, Section 4.2) and 
transferred onto a nitrocellulose filter using a semi-dry blotting technique. Prior to transfer, 
nitrocellulose membrane and 6 sheets of 3mm blotting paper, cut to the same size as the 
SDS-polyacrylamide gel, were soaked in Western Transfer buffer. Three pieces of 3mm 
paper were placed on the anode and onto this stack was placed the nitrocellulose membrane. 
The gel was placed on the membrane, and to complete the transfer unit, a further three pieces 
of 3mm paper was stacked on top of the gel. The cathode was placed on the transfer unit 
and electrophoresis was carried out for one hour at 0.8mA/cm^. After transfer, the 
nitrocellulose membrane was washed twice with TBS (5 minutes per wash). The 
membrane was then blocked with 3% gelatin in lxTBS for 1 hour at 37°C followed by two 
5 minute washes in TBS containing 0.05% Tween 20 (TTBS). The membrane was 
incubated with primary antibody at the appropriate dilution for 1 hour at 37°C in TTBS
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containing 1% gelatin (mouse monoclonal antibodies were all used at a 1:2000 dilution). 
Following removal of the primary antibody, the membrane was given two 5 minute washes 
with TTBS and then incubated with secondary antibody diluted in TTBS containing 1 % 
gelatin for 1 hour at 37°C. For most western blot analysis, the secondary antibody was anti­
mouse IgG conjugated to horseradish peroxidase which was used at a dilution of 1:1000. 
The anti-mouse IgG conjugated to horesraddish peroxidase allowed the development of the 
blot with ECL colour development reagent. This involved washing the membrane twice (5 
minutes per wash) with TTBS and then immersion in ECL colour development solution for 
60 seconds. Proteins were visualised by exposing the membrane to Kodak X-Omat XS-1 
film for times which varied from 5-15 seconds.
Following incubation with rabbit polyclonal antibody, anti-rabbit Protein A 
conjugated secondary antibody was used and development involved washing the membrane 
twice with TTBS (5 minutes per wash) followed by incubation for 2 hours at 37°C with 125I 
protein A (5x 105 counts/strip) in protein A solution. The membrane was then washed in 
TTBS and bands were visualised by exposing the membrane to Kodak X-Omat XS-1 film 
overnight.
To reuse membranes for probing with other antibodies, the membrane was shaken in 
regeneration buffer for 1 hour at 55 °C. The membrane was then washed twice (5 minutes 
per wash) in TBS. Prior to probing with another antibody the membrane was blocked with 
3% gelatin in lx  TBS for one hour at 37°C. Subsequent probing with antibody was 
performed as described above.
4.4. Visualisation of Proteins Separated by SDS 
Polyacrylamide Gel Electrophoresis
a) Coomassie Brilliant Blue Staining.
Following electrophoresis, gels were fixed and stained by shaking in 0.2% 
Coomassie brilliant blue R250 in methanol:water:acetic acid (50:50:7) for 30 minutes. The 
gels were then destained with extensive washes in 5% methanol, 7% acetic acid. Coomassie 
brillant blue can detect protein to a limit of approx 0.5jig and was therefore suitable for 
visualising the major and most of the minor components of virus particles.
b) Silver Staining
Silver staining is a more sensitive method for visualising proteins than Coomassie 
brilliant blue, but it is not a quantitative staining technique. Gels were fixed in 30%
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ethanol, 10% acetic acid for at least 30 minutes followed by a 30 minute incubation in 30% 
ethanol, 0.5M sodium acetate, 0.5% gluteraldehyde and 0.2% sodium thiosulphate. The gels 
were then thoroughly rinsed in water (3x 30 minutes) and subsequently shaken for 20-60 
minutes in 0.1 % silver nitrate, 0.02% formaldehyde. The protein bands were visualised by 
placing the gels in 2.5% sodium carbonate, 0.01% formaldehyde for 5-15 minutes. 
Development was stopped by the addition of 0.5M EDTA for 10 minutes followed by 
extensive washes in water. All water used throughout this procedure was double distilled 
H2O.
c) Detection of Radiolabelled Proteins
Gels were fixed for 1 hour in methanokacetic acidrwater (50:7:50) and then soaked in 
several changes of 5% methanol, 7% acetic acid. The gels were then dried under vacuum, 
onto Whatman grade 182 filter paper and exposed to Kodak X-Omat XS-1 film.
4.5. CAT Assay
CAT assays were performed on extracts of cells infected with virus expressing CAT 
protein as well as purified virions and light particles. For assaying activity in infected cell 
extracts, 35mm plates of BHK cells were infected with virus at a moi of 5 and incubated at 
37°C until full cpe was visible. Cells were washed twice in PBS (3ml/wash) and 
resuspended in 200 j l x 1 of 250mM Tris-HCl (pH 8.0). The cells were disrupted by freezing 
the samples on dry ice followed by thawing in a 37°C water bath and this process was 
performed a total of three times. The cellular debris was removed by centrifuging the 
samples at 1 l,500g 1 for 5 minutes, and the supernatant was used as the CAT extract. For 
each reaction, 0 .5 j l l 1 14C-chloramphenicol, ljil of Butyryl-CoA (25mM) and 18.5jil H 2O
was added to 25p.l of CAT extract. The mix was vortexed and incubated at 37°C for 30 
minutes. The reaction was terminated by adding 200|il TMPD/Xylene (2:1) mix. The 
solutions were vortexed and then spun at ll,5 0 0 g  1 for 2 minutes. 150fil of the top 
organic phase was transferred to a scintillation vial, taking care not to disturb the lower 
aqueous phase. 5ml of scintillant was added to the vial and the samples counted using a 
Beckman Scintillation Counter.
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4.6. Indirect Immunofluorescence
Cells grown on 13mm coverslips were infected with virus or transfected with 
plasmid DNA ( Methods, Section 1.9). After overnight incubation the coverslips were 
removed, rinsed in PBS and fixed in pre-cooled acetone (-20°C) for 20 minutes, or 
methanol (-20°C) for 20 seconds. The coverslips were then rinsed in PBS and, in order to 
rehydrate the cells, lOOjil of PBS/1 % calf serum was added to the coverslip and incubated at 
room temperature for 5 minutes. The coverslips were then washed 3 times in PBS/1 % calf 
serum. Just prior to the addition of antibody, coverslips were drained, and lOOjil of pp65 
antibody (diluted to 1:300 in PBS/1 % calf serum) was added to each coverslip. After one 
hour at room temperature, the antibody was drained from the coverslips and they were 
washed three times in PBS/1 % calf serum. The coverslips were then drained and the 
secondary FITC-conjugated goat anti-mouse antibody was placed on the coverslip at 1:100 
dilution, and left at room temperature in the dark for one hour. The coverslips were drained 
and rinsed in PBS/1 % calf serum, followed by rinsing in PBS and H 2O and finally mounted 
onto slides with PBS/glycerol (50:50). Cells were visualised using a Nikon Microphot-SA 
fluorescent microscope.
4.7. In vitro Transcription/Translation Reactions
In vitro transcription/translation reactions were performed using the Promega TnT 
Coupled Reticulocyte Lysate System. l|ig  of plasmid DNA was added to a total volume of 
50 j l x 1 nuclease free H2O containing 25|il TNT rabbit reticulocyte lysate, 1 JJ.1 TnT reaction 
buffer, 40 units of T3 RNA polymerase, lp.1 ImM amino acid mix (minus methionine), 4jil 
[35S]-methionine (10|LiCi/jil) and 1 jlxI RNasin ribonuclease inhibitor (40 units/fil). The 
mixture was vortexed and incubated at 37°C for 30 minutes. Boiling mix was then added to 
the tubes and 5 jil of the sample was run on a 12% SDS-polyacrylamide gel. The gel was 
then fixed in methanol:water:actetic acid (50:50:7), for 15 minutes and washed thoroughly in 
5% methanol, 7% acetic acid. After drying the gel onto 3mm Whatman paper, it was 
exposed to Kodak X-100 film.
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4.8. FPLC Purification of IgG
Anti-CAT monoclonal antibody was purified from the medium harvested following the 
passage of the antibody producing hybridoma cell line (5/24). In order to delipidate the 
hybridoma cell supemate 15mg/ml 'Cab-o-sil' was added and stirred for 30 minutes at room 
temperature, and then clarified by centrifugation at 2000rpm for 20 minutes. The 
delipidated solution was chilled to 4°C and mixed with ammonium sulphate (312 jig/ml) for 
20 minutes on ice. To obtain the IgG extract from this solution it was centrifuged at 10,000g 
for 10 minutes and the pellet was resuspended in approx 5ml of 20mM Na-Phosphate 
buffer. Following dialyisis of this extract overnight in Na-Phosphate buffer, it was filtered 
using an 0.2|im  Acrodisc and injected into a 10ml FPLC loop. FPLC purification of the 
sample through a Pharmacia Proten G column was then performed. Elution of the purified 
IgG from the column was carried out with 0 .1M glycine-HCl pH 2.7. In order to neutralise 
the acidic elution buffer, 1.0M Tris-HCl pH 9.0 was added to each sample eluted from the 
column. The purified antibody was stored at -20°C in lOOjil aliquiots.
S or vail SS34 Rotor
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Part 1
Incorporation of vhs-CAT Fusion Protein 
into the HSV-1 Tegument
As outlined in the Introduction, acquisition of tegument is an intrinsic part of virion 
assembly among herpesviruses yet the pathway and factors which influence this process are 
poorly understood. Since only a subset of viral proteins are found in the tegument, it is 
reasonable to assume that targeting of proteins to this region of the virus particle is at least 
partly dependent on sequences resident within the tegument proteins. Identification of such 
sequences, and an understanding of their biological properties, would have significant impact 
on our knowledge of tegument assembly. A key aim of this study was to devise a 
m anipulate experimental system that would enable characterisation of sequences that direct 
proteins to the tegument.
Initially, the strategy was to construct a fusion gene composed of the sequences from 
a tegument gene linked to a non-viral, non-structural gene. In the event that the resultant 
fusion product could be incorporated into virus particles, this system could then be used to 
manipulate the fusion gene and monitor how alterations to the sequence influenced targeting 
to the tegument. The tegument protein selected was the vhs polypeptide encoded by UL41 
(Chapter 4; Introduction, Section 4) . Since this protein is not essential for virus growth, it 
was unlikely that alteration of its sequences would have any deleterious effect on virus 
viability. The non-structural component of the fusion protein was the bacterial 
chloramphenicol acetyl transferase (CAT) protein. This was deemed suitable since it was a 
polypeptide of reasonable size (25KDa), its enzymatic activity could be easily assayed and 
an antibody was commercially available to detect the protein. In combination, these factors 
would allow short stretches of amino acids from the vhs coding sequences (or sequences 
from other tegument genes) to be assayed for their ability to direct proteins to the tegument.
The system which was developed made use of data from previous studies where the 
HSV-2 strain G vhs gene had been inserted into the TK locus of HSV-1 strain 17 (Fenwick 
& Everett, 1990) These studies had shown that the HSV-2 vhs polypeptide was extremely 
efficient at abrogating polypeptide synthesis and was incorporated into HSV-1 virus 
particles.
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Figure 7. Details of plasmid vectors used to construct a vhs-CAT fusion 
gene. Plasmid pM Fl contains an SstI DNA fragment spanning the HSV-2 
vhs sequences, inserted into the unique SstI site of pTK l (Fenwick & 
Everett, 1990). The unique Hindlll site within plasmid pM Fl was removed 
resulting in plasmid pVHSl (7a). Partial digestion of pVHSl with AatH and 
insertion at the AatH site at position 8.50 of an oligonucleotide that 
regenerated the C-terminal portion of the vhs gene resulted in plasmid 
pVHS2 (7b). The oligonucleotide inserted contained a H indlll site 
immediately following the codon specifying the C-terminal amino acid 
which enabled the insertion of the polypeptide coding seqences for the CAT 
gene as a H indlll fragment from plasmid pCA Tl (7c), This generated 
plasmid pVHS6 in which the CAT coding sequences are fused in frame 
downstream of the vhs coding sequences (7d).
Figure 8. Sequence read from plasmid pVHS6 across the oligonucleotide 
linker sequence. The oligonucleotide linker sequence and the CAT primer 
sequence are underlined. The CAT initiation codon and the vhs sequence are 
in bold type.
v h s sequence
5’ CCC CCG CCC GCG TTT TAC AAG GAC GTA_ 
P R P A F Y  K N V
oligonucleotide linker Hindlll BamHI
CTG GCT AAA TTC TGG GAC GAA AGC TTG GAT CCG 
L A K F W N  E S L D  P
CAT initiation codon
TCG AGA TTT TCA GGA GGT AAG GAA GCT AAA ATG 
S R F S G G K E A K M
CAT primer sequence
GAG AAA AAA ATC ACT GGA TAT ACC ACC GTT GAT 
E K K I T G Y T T V N
A1A.CCA CCG TTG ACC CAA TAT ATT GGC ATG 3’
I P P L T Q Y I G M
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After promising initial results, the antibody which was used to detect the CAT 
component of the fusion protein was found to have poor avidity for the CAT protein and 
gave unreliable results. This necessitated the production of a new CAT antibody (Chapter 7; 
Results, Part 2) which delayed progress and prevented further use of CAT as a marker 
polypeptide.
Section 1
Construction of the vhs-CAT Fusion Gene
In order to construct a plasmid which would express the vhs-CAT fusion gene a 
series of cloning steps were performed (Fig. 7). The parent plasmid was pM Fl, which had 
been constructed by Fenwick and Everett (1990). pM Fl contains a SstI DNA fragment, 
which spans the HSV-2 strain G vhs polypeptide coding sequences as well as its promoter 
and poly A sequences, inserted into the unique SstI site of plasmid pTKl (Wilkie et al., 
1979). This site lies within the TK polypeptide coding sequences and therefore insertion at 
this site disrupts the gene. Plasmid pMFl contains a unique Hindlll restriction enzyme site, 
and to facilitate further manipulation of the plasmid this site was removed by digesting with 
Hindlll and filling in the overhanging termini with Klenow polymerase. Ligation of the 
blunt ends resulted in the loss of the H indlll site and the derived plasmid was termed 
pVHS 1 (Fig 7a). For the second stage of the cloning strategy pVHS 1 was partially digested 
with AatH. This enzyme cleaves pVHSl at 6 sites one of which lies 22bp upstream from 
the stop codon of the HSV-2 vhs polypeptide coding sequences. An oligonucleotide which 
regenerated the C-terminal portion of the vhs gene and contained a Hindlll site immediately 
following the codon specifying the C-terminal amino acid was inserted at this AatH site to 
give plasmid pVHS2 (Fig. 7b). A Hindlll DNA fragment from pCATl (Fig. 7c) which 
contained the polypeptide coding sequences of the CAT gene was inserted into the Hindlll 
site of pVHS2; this generated plasmid pVHS6 (Fig. 7d).
In order to ensure that the oligonucleotide linker that fused the vhs sequences to the 
CAT sequences maintained the correct reading frame, the DNA sequence of the region 
spanning the oligonucleotide in plasmid pVHS6 was determined. An oligonucleotide was 
designed for use as a primer that annealed to sequences within the CAT open reading frame. 
The sequence obtained (Fig. 8) confirmed that the vhs and CAT polypeptide coding 
sequences would be read in the same open reading frame, generating a fusion protein with a 
predicted size of approximately 84KDa.
74.
Chapter 7; Results
Section 2
Construction of Virus Recombinant vVHS-CAT
To insert the vhs-CAT fusion gene into HSV-1 DNA, pVHS6 was linearised by 
digestion with B glll (Fig. 7d) and transfected into sub-confluent BHK cells with HSV-1 
strain 17 DNA. The resultant virus progeny were grown in the presence of BCdR which 
enables the selection of TK negative recombinants ( Chapter 6; Methods, Section 1.8). From 
these progeny, 12 plaques were picked for further screening. Cells infected with each of the 
plaques were analysed for CAT activity. During the screening process CAT activity was 
recorded as being either positive or negative, and was not quantified. Extracts prepared from 
cells infected with all 12 plaques produced enzyme activity. One of the 12 isolates was 
chosen and used to infect cells again in the presence of BCdR. The process of screening for 
CAT activity was repeated on a further 12 isolates. After three rounds of such plaque 
purification one of the isolates was chosen and analysed by Southern blot analysis. This 
isolate was termed vVHS-CAT .
Section 3
Southern Blot Analysis of vVHS-CAT DNA
To verify that the vhs-CAT sequences had inserted at the predicted site within the TK 
gene, vVHS-CAT DNA was digested with BamHI along with the parent plasmid pVHS6, 
plasmid pT K l, wild-type HSV-1 strain 17 viral DNA, and vSau3 (Chapter 5; Materials, 
Section 4) viral DNA. Plasmid pTK l consists of the HSV-1 strain 17 BamHI p fragment, 
which has a size of 3.7Kbp and contains the TK gene, inserted into the BamHI site of 
pAT153. Virus vSau3 contains the CAT open reading frame within the US region of the 
genome under the control of the promoter sequence from HSV-2 UL40 gene. Following 
digestion, viral and plasm id DNAs were electrophoresed on a 1% agarose gel and 
transferred to Hybond membrane. Hybridisation was carried out using radiolabelled pTKl 
which would recognise TK sequences and a 960bp Hindlll fragment from pCATl (Fig. 7c) 
to detect CAT sequences.
Hybridisation with pTK l detected a 3.7Kb band in pTKl which is a doublet 
comprising of the pAT backbone and the BamHI p sequences (Fig. 9a, lane 1) The latter
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Figure 9. Southern blot analysis of vVHS-CAT viral DNA. 0.5(ig of each DNA 
was digested with BamHI and then electrophoresed on a 1% agarose gel followed 
by transfer to Hybond-N membrane. Duplicate membranes were probed with 
radiolabelled pTKl probe (9a) and with a 960bp H indlll fragment containing the 
CAT gene (9b). The DNAs in each lane were as follows: lane 1: pTKl plasmid 
DNA; lane 2: HSV-1 strain 17 viral DNA; lane 3: vSau3 viral DNA; lane 4: 
vVHS-CAT viral DNA and lane 5: pVHS6 plasmid DNA. (9c) Plasmid pVHS6, 
illustrating the positions of the BamHI sites and the sizes of the fragments obtained 
following BamHI digestion. (9d) A diagramatic representation of the vVHS-CAT 
genome, containing the additional copy of vhs linked to the CAT sequence within 
the viral TK gene.
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fragment was also recognised in HSV-1 strain 17 and vSau3 viral DNAs (Fig. 9a, lanes 2 & 
3); these virus genomes contain the intact viral TK gene. However, a band of similar size 
was not detected in vVHS-CAT DNA, but two bands of 3.2 and 2.8 Kbp were detected 
(Fig. 9a, lane 4). These bands are identical in size to two of the bands in the lane containing 
pVHS6 (Fig. 9a, lane 5). These correspond in size to BamHI fragments derived from 
pVHS6 which contain TK and vhs (2.8Kbp band; Fig. 9c, fragment 1) and CAT and TK 
sequences (3.2Kbp band; Fig. 9c, fragment 3). The pTK l probe also detected a 3.7Kbp 
band in the lane containing pVHS6 which corresponds to the plasmid backbone (Fig. 9c, 
fragment 4).
Hybridisation with a fragment containing CAT sequences obtained from plasmid 
pCATl, detected principally the 3.2Kbp band in pVHS6 (Fig. 9b, lane 5). This band 
corresponds to fragment 3 (Fig. 9c), which contains the CAT coding sequences. Weak 
hybridisation was also detected to a 1.54Kbp band that corresponds to fragment 2 (Fig. 9c). 
This fragment contains the linker sequences between the CAT and vhs coding sequences 
some of which would be detected by the CAT DNA probe. In vVHS-CAT viral DNA, the 
3.2Kbp band corresponding to fragment 3 was detected (Fig. 9b, lane 4) but the probe did 
not hybridise to either pTKl or HSV-1 strain 17 DNA (Fig. 9b, lanes 1 and 2). In vSau3 
DNA, a 5.7Kb band was detected (Fig. 9b, lane 3) which corresponds in size to a BamHI 
fragment derived from insertion of the CAT ORF and LacZ  sequences into the unique Xbal 
site of virus strain 1802 (Rixon & McLauchlan, 1990; McLauchlan et al., 1989).
These results indicated that the fusion gene had inserted at the TK locus and that no 
apparent rearrangement of the inserted sequences had occurred. The genome structure of 
vVHS-CAT DNA shows that the recombinant virus has two copies of vhs sequences, the 
endogenous HSV-1 strain 17 copy and the HSV-2 strain G counterpart linked to CAT that 
lies within the TK gene (Fig. 9d).
Section 4
Polypeptides Synthesised by vVHS-CAT
The polypeptides synthesised by vVHS-CAT were compared to those made by virus 
controls. Fig. 10 compares the ^^S-methionine labelled polypeptide profiles of cells infected 
with vVHS-CAT, 17G41, and vFJIO. vFJIO is derived from HSV-1 1802, contains an 
intact TK gene and expresses CAT protein under the control of the HSV-2 IE 4/5 promoter.
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Figure 10. Polypeptide profile of cells infected with vVHS-CAT. Aliquots 
containing 5xl0^cpm  from radiolabelled extracts of cells infected with 17G41 (lane 
2), vVHS-CAT (lane 3), vFJIO (lane 4) and mock infected cells (lane 1) were 
electrophoresed on a 9% polyacrylamide gel. The band corresponding to TK is 
indicated as are some of the major viral polypeptides.
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Figure 11. Detection of vhs-CAT fusion protein in infected cell extracts. 
Approxim ately 6 x l0 4 infected cell equivalents were loaded onto a 9% 
polyacry lam ide gel, and following electrophoresis were transferred to 
nitrocellulose membrane. The membrane was then incubated with anti-CAT 
monoclonal antibody 5/24. Samples were loaded as follows; lane 1: vVHS-CAT; 
lane 2: v65-CAT; lane 3: vSau3; lane 4: 17G41 infected cell extracts. The 84KDa 
vhs-CAT fusion protein is indicated, as is the 24KDa native CAT protein.
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17G41 was made in a similar manner to vVHS-CAT by recombining the HSV-2 strain G 
vhs gene into the TK locus of HSV-1 strain 17 DNA (Fenwick & Everett, 1990a). 
Approximately 2 x l0 6 BHK cells were infected with 5 pfu/cell of each of these viruses or 
mock infected and the cells were labelled with 35S-methionine from 3 hours post infection. 
Cells were harvested after 18 hours and extracts were made by resuspending the cells in 
500 j l l 1 of boiling mix. Polyacrylamide gel electrophoresis showed that the polypeptide 
profiles for each of the infected cell extracts were very similar, the most notable difference 
being the absence of TK protein in the vVHS-CAT and 17G41 samples (Fig. 10, compare 
lanes 2 and 3 with lane 4). This is the expected result since both of these recombinants have 
sequences inserted into their TK genes. However a novel band of 84KDa, the predicted size 
of the vhs-CAT fusion protein, was not visible in the vVHS-CAT sample (Fig. 10, lane 3). 
Western blotting, which is a more sensitive method for detecting proteins, was therefore 
used to reveal whether the fusion protein was synthesised in infected cells.
To determine whether vVHS-CAT-infected cells synthesised the fusion protein, 
extracts were made following an 18 hour infection of BHK cells with vVHS-CAT, 17G41, 
vSau3 and v65-CAT. v65-CAT is a vims containing CAT linked to a 10 amino acid epitope 
tag sequence under the control of the HCMV IE promoter sequences that was inserted into 
the unique Xbal site present in 1802 ( Chapter 8; Results, Part 1, Section 2). Western blot 
analysis of these extracts was performed using an anti-CAT monoclonal antibody termed 
5/25 (Chapter 7; Results, Part 2). The antibody detected a band of 24KDa in the vSau3- 
infected cell extract which corresponds to the size of CAT protein (Fig. 11, lane 3). In the 
v65-CAT-infected cell extract a major band of 25KDa was recognised (Fig. 11, lane 2) 
which represents CAT protein with the 10 amino acid epitope tag fused to the N-terminus of 
the protein (Chapter 8; Results, Part 2). A second minor band of 23KDa also was detected 
which presumably represents epitope-tagged CAT protein cleaved at either the N- or C- 
terminus by proteolysis. In the vVHS-CAT sample, two species were detected of 84KDa 
and 23KDa (Fig. 11, lane 1). The 84KDa protein corresponds to the predicted size of vhs- 
CAT polypeptide while the 23KDa species precisely coincides with the minor component in 
the vSau3 sample (Fig. 11, lane 2). From these data, it was concluded that the vhs-CAT 
protein is synthesised in vVHS-CAT infected cells. The 23KDa species was presumed to 
be a breakdown product o f the vhs-CAT protein although it may also represent the product 
of internal initiation.
Preparation of vVHS-CAT had shown that CAT fused to vhs was expressed in an 
enzymatically active form. In order to quantify the levels of CAT activity expressed by
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vVHS-CAT- 
infected cells
vSAU3- 
infected cells
V65-CAT- 
infected cells
CAT activity 
(% conversion/fig of protein) 3.6 9.3 24.1
Relative CAT activity 1 2.6 6.7
Table 5. Relative levels of CAT activity in vVHS-CAT-, vSAU3- and v65-CAT-infected 
cells. 35mm dishes containing confluent BHK cells were infected with each virus at a moi. 
of 5 pfu/cell. The cells were harvested following an 18 hour infection, and extracts were 
prepared as described in Chapter 6; Methods, Section 4.5. CAT assays were performed on 
known quantities of protein(determined by Bradford assay)present in extracts prepared from 
cells infected with either vVHS-CAT, vSAU3 or v65-CAT. CAT activity is expressed as 
the % conversion/|Lig of protein. The calculated increase in CAT activity in vSAU3 and v65- 
CAT infected cells are shown relative to the activity expressed in vVHS-CAT infected cells.
Figure 12. Detection of vhs-CAT fusion protein in purified virions and light 
particles. Approximately 20jig gradient purified virions and light particles were run 
on a 9% polyacrylamide gel along with the equivalent quantity of 17G41 virions. 
The polypeptides were transferred to nitro-cellulose membrane and the membrane 
was incubated with anti-CAT polyclonal antisera. Lane 1: 17G41 virions; lane 2: 
vVHS-CAT virions; lane 3: vVHS-CAT light particles. The size of the band 
detected (84KDa) was determined by staining the membrane with imido black.
1 2 3
84KDa
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vVHS-CAT infected cells, known quantities of infected cell protein (determined by Bradford 
assay) were serially diluted, analysed for CAT activity and compared with levels expressed 
in both vSAU3- and v65-CAT- infected cells (Table 5). The results indicated that vSAU3 
expressed approxim atley 2.6-fold more CAT activity than vVHS-CAT but more 
dramatically, v65-CAT expressed approximately 6.7-fold more CAT activity than vVHS- 
CAT.
Section 5
The vhs-CAT Fusion Protein is Present in Purified 
Virions and Light Particles
In an initial attempt to determine whether the fusion protein was incorporated into 
vVHS-CAT virus particles, Western blot analysis was performed on gradient-purified 
virions and light particles. These were prepared from six roller bottles of BHK cells which 
were infected with vVHS-CAT at a moi of 1 pfu per 300 cells and incubated at 37°C until 
full cpe was visible. The virus was harvested from the culture medium and purified on 5- 
15% ficoll gradients. Virions and light particles were collected and pelleted for further
analysis. Following resuspension approximately 20 |ig  of the virion and light particle 
samples were analysed by Western blot using a rabbit polyclonal antisera raised against 
CAT protein. This antisera detected a polypeptide of 84KDa, the predicted size of the vhs- 
CAT fusion protein, in both vVHS-CAT virions and light-particles (Fig. 12, lanes 2 and 3). 
The antisera did not react with similar quantities of virions from a control virus, 17G41 (Fig. 
12; lane 1), which contains the HSV-2 strain G vhs gene within its TK locus. This indicated 
the presence of the vhs-CAT fusion protein in purified virions and light particles. However 
from data presented in Chapter 8; Results, Part2, Section 5, it is possible that detection of 
certain proteins by antibodies in purified virus particle preparations results from the 
smearing through gradients of proteins which are not incorporated into virus particles. 
Therefore, a more thorough characterisation of the polypeptides present in vVHS-CAT virus 
particles was performed. For comparative purposes, 2 viruses, vSau3 and v65-CAT were 
used as controls to determine the behaviour of native CAT protein.
a)
vSau3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 192021
VP1
VP5
gB, gC, gH 
VP11/12 (90KDa)
VP13/14 
(81/82KDa) 
VP16^   vrio
• < —  VPl^P
actin
VP22
virions light particles
b)
vVHS-CAT
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
J Z L .V P 5
gB, gC, gH 
VP 11/12 (90KDa)
VP13/14
(81/82KDa)
VP16gD
VP 19c 
actin 
VP22
virions light particles
Figure 13. Comparison of polypeptide profiles of virus particles collected 
from across ficoll gradients. Virus was harvested 72 hours after infection 
and the cell released material for each virus was banded on 13ml 5-15% 
Ficoll gradients. Twenty, approximately 500|il aliquots were collected from 
about 2cm above the bottom of the tube to the top of the gradient. 40pl of 
radiolabelled material from each fraction across both gradients were 
electrophoresed on 5-12% polyacrylamide gels, a) represents the material 
from a vSau3 gradient, and b) is the vVHS-CAT equivalent. The bottom of 
the gradient is at the left of the gel and the top is to the right. The major 
polypeptides are indicated, as are the regions in which virions and light 
particles were seen to migrate. The apparent molecular weights of VP 11/12 
(90KDa) and VP13/14 (81/82KDa) are indicated.
* how ever in the vVHS-CAT gradient a band o f similar 
molecular weight to VP19C appeared to increase in intensity in 
fractions 16 to 19.
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Section 6
Analysis of Polypeptides Present in vVHS-CAT 
Virions and Light Particles
Previous studies have shown that virus particle purification on ficoll gradients 
provides both virions and light particles in a highly purified state (Szilaygi & Cunningham,
1991). However analysis of the changes in the patterns of polypeptides across a gradient in 
which virions and light particles had been separated from each other and from other cellular 
material had not been carried out. From such analysis, it would be predicted that structural 
proteins should primarily co-localise with the positions of virions and light particles in the 
gradient. To perform such a study and to determine whether the vhs-CAT fusion protein, 
which was found in preliminary analysis in virions and light particles, could be conclusively 
identified as a structural component, ficoll gradients containing vVHS-CAT virus particles 
were studied by three separate methods; i) by analysing the changes in polypeptide patterns 
across gradients, ii) by assaying CAT activity across gradients, iii) by performing Western 
blot analysis on gradient fractions.
i) Analysis of the changes in polypeptide patterns across ficoll gradients
To analyse the changes in polypeptide patterns across ficoll gradients 4 roller bottles 
of BHK cells were infected with either vVHS-CAT or vSau3 at a moi of 1 pfu per 300 cells 
at 31°C. 24 hours after infection, 250pCi of 35S-methionine was added to each of the roller 
bottles. 4 days after infection, cell-released virus was prepared and ran on ficoll gradients. 
500pl fractions across each gradient were collected and 40jil aliquots were ran on 5-15% 
polyacrylamide gels (Fig. 13). During collection of the fractions it was noted that virions 
were concentrated in fractions 6 to 10 and light particles were present in fractions 12 to 16.
Analysis of the polypeptides present in each fraction revealed that the major capsid 
protein, VP5 was most abundant in fractions 6 to 8 in each gradient. These fractions 
correspond to those containing virions. Thereafter, abundance declined and beyond fraction 
14, VP5 was barely detectable. A second capsid protein, VP 19c showed a similar pattern of 
appearance and disappearance across tl^^raclient. The other major species identified in the 
virion fractions included tegument proteins, (VP1, V P11/12, VP13/14, VP16 and VP22) 
and glycoproteins (gB/gC/gH and gD). Beyond the virion fractions, the abundances of these
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Figure 14. Detection of CAT activity in vVHS-CAT virions and light particles. 
Following the inoculation of 4 roller bottles of BHK cells with either vVHS-CAT or 
vSau3 at a moi of 1 pfu per 300 cells, virus was harvested after 72 hours incubation 
at 31°C, and the cell released material for each virus was banded on 13ml 5-15% 
ficoll gradients. 43x 250pl fractions were collected from each of the gradients from 
aproximately 2cm below the virion band. CAT assays were performed on 25 pi of 
each fraction and activity is expressed as a percentage of the total CAT activity 
loaded onto each gradient.
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tegument and envelope proteins did not diminish. Indeed, certain proteins increased in 
abundance (eg. VP11/12, VP13/14, VP16, VP22) and other novel species appeared 
(Vmwl75). These fractions (12 to 16) correspond to the region in the gradient containing 
light particles. Previous data has shown that Vmwl75 is specific to light particles made in 
BHK cells (McLauchlan et al., 1992a). From fractions 17 to 19 the abundance of the 
tegument proteins markedly decreases and the polypeptide pattern progressively resembles 
that of the soluble protein which has not entered the gradient (fraction 19). However at the 
top of the gradient there remain low but detectable amounts of tegument proteins. It is 
interesting to note that the glycoprotein band that contains gB, gC and gH does not 
specifically localise to virions and light particles but is present in high abundance towards the 
top of the gradient. A band of 45KDa which presumably corresponds to actin, a very 
abundant cellular protein, is present in low concentrations throughout the gradient but is 
most intense at the top. These results show that although protein is present throughout the 
ficoll gradients, the fractions containing virions and light particles can clearly be 
distinguished by the abundance of major capsid protein (for virions) and that of tegument 
proteins (for virions and light particles).
Comparison of the vVHS-CAT and the vSau3 gradients failed to identify any novel 
protein of 84KDa which would correspond to the fusion protein. This protein is therefore 
likely to be of minor abundance in vVHS-CAT virions and light particles.
ii) Analysis of CAT activity
Since the fusion protein could not be directly detected by analysing the polypeptides 
in virions and light particles, CAT assays were performed on fractions collected from ficoll 
gradients of vVHS-CAT and vSau3 virus preparations. Preliminary studies had shown 
that CAT activity could be directly determined without the need for biochemical disruption 
of the virus particle (data not shown). Gradients of vVHS-CAT and vSau3 virus particles 
were run and fractions collected. 25pi aliquots from each sample were analysed for CAT 
activity and the results are presented in Fig. 14. Since the level of CAT activity present in 
vSau3-infected cells was considerably higher than that in vVHS-CAT infected cells, CAT 
activity in each sample is expressed as a percentage of the total CAT activity loaded onto 
each gradient. In the vVHS-CAT gradient, a broad peak of activity was formed across the 
region in which virions and light particles migrated. In contrast the equivalent location 
within the vSau3 gradient had very low levels of CAT activity. In both gradients levels of 
CAT activity were seen to rise at the top where the soluble infected cell material is found.
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Figure 15. Detection of vhs-CAT fusion protein in material collected from across a 
ficoll gradient. Follow ing banding of the vVHS-CAT and v65-CAT virus 
preparations on 13ml ficoll gradients, fourteen 700pl fractions were collected from 
2cm above the bottom of each tube to the top of each gradient and 15pi of each 
sample was loaded onto 12% SDS polyacrylamide gels. The polypeptides were then 
transferred to nitro-celloulose membranes. The membranes were incubated with anti- 
CAT monoclonal antibody, and the v65-CAT membrane was then stripped and 
reprobed with LP-1 monoclonal antibody, a) The vVHS-CAT membrane probed 
with anti-CAT monoclonal antibody 5/25. The 84KDa band representing the vhs- 
CAT fusion protein is indicated, as are the sizes of the major breakdown products of 
the vhs-CA T fusion protein, b) The v65-CAT membrane probed with pp65 
monoclonal antibody, c) v65-CAT membrane reprobed with LP-1 monoclonal 
antibody. VP 16 is indicated. In lane 1 of b) and c), vUL49ep infected cell extract 
was included as a positive control. This virus is described in Chapter 8; Results, 
Part 2. The sizes of the polypeptides detected by the antibody are indicated.
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The coincidence of CAT activity in fractions containing virions and light particles provide 
evidence that the vhs-CAT fusion protein, but not native CAT protein, is incorporated into 
virions and light-particles.
iii) Western Blot Analysis
For Western blot studies virions and light-particles were prepared from four roller 
bottles which had been infected with vVHS-CAT (as described in the previous two 
sections). On this occasion a parallel preparation of control virus, v65-CAT, was made. 
Following banding of the vVHS-CAT and v65-CAT virus preparations on ficoll gradients, 
fractions were collected and 15|il of each fraction was loaded onto 12% SDS 
polyacrylamide gels. After transfer onto nitrocellulose membranes, both membranes were 
incubated with anti-CAT monoclonal antibody (Fig. 15a and 15b). Results showed that the 
vhs-CAT fusion protein was detected in all fractions collected, and the intensity of the bands 
peaked in fractions 5 to 12 which is the region of the gradient that contains virions and light 
particles (Fig. 15a). This pattern of appearance of the vhs-CAT protein reflects that of 
tegument proteins in Fig. 13 where they were most abundant in fractions containing virions 
and light particles but could be detected even in fractions at the top of the gradient. In 
contrast, the v65-CAT gradient indicates that CAT protein cannot be detected within the 
gradient (Fig. 15b). Reprobing this membrane with LP-1 monoclonal antibody, specific for 
VP 16, demonstrated the presence of the virus-specific VP 16 polypeptide within the samples 
containing virions and light particles (Fig. 15c). This data strongly suggests that the vhs- 
CAT fusion protein is incorporated into vVHS-CAT virions and light particles.
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Figure 16. a) Detection of breakdown products of the vhs-CAT fusion protein. 
Ficoll purified vVHS-CAT virions were loaded onto a 9% polyacrylamide gel in the 
quantities indicated. Following electrophoresis the polypeptides were transferred to 
nitrocellulose membrane and then incubated with anti-CAT polyclonal antisera (1: 
3000 dilution). The sizes of the polypeptides detected are indicated, b) Illustrates the 
possible cleavage sites which would give rise to the breakdown products.
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Detection of Breakdown Products of the 
vhs-CAT Fusion Protein
From the Western blot studies shown in Figs. 11 and 15a, it was apparent that the 
monoclonal mouse CAT antibody detected not only the 84KDa vhs-CAT fusion protein but 
also lower molecular weight species in extracts from vVHS-CAT infected cells and vims 
particles. Further Western blot analysis with the rabbit polyclonal anti-CAT antiserum also 
identified breakdown products of the vhs-CAT fusion protein. Fig. 16a shows a further set 
of data where the breakdown products were detected in vVHS-CAT virions. The major 
polypeptides detected by the antiserum have sizes of 84KDa (full-length vhs-CAT fusion 
protein), 44KDa and 23KDa. These are consistent with the molecular weights of the smaller 
products found in Figs. 11 and 15a. Since these antibodies detect the C-terminal CAT 
portion of the fusion protein, Fig 16b illustrates the possible cleavage sites which would give 
rise to the breakdown products assuming that cleavage of the vhs-CAT protein does not 
occur in the CAT sequences. Interestingly, the 23KDa polypeptide is similar in size to 
native CAT protein, suggesting that cleavage of the fusion protein may occur in the region 
linking the vhs and CAT proteins. The 44KDa protein detected would suggest a region 
sensitive to proteolysis within the vhs protein.
F igure  17. W estern blot analysis of v65-CAT infected cell extracts using undiluted 
supernatant from each of the selected hybridoma cell lines. As a positive control one strip 
(13) was incubated with pp65 monocloanl antibody at a 1:2000 dilution. The hybridoma 
cell lines producing anti-CAT IgG are indicated (16 and 25).
pp65
F igure 18. Western blot analysis of v65-CAT infected cell extracts using 
undiluted supernatant from hybridoma cell line numbers 16 and 25. As a 
positive control one strip was incubated with pp65 monocloanl antibody at a 
1:2000 dilution.
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Part 2
Purification of Anti-CAT Monoclonal 
Antibody
The commercially available anti-CAT antibody was found to have poor avidity for 
the CAT component of the vhs-CAT fusion protein, and gave unreliable results. This 
necessitated the production of a new CAT antibody, which delayed progress and prevented 
further use of CAT as a marker polypeptide.
The production of an anti-CAT monoclonal antibody was performed by Dr. S. 
Graham and involved the inoculation of Balb/c mice with purified CAT protein (supplied by 
Professor W. Shaw, University of Leicester). Spleen cells were removed from the mice and 
fused with SP2/OAg-14 Balb/c myeloma cells (supplied by Flow Laboratories), and 
colonies were selected in Dulbecco's modified Eagles medium supplemented with 100p,M- 
hypoxanthine, 0.42|iM-aminopterin and 63p.M-thymidine (HAT). The supernatants were 
screened for reactivity with purified CAT protein by ELISA assay. The resulting cell lines 
were screened for the production of anti-CAT antibody via Western blot analysis.
Section 1
Screening of Hybridoma Cell Lines for the Production 
of Anti-CAT IgG
Western blot analysis was performed on v65-CAT-infected cell extracts ( Chapter 8; 
Results, Part 2). This virus synthesises CAT protein tagged at the N-terminus with a 10 
amino acid epitope tag that is recognised by a monoclonal antibody, pp65 (Chapter 8; 
Results, Part 1). Following separation of the v65-CAT infected cell extracts, and transfer to 
nitrocellulose membrane, the membrane was cut into 0.5cm strips, and each strip was 
incubated with undiluted supernatant from hybridoma cell lines which were reactive with 
CAT in ELISA assays. As a positive control, one strip was incubated with pp65 
monoclonal antibody. Results indicated that supernatants from two cell lines detected the 
CAT protein which was also recognised by the pp65 antibody (Fig. 17, strips 16 and 25).
These two cell lines were then passaged a further twice, and the Western blot 
analysis of v65-CAT infected cell extracts was repeated using undiluted supernatant from 
these cell lines (Fig. 18). The hybridoma cell line derived from clone number 25 (Fig. 18),
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F igure 19. Titration of FPLC purified anti-CAT IgG by Western blot analysis. 
Follow ing separation of v65-CAT infected cell extracts on a 14% 
polyacrylam ide gel, the polypeptides were transferred to nitrocellulose 
m embrane. The membrane was cut into 0.5cm strips and each strip was 
incubated with a different concentration of anti-CAT IgG. The dilutions of 
antibody are indicated.
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appeared to have the greatest avidity for CAT. This hybridoma cell line was therefore 
selected for the production of anti-CAT IgG, and the antibody was termed 5/25. As 
described in Chapter 6; Methods, Section 1.1, cells were maintained in Dulbecco's modified 
medium which was harvested following each passage of the hybridoma cell line.
Section 2
FPLC Purification and titration of the anti-CAT 
Antibody
Anti-CAT monoclonal antibody (5/25) was FPLC purified through a Pharmacia 
Protein G column as decribed in Chapter 6; Methods, Section 4.7. In order to determine 
the optimal concentration at which the purified anti-CAT monoclonal antibody should be 
used during Western blot analysis, the purified anti-CAT antibody was titrated. 0.5cm 
nitrocellulose strips containg v65-CAT infected cell extracts were each incubated, for 1 hour 
at 37°C, with different concentrations of purified anti-CAT IgG. This showed that the CAT 
fusion protein could be detected by the antibody at dilutions as low as 1:20,000 (Fig. 19). 
The CAT protein was an abundant species in the v65-CAT infected cell extract, however the 
amount of CAT protein produced by vVHS-CAT was considerably less and therefore it was 
decided to use the antibody at a dilution of 1:2000.
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Discussion
One of the key aims of this study was to devise a manipulatable experimental system 
that would enable the characterisation of sequences that direct proteins to the tegument. The 
tegument protein chosen for investigation was the vhs protein encoded by UL41. As a first 
step in determining which sequences were responsible for directing vhs into the tegument, it 
was decided to construct a fusion gene consisting of the HSV-2 UL41 gene, fused to the 
bacterial reporter gene chloramphenicol acetyl transferase (CAT). These sequences were 
recombined into the HSV-1 genome at the TK locus, and it was shown that the resulting 
fusion product was incorporated into virions and light particles.
This system of tagging structural polypeptides of viruses has previously been shown 
to be effective by two different groups (Haung et al., 1988; Wu et al., 1995). Haung etal. 
(1988) constructed a fusion protein composed of the 1 lKDa vaccinia virus structural protein 
linked to the bacterial Lac Z  protein in order to develop a rapid selection procedure for 
vaccinia virus recombinants. Results showed that a vaccinia virus recombinant expressing 
the llK D a-L ac Z fusion protein incorporated an enzymatically active Lac Z  into virus 
particles, which could also be detected using anti-Lac Z  antibodies in indirect 
immunoflourescence studies and immuno-gold labelling. More recently, in order to test 
whether HIV-1 and HIV-2 Vpr and Vpx proteins could be used as vehicles to target foreign 
proteins to HIV virions, the genes encoding these proteins were fused with the bacterial 
staphylococcal nuclease and CAT genes (Wu et al., 1995). This study demonstrated the 
capability of HIV-1 Vpr and HIV-2 Vpx to direct the packaging of foreign proteins into 
HIV virions when expressed as heterologous fusion proteins (Wu et al., 1995).
The characterisation of vVHS-CAT showed that not only was the vhs-CAT fusion 
protein incorporated into virus particles, but the enzymatic activity of CAT remained 
assayable in both purified virions and light particles. Similarly, CAT fused to HIV-1 Vpr 
and HIV-2 Vpx proteins was enzymatically active in recombinant virus particles (Wu et al., 
1995). Taken together, the results of Wu et al., (1995) and those presented in this thesis 
indicate that CAT appears to play a passive role when fused to structural proteins but is 
sufficiently robust to retain enzymatic activity. Thus its use may be generally applicable to 
analysing the ability of short peptide sequences to be incorporated into virus particles.
The levels of CAT activity detected in vVHS-CAT infected cell extracts, as well as in 
purified virus particles, were low in comparison to the CAT activity detected within both 
vSAU3- and v65-CAT-infected cells. In vSAU3 the gene expressing CAT is under the 
control of the UL40 gene promoter which results in approximately 2.6-fold more activity, 
while in v65-CAT the strong HCMV IE gene promoter expresses approximately 6.7-fold
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greater levels of CAT activity in comparison to the levels expressed in vVHS-CAT infected 
cells (Section 4). The low levels of expression of the vhs-CAT fusion protein were also 
evident in the 35S-methionine labelled vVHS-CAT virion and light particle profiles. These 
did not appear to contain a novel 84KDa band corresponding to the predicted size of the 
fusion protein. HSV-1 and HSV-2 vhs proteins are minor components of infected cells and 
virus particles, and it is likely that these low levels of expression reflect the activity of the 
UL41 gene promoter. In an attempt to avoid this problem in subsequent experiments 
(■Chapters 8 and 9), tagged tegument protein constructs were placed under the control of the 
strong HCMV immediate early promoter.
The detection of 35S-methionine labelled virus polypeptides across gradients 
illustrated the different patterns of distribution of virion and light particle polypeptides 
compared with the abundant cellular protein, actin. This showed that cellular material did 
migrate through gradients. In addition, Western blot analysis across ficoll gradients of 
material collected from cells infected with v65-CAT ( Chapter 8; Results, Part 2) illustrated 
how a non-structural protein migrated through a gradient. The 65-CAT fusion protein 
detected did not preferentially localise in the region of the gradient where virions and light 
particles banded, and the pattern was clearly distinct from that of the major virion 
polypeptide VP 16. These results were of general interest since several other proteins have 
been identified as virion components solely on the basis of Western blot analysis of purified 
virions. For example, the 2 IK protein encoded by US 11 was classified as a virion 
component on this basis (Roller & Roizman, 1992). It may also be significant that the 
purification of virus particles, by Roller & Roizman, was performed on sucrose gradients, 
and this method does not separate virions from light particles. In view of the potential for 
misleading results due to the high sensitivity of antibody detection, Western blotting across a 
ficoll gradient was adopted as a diagnostic test for incorporation of tagged proteins into the 
tegument of virions and light particles in all subsequent experiments.
The results presented in this section demonstrate that the vhs-CAT fusion protein 
was incorporated into virus particles, but sequences which were necessary for the 
incorporation of vhs were not identified. Following the conclusion of the investigation of 
vhs, Smibert et al. (1994) demonstrated that vhs from HSV-1 strain KOS PAAr5 (bearing a 
wild type vhs gene) forms a complex with VP 16, and a 21 amino acid domain spanning 
residues 310-330 of vhs is responsible for the interaction (Schmelter et al., 1996). It has 
been suggested that this interaction serves to negatively regulate vhs activity but it may also 
provide a route for translocation of vhs into the viral assembly pathway. There are a number 
°f pieces of evidence supporting these conclusions. Firstly, it was recently demonstrated 
that infection of non-permissive cells with the VP 16 null mutant 8MA (Weinheimer et al.,
86.
I
Chapter 7; Discussion
1992) results in an abrupt decline in viral protein synthesis at early and late times, due in part 
to a rapid degradation of viral mRNAs (Lam et al., submitted). Viral mRNA levels and 
protein synthesis are restored in virus expressing a transactivation defective, vhs-binding 
derivative of VP 16 and in an 8MA derivative deleted in vhs, suggesting that rapid mRNA 
turnover in non permissive cells infected with 8MA is the result of uninhibited vhs activity 
due to the absence of VP 16 (Lam et al., submitted). These findings indicated that VP 16 can 
regulate viral gene expression at the post translational level by suppressing the activity of vhs 
at early and late times during infection, thereby sparing the viral mRNAs from destruction 
(Schmelter et al., 1996; Lam et al., submitted). Circumstantial evidence supporting the 
proposal that VP 16 is involved in the incorporation of vhs into virus particles includes the 
fact that VP16 is essential for virion assembly (Ace et al., 1988; Weinheimer et al., 1992), 
while vhs is dispensable (Fenwick & Everett, 1990), such that within vhs negative mutant 
viruses levels of VP 16 are normal. Thus it is reasonable to suggest that VP 16 would help to 
package vhs not vice versa. Most significantly, a mutant virus that synthesises a vhs protein 
lacking residues 149-344 cannot bind to VP16, and is not packaged into virus particles 
(Read eta l., 1993). The 21 amino acid sequence that interacts with VP16 is conserved in 
both HSV-1 and HSV-2 vhs proteins (Berthomme e ta l., 1993; Schmelter et al., 1996). 
Therefore if HSV-1 vhs is packaged into the tegument via an interaction with VP 16 it is 
reasonable to suggest that the vhs-CAT fusion protein which contains a HSV-1 vhs moiety 
is also packaged following an interaction with VP 16.
The 44KDa band detected by Western blot analysis of purified vVHS-CAT virions 
{Section 7) suggested that breakdown of VHS-CAT was occuring. Breakdown of a vhs- 
protein A fusion protein was also observed by Smibert et al., (1994) and electrophoretic 
analysis of this protein revealed that it was cleaved within its vhs moiety, two thirds from the 
amino terminus, in approximately the same position as the cleavage within vhs-CAT. vhs 
homologues from other alphaherpesviruses, such as PRV, EHV, and VZV, have regions of 
sequence identity with HSV-1 vhs throughout their lengths (Berthomme et al., 1993). The 
comparison of different vhs homologues suggested that vhs is composed of four individual 
functional domains. Recently, mutational analysis verified this data by demonstrating that 
mutations which mapped to regions conserved among vhs homologues inactivated function; 
in contrast four out of five mutations that mapped to regions that are poorly conserved 
among the vhs homologs had no effect (Jones et al., 1995). It is likely that cleavage of both 
the vhs-protein A and the vhs-CAT fusion proteins is occuring at the same position, 
immediately downstream of residues 310-330, which contains the 21 amino acid sequence 
that interacts with VP 16. This region corresponds to a region of low homology and is likely 
to separate two different functional domains of vhs.
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This chapter has demonstrated that a fusion protein between a bacterially derived 
reporter gene, CAT, and the gene encoding the vhs structural protein was incorporated into 
the tegument of both HSV-1 virions and light particles. This, together with the fact that the 
CAT component of the fusion protein retained its activity within virus particles, opens the 
possibility that such an approach could be used to construct multivalent vaccines. HLA 
class I-restricted cytotoxic T lymphocytes are considered to be a major mediator for the 
clearance of HS V infections as demonstrated by their role in limiting recurrent infections in a 
mouse model system. Tigges et a l, (1993) were able to demonstrate that the major 
target antigens for CTL recognition are internal virion proteins that can be effectively 
introduced into the cell by infection even in the absence of de novo gene expression. This 
would suggest that light particles engineered to contain foreign proteins could be effective 
vaccine candidates against a range of different viral infections.
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Part 1
The Construction of vUL49ep
The previous chapter had shown that it is possible to modify the vhs protein without 
disabling its ability to enter the tegument. However, vhs is a minor component of virus 
particles and direct quantitation of the amount of vhs-CAT protein incorporated was not 
possible by standard staining methods. Since the vhs studies were hampered due to 
difficulties with immunological reagents, quantitative analysis of vVHS-CAT mutant 
proteins would have been difficult to perform. For this reason, studies on the factors that 
influence incorporation into the tegument were continued with a major tegument protein 
VP22, which is encoded by UL49. Since it was not known whether VP22 is essential for 
virus growth, a second copy was placed under the control of the HCMV IE promoter which 
gives high levels of gene expression in heterologous systems. In order that the properties of 
the inserted copy could be compared with those of VP22 produced by the endogenous UL49 
gene, an epitope tag was linked at the C-terminus of the VP22 coding sequences. The use of 
the HCMV IE promoter also allowed, for the first, time, studies to be carried out on the 
effects of protein levels on the amount of protein incorporated into virus particles. 
Therefore, this section describes the basis of the system used for the mutagenesis studies in 
the following chapter and also addresses constraints placed on tegument assembly.
Section 1
Construction of Plasmids
To construct a plasmid that would express epitope-tagged VP22, a number of 
cloning steps were undertaken. The plasmids resulting from these steps are illustrated in 
Figs. 20a-c. The parent plasmid, pFJ22 is a derivative of pFJ3 (Rixon & McLauchlan, 
1990; Chapter 8; Results, Part 2, Section 1) which lacks the LacZ gene cassette but does 
contain a 744bp Bglll fragment containing the HCMV IE promoter sequence (Stinski & 
Roehr, 1985) and a 300bp Sau3AI fragment containing the HSV-2 UL38 polyadenylation 
sequences (McLauchlan et al., 1989). A 40bp oligonucleotide which encodes the epitope 
tag sequence was inserted into the BamHI site of pFJ22, which resulted in plasmid pFJ22ep 
(Fig. 20b). Due to the design of the oligonucleotide, only the BamHI site at the 5' end of the 
°ligonucleotide was retained, which enabled the linkage of the epitope tag directly to protein
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Figure 20. Details of plasmids used to construct vUL49ep. a) Plasmid 
pUL492 which contains the reconstructed UL49 ORF in pBluescript KSII 
DNA. The nucleotide and amino acid sequences at the 3' end of the UL49 
ORF are shown along with the position of the BamHI site within the 
oligonucleotide, b) Plasmid pFJ22ep which comprises a 744bp sequence 
containing the HCMV IE promoter, a 40bp oligonucleotide that encodes the 
epitope tag sequence (ep) and a 300bp fragm ent containing the 
polyadenylation sequences fron the HSV-2 UL38 gene (LpA). The 
nucleotide sequence of the oligonucleotide, the amino acid sequence of the 
epitope tag and the location of the unique BamHI site at the 5' end of the 
oligonucleotide are shown, c) Plasmid pUL49ep which contains the UL49 
ORF from pUL492 inserted into the unique BamHI site of pFJ22ep. Also 
shown are the positions of the Xbal sites which were used for inserting 
epitope-tagged UL49 into 1802 viral DNA.
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coding sequences (Fig. 20b).
The ORF encoding the UL49 gene product was cloned by firstly inserting a 864bp 
Stul/Xhol fragment from plasmid pKpnu (nucleotides 105570-106433 in HSV-1 strain 17 
DNA, McGeoch et al., 1988) into Smal/Xhol digested pBluescript II KS DNA. The 
resultant plasmid, pUL491, contained sequences from 47bp upstream from the 5’ end of the 
UL49 ORF to 80bp upstream from the 3’ end. A 98bp oligonucleotide encoding the 3’ 
terminal portion of the UL49 coding region was inserted into the Xhol site in pUL491 to 
regenerate the 3' end of the UL49 open reading frame, which resulted in plasmid pUL492 
(Fig. 20a). To facilitate further manipulation of the UL49 ORF, this oligonucleotide also 
introduced a second BamHI site one codon before the 3 ’ terminal codon of the UL49 ORF 
(Fig. 20a). Thus, cleavage of pUL492 with BamHI results in a DNA fragment containing 
the entire coding sequences for UL49, but lacking the stop codon at the 3’ terminus of the 
ORF.
To construct an epitope-tagged version of VP22 which could be synthesised under 
the control of the HCMV IE promoter, the 962bp BamHI fragment from plasmid pUL492 
was inserted into the unique BamHI site in plasmid pFJ22ep (Fig. 20b), generating plasmid 
pUL49ep (Fig. 20c).
Section 2
Construction of Virus vUL49ep
To construct a virus which would express the epitope-tagged UL49 ORF under the 
control of the HCMV IE promoter, the 2.07Kbp Xbal fragment containing the UL49 gene 
cassette (Fig. 20c) was purified from pUL49ep and ligated with 1802 virus DNA which had 
been digested with Xbal; this virus is a HSV-1 variant which contains an unique Xbal site in 
the intergenic region between U s genes 9 and 10 (Rixon & McLauchlan, 1990). The 
products of the ligation were transfected into BHK cells and from the resultant progeny, 
individual plaques were selected. Monoclonal antibody, pp65, which recognises the epitope 
tag sequence does not cross-react to any significant extent with other HSV polypeptides 
(DuPont, UK; Weiner e ta l., 1985; McLauchlan eta l., 1994) and thus the VP22 protein 
rnade from the inserted copy of UL49 could be readily distinguished from that made by the 
endogenous UL49 gene. Initially 12 plaques were picked and screened by Western blot 
analysis. Four of the 12 selected plaques synthesised a protein of about 40KDa which was 
recognised by monoclonal antibody pp65 (data not shown). One of these plaques was
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Figure 21. Analysis of vUL49ep viral DNA. a) 0.5|Hg of each plasmid DNA and 2pg 
of each viral DNA was digested with the appropriate enzyme and then electrophoresed on 
a 1% agarose gel. In lane 1, DNA was digested with Xbal while lanes 2 to 4 contain 
BamHI digestion products. The DNAs in each lane were as follows: lanes 1 and 2, 
plasmid pUL49ep; lane 3, vUL49 virus DNA; lane 4, 1802 virus DNA. b) Following
transfer of the DNA to Hybond-N membrane, it was probed with 32P-radiolabelled 
pUL49ep plasmid DNA. Two exposures are shown in (b). c) Organisation of the 
vUL49ep genome at the US9/US10 gene locus. The sizes of the fragments generated by 
BamHI and Xbal digestion in the region where the epitope-tagged UL49 gene was 
inserted are shown.
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chosen and further purified to homogeneity. The resulting virus was designated vUL49ep.
Section 3
Analysis of vUL49ep DNA
To verify that insertion of a second copy of UL49 did not result in rearrangement of 
the virus genome, virus DNA prepared from vUL49ep virions was digested with BamHI 
and the restriction enzyme profile was compared with that of 1802 viral DNA. For size 
markers, pUL49ep was digested with Xbal and BamHI. BamHI digestion of pUL49ep 
released the 962bp UL49 ORF, and a 4 .14Kbp fragment containing the remainder of the 
plasmid (Fig. 21a, lane 2), while Xbal digestion of pUL49ep released two fragments of 
2.08Kbp and 3.0Kbp (Fig. 21a, lane 1). The DNA profile of BamHI digested vUL49ep 
indicated the loss of BamHI z, and the appearance of a doublet of approximately 1.45Kbp, 
as well as an increase in the intensity of the 962bp band. There were no other apparent 
differences in the restriction enzyme patterns of the two viral DNAs (Fig. 21a, compare 
lanes 3 and 4).
The DNA was then transferred to Hybond-N membrane and incubated with 32P- 
radiolabelled pUL49ep which hybridises to all of the sequences within the vUL49ep virus 
that are derived from pUL49ep as well as the endogenous virus-encoded UL49 sequences. 
Hybridisation with this probe revealed that the 8.1 Kbp BamHI f fragment which contained 
the unmodified copy of UL49 was identical in size for both viral DNAs (Fig. 21b, lanes 3 &
4). This probe also detected a DNA fragment of 962bp in vUL49ep DNA which 
corresponds to the inserted UL49 ORF derived from pUL49ep (Fig. 21b, compare lanes 2 
and 3). Two other bands of approximately 1.45Kbp also were unique to vUL49ep DNA. 
The unique Xbal site in 1802 viral DNA lies within the BamHI z fragment and digestion of 
this fragment with BamHI and Xbal generates two products of 1.1 Kbp and 0.7Kbp. Thus 
the 1.4Kbp fragments are derived from fragments containing the HCMV promoter and the 
HSV-2 UL38 late polyadenylation sequences linked to 1.1 Kbp and 0.7Kbp portions of the 
BamHI z fragment. From the sizes of these fragments, it was apparent that the inserted 
UL49 cassette is transcribed in the same direction as genes Us 10-12 (Fig. 21c). In 
conclusion, the introduction of a second copy of UL49 into 1802 viral DNA did not generate 
any gross rearrangements in vUL49ep viral DNA.
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Figure 22. Comparison of the proteins produced by viruses vUL49ep and HSV-1 strain 17 at 
different stages of infection. Aliquots containing 5xl05cpm from radiolabelled extracts prepared 
from strain 17-, vUL49ep- and m ock-infected cells were electrophoresed on a 9% 
polyacrylamide gel. The times, in hours post infection, at which samples were harvested are 
indicated. The bands corresponding to VP22 and epitope-tagged VP22 (VP22t) are shown, as 
are some of the major virus-specific polypeptides.
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Figure 23. Western blot analysis of vUL49ep- and strain 17-infected cell extracts. 
A pproxim ately 2 x l0 4 cell equivalents of 35S-methionine radiolabelled infected cell 
extracts were electrophoresed on a 9% polyacrylamide gel and then transferred to 
nitrocellulose membrane, a) The membrane was probed with monoclonal antibody 
pp65 (1:2000 dilution), b) The membrane was autoradiographed in order to determine 
the size of the polypeptide detected in a). The polypeptides are indicated (-► ).
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Synthesis of Epitope-Tagged VP22 in vUL49ep- 
Infected Cells
The polypeptides made by 1802, the parental virus for vUL49ep, and HSV-1 strain 
17 are indistinguishable (Rixon & McLauchlan, 1990) and therefore in the following 
experiment, HSV-1 strain 17 was used as the control virus. To compare the polypeptides 
produced by vUL49ep with those made by HSV-1 strain 17, 35mm dishes containing 
2 x l0 6 BHK cells were infected with either virus at a moi of 5 pfu/cell, and were labelled 
with 35S-methionine from 3 hours post infection. Cells were harvested at various times 
after infection (up to 18 hours) and extracts were prepared. Examination of the radiolabelled 
proteins revealed that at equivalent times after infection the polypeptide profiles of the two 
viruses were very similar, however virus-encoded proteins did accumulate to slightly lower 
levels in vUL49ep-infected cells (Fig. 22). The major exception was a polypeptide of 
slightly lower mobility than that of VP22 produced in vUL49ep-infected cells (Fig. 22, 
labelled as VP22t).
To show that this protein represented expression of the tagged version of VP22, 
Western blot analysis was performed on the 35S-methionine radiolabelled vUL49ep-infected 
cell extracts using monoclonal antibody pp65. Results showed that the antibody detected a 
protein in the vUL49ep samples which was absent in the HSV-1 strain 17 extracts (Fig. 
23a). This protein could be detected by 3 hours after infection and continued to accumulate 
during the remainder of the infection (Fig. 23a). To verify that this protein corresponded to 
epitope tagged VP22, the membrane was autoradiographed (Fig. 23b). Alignment of the 
proteins detected with the pp65 antibody with those detected by autoradiography confirmed 
that the protein identified in the vUL49ep samples in Fig. 22 comigrated precisely with 
VP22 protein (compare Figs. 23a and 23b). Thus, it was concluded that vUL49ep produces 
high levels of VP22 which can be attributed to expression of the tagged version of this 
protein. The epitope-tagged form of VP22 shall be referred to as VP22t.
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Figure 24. Growth characteristics of vUL49ep compared with the parent virus 1802. 
On two separate occasions, a) and b), 35mm dishes containing approximately 2 x l0 6 
BHK cells were infected at a moi of 5 pfu per cell and harvested at various time points 
ranging between 0 and 36 hours after infection. The total amount of virus present at 
each time point was determined by titration.
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Section 5
Growth characteristics of vUL49ep
In order to determine whether the growth of vUL49ep was affected by the insertion 
of a second epitope tagged copy of UL49, the growth characteristics of vUL49ep were 
compared to those of the parent, 1802. The experimental procedure was as described in 
Chapter 6; Methods, Section 1.7. Two sets of data were obtained on separate occasions, and 
both are presented (Fig. 24a & b).
In order to determine the rate of growth from a growth curve, the gradient of the 
slope during the exponential phase of growth is calculated, and the steeper the gradient the 
faster the rate of growth. In addition, the final virus yields are also taken into account. In 
both Figs. 24a and 24b, the gradients of the slopes during the exponential growth phase 
(between 12 and 24 hours in Fig. 24a; between 3 and 15 hours in Fig. 24b) for vUL49ep are 
not as steep as that for 1802, which would suggest a slower rate of growth for vUL49ep as 
compared to 1802. However, in both of the vUL49ep examples the virus titre during the 
eclipse phase does not fall as significantly as does 1802. There is however variability 
between the yields of preparations of vUL49ep as shown in Figs. 24a & 24b and Table 6, 
and these differences suggest that yields of vUL49ep are either equivalent to or slightly less 
than 1802. The growth curve data therefore suggests that the insertion of the epitope tagged 
copy of UL49 into the Us region of strain 1802 does not have a significant effect on the 
growth of the virus.
Section 6
Properties of Virus Particles Produced by vUL49ep
To analyse the migration characteristics of virus particles made by vUL49ep, four 
roller bottles of BHK cells were infected with either vUL49ep or 1802 at a moi of 1 pfu per 
300 cells, incubated at 37°C for 3 days, and the cell released material was banded on 5-15% 
ficoll gradients. Examination of these gradients revealed that the vUL49ep virions and light 
particles each sedimented further than those of HSV-1 1802 (Fig. 25). Also the band 
containing the vUL49ep virions was more diffuse than the corresponding 1802 virion band. 
From electron microscopic analysis of the virus particles purified from these gradients, the
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Figure 25. Comparison of virions and light particles produced from cells 
infected with 1802 or vUL49ep. Particulate material pelleted from cells infected 
with 1802 or vUL49ep was banded on 5-15% ficoll gradients. Bands 
corresponding to virions (V) and light particles (L) are indicated.
Virion Sample Virions Light particles
1802 (Prepn. 1) 4.2x10“  (75%) 1.4x10“  (25%)
vUL49ep (Prepn. 1) l.lx lO 11 (46%) 1.3x10“  (54%)
1802 (Prepn. 2) 5.9x10“  (67%) 2.9x10“  (33%)
vUL49ep (Prepn. 2) 5.2x10“  (50%) 5.1x10“  (50%)
Table 6. Numbers of virions and light particles in vUL49ep and 1802 virion 
populations. Particle counts were calculated as the number of virus particles per ml. 
Values in brackets are the percentage of either virions or light particles in each virion 
preparation.
virions light-particles
F igure 26. Western blot analysis across a vUL49ep gradient. Material was collected in 
500|il aliquots from 2cm below the virion band in a 13ml, 5-15% ficoll gradient that was 
loaded with material from vUL49ep-infected cells. 15fil of each sample was loaded onto a 
12% polyacrylamide gel and following separation the polypeptides were transferred to 
nitrocellulose membrane. The membrane was incubated with pp65 monoclonal antibody 
(1:2000 dilution), and the band detected represents epitope-tagged VP22 (VP22t) which is 
present in the regions where virions and light particles migrate through the gradient. The 
locations of visible virion and light particle bands are indicated below the blot. * represents 
v65-CAT-infected cell extract, and was included as a positive control for antibody binding.
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population of vUL49ep virions had a high concentration of light particles while the number 
of light particles in the 1802 virion population corresponded to the level typically present in 
preparations of wild-type virus (Table 6; Szilagyi & Cunningham, 1991). Other 
preparations of vUL49ep and 1802 grown in parallel consistently revealed similar 
differences, and two examples of preparations are shown in Table 6. These results suggest 
that vUL49ep virus particles have a greater mass than those of 1802 and the increased 
abundance of light particles in vUL49ep virion preparations may suggest that there is a 
greater size heterogeneity in these particles as compared to 1802 light particles.
Section 7
Incorporation of Tagged VP22 into Virus Particles
In order to establish whether VP22t was incorporated into vUL49ep virions and light 
particles the distribution of VP22t through a gradient of vUL49ep prepared from four roller 
bottles of BHK cells was analysed by Western blot. Incubation of the blot with pp65 
monoclonal antibody revealed that VP22t was distributed throughout the region of the 
gradient containing virions and light particles (Fig. 26). This distribution was consistent 
with that described for tegument proteins such as VP16 (Chapter 8; Results, Part 2, Section 
5). In contrast, non-structural proteins, such as CAT ( Chapter 8; Results, Part 2, Section
5), are detected only in the fractions towards the top of the gradient containing soluble 
material, if at all. This result suggests that VP22t is incorporated as a structural component 
of virions and light particles.
Section 8
Polypeptide Content of vUL49ep Virus Particles
To further characterise vUL49ep virions and light particles their polypeptide profiles 
were compared with those of the parental virus 1802 (Fig. 27). The most striking difference 
in the polypeptide content was a novel abundant protein in vUL49ep virions and light 
particles which had a slightly slower mobility than the VP22 present in 1802 virus particles 
(Fig. 27). This polypeptide was confirmed to be VP22t by Western blot analysis (Fig. 29a).
Examination of the gel shown in Fig. 27 revealed that vUL49ep virions and light
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Figure 27. Comparison of polypeptide profiles of gradient-purified particles produced 
by 1802 and vUL49ep. Approximately 3 x l0 9 virus particles were analysed on a 9% 
polyacrylamide gel. Following electrophoresis, the gel was stained with Coomassie 
Brilliant blue. Samples in each lane are as shown. C represents purified HSV-1 (B) 
capsid proteins, which were included as size markers. The major structural 
polypeptides are indicated, as is the band corresponding to epitope-tagged VP22 
(VP22t).
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Figure 28. Densitometric analysis of vUL49ep virions and HSV-1 strain 17 
virions. The major polypeptides are indicated, as is the area corresponding to 
epitope tagged VP22 (VP22t). The amount of each of the major polypeptides 
is expressed as a % of the total protein content within the polyeptide profile.
Polypeptides analysed
VP5d gB, gC, gHd VP13/14d VP16C VP22d
predicted copy 
numbers
960 1750 1846 1647 ND
(average)0
V 895 1307 1691 1647 2872
1802a
L 1828 1730 1647 4349
V
vUL49epa
L
477 1177
1462
992
1076
1647
1647
7745
8668
1802b v 1100 1288 1753 1647 2531
L 1824 14 66 1647 3570
vUL49epb v 582 1191 723 1647 6365
L 1668 933 1647 7090
Table 7. The copy numbers of VP5, gB(gC, gH), VP13/14 and VP22 were estimated 
following the excision of these bands from Coomassie Brilliant blue stained gels. The protein 
concentration was estimated following the elution of the Coomassie Brilliant blue stain in each 
band in 25% piperidine solution followed by spectrophotometric analysis at 605nm. The copy 
number for each polypeptide was calculated assuming that the copy number of VP 16 remains 
constant in each virus.
a vUL49ep and 1802 virus particles corresponding to preparation 1 in Table 6. 
b vUL49ep and 1802 virus particles corresponding to preparation 2 in Table 6. 
c average number of copies of VP 16 present in virions was taken from Zhang & McKnight 
(1993).
d number of copies of major structural species was calculated relative to the estimated copy
number of VP 16.
ND = not determined
Chapter 8; Results
particles contain both species of VP22 expressed by the recombinant, however, the epitope- 
tagged version is considerably more abundant than the unmodified copy of VP22. Indeed, 
epitope-tagged VP22 is the most abundant polypeptide in vUL49ep virus particles. Two 
methods were used to quantitate the amount of VP22 present in vUL49ep virions and light 
particles as compared to strain 17 and/or 1802 virions and light particles. Initially, the 
Coomassie Brilliant blue stained polypeptide profiles of vUL49ep and strain 17 virions were 
scanned using a densitometer. The use of strain 17 rather than strain 1802 for comparative 
purposes in these analyses did not significantly affect the results since both of these viruses 
have indistinguishable polypeptide profiles. From densitometric analysis it was determined 
that there was approximately a 3-fold increase in the total amount of VP22 in vUL49ep virus 
particles (Fig. 28).
An alternative method of quantitation further supported the densitometric data. 
Following sepparation of the polypeptides on an acrylamide gel, and staining with 
Coomassie Brilliant blue, the amount of stain in each of the polypeptides was used to 
estimate the copy number of each polypeptide. Following excision of each band from the 
Coomassie stained gel, the stain was eluted in a 25% piperidine solution and 
spectrophotometrically analysed. The following bands from a gel containing two different 
preparations of both vUL49 and 1802 were excised: VP5, gB, VP13/14, VP16 and VP22. 
Due to the densitometric analysis it was clear that the abundances of two major virion bands 
(the 120KDa band containing gB, gC, gH and the protein encoded by UL37, and the 65KDa 
band containing VP 16) did not significantly differ, and it was therefore assumed that the 
copy number for VP 16 in each virus strain remained constant. With this in mind the copy 
numbers for each of the polypeptides excised were calculated. Both sets of data indicated 
that there were reductions of 40-50% in the quantities of the major capsid protein, VP5, and 
two related tegument proteins, VP 13/14. The apparent decrease in abundance of VP5 in 
vUL49ep virions is likely to be a result of the high levels of light particles present in 
vUL49ep virion preparations (Table 6). As a result the capsid proteins will appear to be 
under represented in the polypeptide profiles of vUL49 virions. In the case of VP 13/14, 
these proteins are present in similar amounts in both HSV-1 strain 17 virions and light 
particles. Thus, the higher quantities of light particles in vUL49ep virion preparations does 
not account for the reduced abundance of these proteins in vUL49ep virions and light 
particles. From the data presented in Table 7, there was also a 2-2.5 fold increase in the 
abundance of VP22 in vUL49ep virus particles.
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Figure 29. Proteins in 1802 and vUL49ep virions and light particles solubilised by 
detergent treatment. The material from approximately 3 x l0 9 particles was 
separated on a 9% polyacrylamide gel and transferred to nitrocellulose membrane. 
The membrane was first probed with pp65 monoclonal antibody (at a dilution of 
1:2000), (a) then stripped and reprobed with CY8 monoclonal antibody (at a 
dilution of 1:2000) (b). Samples in each lane have been indicated as follows: V: 
virion, L: light particle, Vp: pelleted material from NP40-treated virions, Vs: 
supernatant material from NP40-treated virions, Lp: pelleted material from NP40- 
treated light particles, Ls-' supernatant material from NP40-treated light particles. 
VP22 and epitope tagged VP22 (VP22t) are indicated (—► ).
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Section 9. 
Solubility of VP22t in vUL49ep Virus Particles
Previous studies have shown that VP22 is not removed from the tegument following 
solubilisation by detergent (McLauchlan & Rixon, 1992) . To determine whether epitope- 
tagged VP22 exhibited similar behaviour approximately 3x l09 virions and light particles 
made by 1802 and vUL49ep were treated with NP40. The resultant insoluble material 
which consists almost entirely of tegument/capsid proteins (from virions) and tegument 
proteins (from light particles) can be separated from the envelope components by 
centrifugation (McLauchlan & Rixon, 1992). Western blot analysis of the soluble and 
insoluble fractions with pp65 monoclonal antibody revealed that epitope-tagged VP22 
remained in the insoluble material and could not be detected in the envelope fraction (Fig. 
29a, compare Vp & Lp with Vs & Ls). Using CY8 antibody, which recognises VP22, to 
probe the same membrane, an identical result was obtained (Fig. 29b). Thus, although 
vUL49ep virus particles contain increased amounts of VP22, the protein remains tightly 
associated with the tegument.
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Part 2 
The construction of virus control v65-CAT
In parallel with the construction of vUL49ep, a control virus, v65-CAT, was also 
made which expressed an epitope-tagged version of the CAT protein. Since results 
presented in Chapter 7; Results, Section 6 had shown that unmodified CAT protein did not 
incorporate into virus particles, the rationale behind the construction of v65-CAT was to 
ensure that the 10 amino acid epitope tag sequence, derived from the major tegument protein 
pp65 of HCMV, was not responsible for the incorporation of proteins into the HSV-1 
tegument.
Section 1.
Plasmid Construction
To enable the expression of an epitope-tagged form of the CAT protein, a series of 
cloning steps were undertaken. The resulting plasmids are shown in Fig. 30a-f. The parent 
plasmid pFJ3 (Rixon & McLauchlan, 1990) has a multiple cloning site at position 3736. 
This contains Xbal, Bgin, Hindlll and BamHI restriction enzyme sites. A second Xbal site 
is present at position 6782 (Fig. 30a).
The cloning steps were as follows:
i) The polyadenylation sequences from the HSV-2 UL38 gene isolated from pSAU30 were 
cloned into pFJ3. Before insertion of these sequences, an Xbal site in pSAU30, was 
removed by digesting the plasmid with Xbal, filling in the overhanging ends with Klenow 
polymerase and re-ligating the blunt ends. This gave rise to plasmid pSAU30(w/o Xbal). 
Following digestion of pSAU30(w/o Xbal) with Hindlll and BamHI a 500bp fragment was 
gel purified and cloned into Hindlll/BamHI digested pFJ3. The resulting plasmid 
pFJ3/SAU30 is illustrated in Fig. 30b.
ii) An immediate early HCMV promoter sequence from pMJ37 (see Chapter 5; Materials 
Section 3) was then cloned into pFJ3/SAU30. pMJ37 was digested with Sau3AI which 
releases a 744bp fragment containing the promoter sequence. This was cloned into Bglll 
digested pFJ3/SAU30 regenerating Bglll sites flanking the promoter sequence. The
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Figure 30. Details of plasmid vectors used to construct v65-CAT. The 
parent plasmid pFJ3 has a polyclonal linker sequence inserted into the 
BamHI site at position 3736, and the PvuII site at position 6782 was 
converted to an Xbal site (a). The Xbal site in the UL38 polyadenylation site 
from pSau30 was removed and it was then cloned into pFJ3 as a 500bp 
Hindlll/BamHI fragment, resulting in plasmid pFJ3/Sau30 (b). A 744bp 
Sau3AI fragment containing the HCMV IE promoter sequence from pMJ37 
was sub-cloned into the B glll site of plasmid pFJ3/Sau30, resulting in 
plasmid pJLl (c). The CAT open reading frame in plasmid pCATl 
(Chapter 7; Results, Fig. 7c) was sub-cloned as a H indlll fragment into 
pGEMl resulting in plasmid pGEM-CAT (d). Into the BamHI site close to 
the 5’-terminus of the CAT gene, the HCMV UL83 epitope tag sequence was 
inserted which resulted in plasmid pGEM-CATep (e). The epitope-tagged 
CAT ORE from pGEM-CATep was cloned into the unique Hindlll site in 
plasmid pJLl resulting in plasmid p65-CAT (f). The positons of the Xbal 
sites that were utilised to insert the epitope tagged CAT sequence into the 
HSV-1 strain 1802 genome are indicated in plasmid p65-CAT.
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resulting plasmid was called pJLl (see Fig. 30c).
iii) The CAT open reading frame was obtained from pCATl and was initially subcloned as 
a 960bp H indlll fragment into pGEMl (see Chapter 5; Materials, Section 3) resulting in 
plasmid pGEM-CAT (Fig. 30d). In order to construct an epitope-tagged CAT fusion 
protein, the unique BamHI site upstream of the N terminus of CAT was utilised. A 40bp 
oligonucleotide which includes sequences encoding the 10 amino acid epitope used to tag the 
VP22 protein that is recognised by a monoclonal antibody, pp65 (DuPont, UK; Weiner et 
al., 1985; McLauchlan et al., 1994) was cloned into this unique BamHI site. Due to the 
design of the oligonucleotide, insertion of the linker regenerated a BamHI site at the 5' end of 
the oligonucleotide. The oligonucleotide linker contained sequences for a further BamHI site 
and therefore insertion of the linker created two BamHI sites, which flanked the initiation 
codon for the epitope-tagged CAT gene (Fig. 31). Insertion of the epitope tag sequence into 
pGEM-CAT resulted in plasmid pGEM-CATep (Fig. 30e). Commercially available 
primers that annealed to sequences within pGEMl were used to sequence the 5' portion of 
the CAT fragment containing the oligonucleotide insert. The sequence data obtained 
confirmed that the HCMV UL83 epitope tag sequence lay in the correct orientation at the 5'- 
terminus of CAT (Fig. 31). Also, the initiation codon within the oligonucleotide was shown 
to be in-frame with the CAT sequences.
iv) Finally the CAT coding sequences containing the epitope tag sequence from pGEM- 
CATep were cloned as a lOOObp Hindlll fragment into the unique Hindlll site in plasmid 
pJLl (Fig. 30c) resulting in plasmid p65-CAT. (Fig. 30f).
Section 2. 
Construction of Virus Recombinant v65-CAT
To insert the epitope-tagged CAT gene into HSV-1 DNA, p65-CAT was digested 
with Xbal, and the products of the digestion which contained the 6.3Kbp fragment 
containing the CAT and LacZ  gene cassettes were ligated into the unique Xbal site 
engineered into the Us region of HSV-1 1802. The products of the ligation were transfected 
into sub-confluent BHK cells. Once full cpe was visible the medium was harvested and 
extracts were prepared from the infected cells. These were then screened by Western blot 
and CAT enzyme assay which showed that virus synthesising the epitope-tagged CAT
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Figure 31. Sequence across the HCMV UL83 epitope tag sequence. The 
oligonucleotide sequence encoding the HCMV UL83 epitope tag sequence is 
underlined. The initiation codons for epitope-tagged CAT and native CAT proteins, 
and the H indlll and BamHI restriction enzyme sites are indicated ).
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Figure 32. Analysis of v65-CAT DNA. a) Following digestion of 2fig of HSV-1 
strain 1802 (lane 1) and v65-CAT (lane 2) viral DNA with BamHI, the resulting 
fragments were electrophoresed on a 1% agarose gel. As size markers, 0 .5(ig of 
plasmid p65-CAT was digested with H indlll (lane 3) and Xbal (lane 4). The sizes of 
the fragments released are indicated, b) Southern Blot analysis of v65-CAT viral 
DNA. Following electrophoresis, the DNA samples on the gel were transferred to 
Hybond-N membrane and hybridised with 32P-radiolabelled p65-CAT DNA. The 
DNAs in each lane were as in (a), c) Diagramatic representation of the fragments 
released following BamHI and Xbal digestion of p65-CAT. d) Diagram illustrating 
the v65-CAT viral genome. The orientation of the inserted epitope CAT cassette, the 
positions of the BamHI sites and the sizes of fragments released following BamHI 
digestion are shown.
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protein was present (data not shown).
After having established that epitope-tagged CAT protein was synthesised in infected 
cells, the virus was plaque purified. 12 individual plaques were picked and cells infected 
with each of the 12 plaques were analysed for CAT activity. Extracts prepared from cells 
infected with three of the 12 plaques produced CAT activity. One of the three isolates was 
chosen and used to infect cells, and the process of screening for CAT activity was repeated 
on a further 12 isolates. After three rounds of such plaque purification one of the isolates 
was chosen and its DNA structure was analysed. This isolate was termed v65-CAT.
Section 3.
Analysis of v65-CAT DNA.
To verify that the epitope-tagged CAT sequences had inserted at the predicted site 
within the HSV-1 genome, the BamHI digestion pattern of v65-CAT was compared to that 
of the parent virus HSV-1 strain 1802. For size markers, p65-CAT was digested with 
Hindlll and Xbal. Hindlll digestion of p65-CAT releases a l.OKbp fragment containing the 
CAT sequences, and a 8.4Kbp fragment containing the remainder of the plasmid (Fig. 32a, 
lane 3). Preparations of H indlll have been shown to exhibit star activity (Nasri & Thomas, 
1986), and it is this activity that is thought to have been responsible for the appearance of 
another minor band of approximately 1.35Kbp in the digested sample (Fig. 32a, lane 3). 
Xbal digestion of p65-CAT released two fragments of 3.05Kbp and 6.33Kbp (Fig. 32a, lane 
4). Examination of the profiles of the viral DNAs revealed that the 1.8Kbp BamHI z 
fragment is absent in the v65-CAT DNA sample (Fig. 32a, lanes 1 and 2); this viral DNA 
fragment contains the Xbal site into which the Xbal fragment containing the CAT and LacZ 
gene cassettes were inserted. In addition to the loss of BamHI z, a novel fragment of 
1.5Kbp was present in the v65-CAT DNA sample but no other significant differences in the 
profiles of the two viral DNAs were apparent.
The DNA was then transferred to Hybond-N membrane and incubated with 
radiolabelled p65-CAT as a probe which hybridises to all of the sequences within the v65- 
CAT virus that are derived from the plasmid p65-CAT. Hybridisation with this probe 
detected three bands that are absent in HSV-1 strain 1802. The unique Xbal site in 1802 
viral DNA lies within the BamHI z fragment and digestion of this fragment with BamHI 
and Xbal generates two fragments of 1.1 Kbp and 0.7Kbp. Into this Xbal site the 6.33Kbp
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Figure 33. Polypeptide profile of cells infected with v65-CAT. Aliquots containing 
5x l05cpm from radiolabelled extracts prepared from HSV-1 strain 17 (lane 2), 1802 
(lane 3), v65-CAT (lane 4) and mock infected cells (lane 1) were electrophoresed on a 
12% polyacrylam ide gel. The 25KDa band in lane 4, corresponding to CAT is 
indicated ( M — ) as are some of the other major infected cell polypeptides, and the 
cellular polypeptide, actin.
45KDa
(actin)
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fragment consisting of the 65-CAT expression cassette and the LacZ  ORF from p65-CAT 
was inserted, however because the Xbal digested p65-CAT DNA was not gel purified 
before being inserted into the 1802 virus genome, the p65-CAT backbone sequences (base 
pairs 5998-9044) were also inserted alongside the 6.33Kbp 65-CAT expression cassette 
(Fig. 32c, fragments 1+2+3). Within this 6.33Kbp fragment there are three BamHI sites, 
two in very close proximity, within the epitope tag sequence at the N-terminus of CAT and 
the other following the LpA site (Fig. 32c, fragment 2). BamHI digestion of v65-CAT 
DNA therefore resulted in a fragment of 1.5Kbp which contained the CAT sequences and 
the LpA site (Fig. 32c, fragment 2). The IE promoter sequence of 0.76Kbp linked to the
1.1 Kbp BamHI z fragment accounts for the 1.85Kbp fragment detected (Fig. 32b, lane 2). 
Finally the 7.85Kbp fragment detected was accounted for by the 4.1 Kbp LacZ fragment and 
the 3.05Kbp p65-CAT plasmid sequences (Fig. 32c, fragment 3) linked to the 0.7Kbp 
BamHI z fragment (Fig. 32b, lane 2). From the sizes of the fragments detected, the inserted 
65-CAT cassette is transcribed in the same direction as genes Us8 and Us9. The orientation 
of the CAT insert is shown in Fig. 32d.
Section 4.
i) Polypeptides synthesised by v65-CAT.
The polypeptides synthesised by v65-CAT were compared with those made by the 
parent virus 1802 and wild type virus. BHK cells were infected with each virus at a moi of 
5 pfu/cell, radiolabelled with 35S-methionine from 3 hours post infection and extracts were
prepared at 18 hours post infection. The volume equivalent to 5 x l0 5 cpm for each sample 
was run on a 12% SDS polyacrylamide gel (Fig. 33).
The gel shows the presence of an additional band of approximately 25KDa, the 
predicted size of epitope-tagged CAT, within the v65-CAT sample as compared to the 1802 
and HSV-1 strain 17 samples (Fig. 33, compare lanes 2 and 3 with lane 4). No other 
significant differences to the infected cell polypeptide profiles were apparent.
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Figure 34. Detection of epitope-tagged CAT fusion protein in v65-CAT infected cell 
extracts and in v65-CAT virion and light particle preparations. Approximately 2 x l0 8 
gradient-purified virions and light particles were run on a 12% polyacrylamide gel 
alongside v65-CAT-, vUL49ep- and 1802-infected cell extracts. The polypeptides were 
transferred to nitro-cellulose membrane and the membrane was incubated with pp65 
monoclonal antibody. Samples were as follows: lane 1: 1802-infected cell extract, lane 
2: vUL49ep-infected cell extract, lane 3: v65-CAT-infected cell extract, lane 4: v65-CAT 
virions, lane 5: v65-CAT light particles. The 25KDa band indicated is of the size 
predicted for the 65-CAT fusion protein. Also indicated is the 40KDa epitope tagged 
VP22 polypeptide, and the sizes of each of the vUL49ep breakdown products which 
were used as size markers.
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ii) Detection of 65-CAT Fusion in Infected Cell Extracts
by Western Blot.
In order to confirm that the novel protein seen in the polypeptide profiles was the 
epitope-tagged form of CAT, Western blots were carried out using the pp65 monoclonal 
antibody that specifically recognises the epitope tag sequence. (Fig. 34). As before, extracts 
were prepared from 35mm dishes of BHK cells infected for 18 hours at a moi of 5 pfu/cell 
with v65-CAT. As a positive control, and size marker, an extract from vUL49ep-infected 
cells was used and as a negative control an extract was made from HSV-1 strain 1802-
infected cells. Approximately 6 x l0 4 cell equivalents were separated on a 12% 
polyacrylamide gel, transferred to nitrocellulose and probed with pp65 monoclonal antibody. 
The v65-CAT extract contained a band of approximately 25KDa (Fig. 34, lane 3). This was 
the size predicted for native CAT linked to the 10 amino acid epitope tag sequence and 
confirmed that the 65-CAT fusion protein was synthesised in infected cells. Data presented 
in Chapter 7; Results, Fig. 11 also shows the comparison of the size of epitope-tagged and 
unmodified CAT protein.
Section 5.
Analysis of v65-CAT Virions and Light Particles.
To determine whether the fusion protein was incorporated into v65-CAT virus 
particles, W estern blot analysis was performed on gradient-purified virions and light 
particles. These were prepared from four roller bottles of BHK cells which were infected 
with v65-CAT at a moi of 1 pfu per 300 cells and incubated at 37°C until full cpe was 
visible. The cell released virus was harvested and purified on 5-15% ficoll gradients. Bands 
containing virions and light particles were collected and pelleted for further analysis. 
Approximately 2 xlO8 virions and light particles were separated on a 12% polyacrylamide 
gel, transferred to nitrocellulose membrane and probed with pp65 monoclonal antibody. 
The 25KDa epitope tagged CAT protein was detected in both virions and light particles (Fig. 
34, lanes 4 and 5). This result was unexpected and initially indicated that fusion of the 10 
amino acid epitope tag sequence to CAT could lead to incorporation of CAT protein into 
virus particles.
In order to determine the origin of the 65-CAT fusion protein in v65-CAT virions 
and light particles, the polypeptides present throughout a gradient of v65-CAT cell released 
material were analysed. A preparation of v65-CAT virus was made as described above and
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Figure 35. Detection of 65-CAT fusion protein in material collected from across a ficoll 
gradient. From a 13ml 5-15% ficoll gradient, 24x 450p,l aliquots were collected from 
about 2cm above the bottom of the tube. 15|il from each sample was loaded onto a 14% 
polyacrylam ide gel, and the polypeptides were then transferred to nitrocellulose 
membrane. The membrane was incubated with two antibodies: (a) The membrane was 
probed with LP-1 monoclonal antibody specific for VP 16; (b) the same membrane was 
stripped and re-probed with pp65 monoclonal antibody, specific for the epitope tag 
sequence. The above experiment was repeated on another preparation of v65-CAT virus. 
13x 700fil aliquots were collected from about 2cm above the bottom of a 13ml ficoll 
gradient loaded with v65-CAT CRV. All other parameters are the same as described 
above, (c) The membrane was probed with pp65 monoclonal antibody, (d) The 
membrane was stripped and reprobed with LP-1 monoclonal antibody. * represents 
vUL49ep-infected cell extract.
c)
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following banding on 13ml ficoll gradients, 24x 450fil fractions were collected from 2cm 
below the virion band to the top of the gradient. 15 pi of each sample was analysed by 
Western blot using two different monoclonal antibodies pp65 and LP-1. Incubation of the 
blot with LP-1 (Fig. 35a) revealed that most of the VP 16 was distributed throughout the 
region of the gradient containing virions and light particles (fractions 6 to 20). Reprobing the 
membrane with pp65 monoclonal antibody (Fig. 35b), revealed that the 65-CAT fusion 
protein, in contrast to VP 16, was detected throughout the gradient but was most abundant at 
the top of the gradient. Significantly, this distribution is markedly different from that for 
VP 16 which is a structural protein but similar to that for actin on ficoll gradients, a cellular 
protein which is not a component of virus particles (see Chapter 7; Results, Fig. 13a and 
13b). This experiment was repeated on several occasions using other preparations of v65- 
CAT virus and following successive incubation of these membranes with pp65 and LP-1 
monoclonal antibodies, the pp65 antibody failed to detect any 65-CAT fusion protein within 
the gradients; an example of such a preparation is shown in Fig. 35c and 35d. These results 
strongly suggest that the 65-CAT fusion protein is not incorporated into v65-CAT virions 
and light particles, and it was concluded that the result obtained in Fig. 34 was due to 
contaminating soluble protein present in the cell released material loaded onto the top of the 
ficoll gradient.
,
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Discussion
This chapter describes the introduction into the HSV-1 genome of a second epitope- 
tagged copy of the UL49 gene, encoding VP22, under the control of the strong HCMV IE 
promoter. The resulting recombinant virus synthesises approximately 5-fold higher levels 
of VP22 than wild type virus. The elevated expression of VP22 results in an increase in the 
amount of VP22 present in the tegument of virions and light particles, thereby 
demonstrating for the first time a direct positive correlation between the abundance of a 
structural component within a herpesvirus particle and its level of expression.
The epitope tag sequence was derived from the HCMV UL83 gene, which encodes a 
structural protein, pp65 (DuPont, UK; Weiner et al., 1985; McLauchlan et al., 1994). To 
ensure that this sequence was itself not capable of directing the proteins to which it was 
tagged into the tegument, a control virus, v65-CAT was also constructed. This virus had 
incorporated into its genome a copy of the bacterial CAT reporter gene, which was tagged at 
the N-terminus. Results presented in Results; Chapter 7, Section6 with vims vSAU3 had 
shown that CAT was not incorporated into vims particles. Western blot analysis across 
gradients containing purified v65-CAT virions and light particles indicated that CAT protein 
could only be detected in the fractions towards the top of the gradient, having a different 
pattern of distribution from virions and light particles across the gradients. The detection of 
CAT protein in the fractions at the top of gradients was thought to have been due to 
contaminating cellular protein smearing into the gradient. It was therefore concluded that the 
pp65 epitope tag sequence was not capable of directing CAT into vims particles, and was not 
resonsible for the increased efficiency of tagged VP22 to enter the tegument of vUL49ep 
virions and light particles.
Much of the understanding of the tegument has evolved from studies on deletion 
mutants which fail to synthesise tegument proteins and on the consequent effects on vims 
particle formation. Most strikingly, it has been shown recently that the UL46 and UL47 
genes which encode the major tegument components VP11/12 and VP13/14 respectively are 
dispensable for production of infectious virus particles (Zhang and McKnight, 1993). 
Several other less abundant tegument proteins are also not required for virus particle 
production (McLean et al., 1989; Fenwick & Everett, 1990; Coulter et al., 1993). It is clear 
therefore that the process of tegument assembly and the stmctural integrity of the tegument 
are sufficiently flexible to to accommodate major alterations in composition without loss of 
vims viability. The data in this chapter demonstrates that it is also possible to increase the 
absolute amount of a particular protein component of the tegument. Based on analysis of 
Coomassie stained gels, it is estimated that vUL49ep virus particles contain approximately
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between 6000 and 8500 copies of VP22, making it by far the most abundant structural 
protein. Despite this major alteration in tegument composition, there is no dramatic 
reduction in either the viability or growth of the virus. There was however, a change in the 
migration of the virus particles through ficoll gradients (Chapter 8; Results, Section 6, Fig. 
25) which suggested that vUL49ep virus particles have a greater mass and also size 
heterogeneity than those of 1802. Examination of the fine strucure of HSV-1 virus particles 
by cryo-electron microscopy suggested that light particles had a significant variation in size, 
and on average they were smaller in diameter than virions (140nm compared to 180nm) 
(Szilagyi & Berriman, 1994). Preliminary examination of vUL49ep virus particles by 
electron microscopy however, failed to detect any appreciable increase in the size of either 
vUL49ep virions or light particles. Therefore the change in migration of vUL49ep virus 
particles through ficoll gradients may have been a result of an increase in the density of these 
particles in comparison to virus 1802. The flexibility in tegument composition contrasts 
markedly with the strict stoichiometry of the proteins present in the capsid (Newcomb et al., 
1993).
In addition to the dramatic changes in VP22 abundance, there is a consistent 
reduction in the abundance of VP 13/14 in vUL49ep virus particles. It is not clear whether 
these lower levels reflect reduced synthesis of VP 13/14 in vUL49ep infected cells although 
levels of VP 13/14 in infected cells do not appear to be reduced in comparison to virus 1802. 
It is possible that the mechanisms for incorporating VP22 and VP 13/14 into the tegument 
are similar and the high concentration of tagged VP22 at the site of assembly results in the 
displacement of VP 13/14. By contrast the lack of any effect on the abundance of VP 16, the 
other major tegument protein common to virions and light particles, suggests that its mode 
of insertion into the tegument is distinct from that of VP22.
The rise in the abundance of VP22 in virus particles was not accompanied by any 
detectable increase in other tegument components. This suggests that incorporation of VP22 
into virus particles is not solely dependent upon interaction with other tegument proteins and 
also that VP22 is not a limiting determinant for the incorporation of other structural 
components. Recent studies have shown that insect cells infected with a baculovirus 
recombinant which expresses high levels of VP22 contain large regular aggregates of the 
protein (J. McLauchlan, unpublished data) presumably reflecting the ability of VP22 to 
interact with itself. In addition, the inability to remove VP22 from the tegument following 
detergent treatment of virions and light particles may have beeen due to interactions between 
VP22. The formation of VP22 multimers may be enhanced in vUL49ep infected cells 
thereby resulting in a higher level of incorporation into virus particles. The characterisation 
of viruses containing mutated forms of epitope-tagged VP22 (Results; Chapter 3) support
104.
Chapter 8; Discussion
the suggestion that the ability of VP22 to interact with itself may be the principal determinant 
of VP22 abundance in the tegument, and increased levels of VP22 could be accommodated 
without requiring increases in the abundance of any other structural components. This does 
not preclude the possibility that VP22 is ultimately assembled into the tegument through an 
interaction with other structural proteins. Indeed, recent evidence indicates that VP22 
interacts with VP 16 (Elliot et al., 1995) and this interaction may be important for 
incorporation of VP22 into virus particles.
These results clearly demonstrate that the abundance of VP22 in virus particles can 
be modulated by altering its level of expression. However, increasing the level of synthesis 
of another tegument protein, encoded by UL37, by as much as 20-fold does not result in a 
measurable increase in its abundance in either virions or light particles (J. McLauchlan, 
personal communication). Thus, in this case there appears to be strict stoichiometric control 
over the abundance of UL37 protein within virus particles. The reasons behind these 
differences are not clear. Some constraints can be suggested, for example, in virions there 
may be an invariant numerical requirement for certain tegument proteins which interact with 
the capsid. However, the behaviour of VP22 indicates that beyond such constraints, the 
composition of the tegument may in part reflect the concentration of proteins present in the 
correct location at the time of assembly and the ability of these proteins to compete for sites 
in the tegument.
In conclusion, this chapter demonstrates that the composition of the tegument can be 
dramatically altered by changing the levels of transcription of a tegument component. This 
suggests that while there may be a process which selects proteins for inclusion into the 
tegument, at least for certain structural components, the relative amounts of protein 
incorporated may be a reflection of their abundance in the infected cell. Thus, the relative 
stoichiometries of certain tegument components may be modulated through transcriptional 
regulation.
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Mutagenesis of UL49ep
The key aim of this study, as described previously, was the development of a 
manipulatable experimental system that would enable the characterisation of sequences that 
direct proteins to the tegument. The preceding chapter has described the development of 
such a system, and this chapter shows how this system was put to use in an attempt to 
identify a sequence or motif within the UL49 sequence that was responsible for directing 
VP22 into the tegument.
The procedure involved the development of a set of insertion and deletion mutants 
derived from the epitope-tagged UL49 gene. Oligonucleotides encoding four amino acids 
were inserted into chosen sites along the gene, thereby making small changes in the coding 
sequence of the protein. The design of the oligonucleotides also allowed a series of UL49 
mutants containing deletions within the coding sequence to be derived from the insertion 
mutants. Viruses expressing mutant forms of the epitope-tagged UL49 gene were generated 
in an identical manner to vUL49ep. Thus, the virus recombinants express not only the 
mutated form of VP22 but also the unmodified endogenous version. This approach to create 
both insertion and deletion mutants in UL49 was adopted for two principal reasons. Firstly, 
no mutants within this gene have previously been described. Hence, the sensitivity of the 
protein to mutagenesis could not be predicted. Secondly, it was not known whether UL49 is 
an essential gene. By creating virus recombinants which contained two copies of the UL49 
gene, it was anticipated that the unmodified version would permit virus assembly and 
growth despite the presence of a mutated variant whose function might be disabled.
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1. CCA GAT CTG GGC
2. GGT CTA GAC CCG
3. TAG ATC TGA TGT
4. ATC TAG ACT ACA
Figure 36. Oligonucleotides for the insertional mutagenesis of UL49. The Bglll sites 
are underlined, and the ATG initiation codon incorporated into oligonucleotides 3+4 is 
indicated in bold type.
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F igure  37. Overview of the restriction enzyme sites used in the construction of the 
UL49 insertion mutants, a) The restriction enzyme sites selected for the construction 
of the UL49 insertion mutants. The base pair positions relative to the 5’ terminus of 
the fragment containing the UL49 coding sequence are indicated, b) The restriction 
enzyme sites and their base pair positions relative to the 5’ terminus of the UL49 
coding sequence into which oligonucleotide insertions were made. Plasmids 
containing the UL49 ORF with insertions at each of these restriction enzyme sites were 
constructed, and are referred to as the pUL494ins plasmid series, c) The amino acid 
positions of the oligonucleotide insertions relative to the UL49 initiation codon are 
illustrated. vUL49ins virus mutants containing the UL49 insertions shown in c) were 
constructed.
Sitea oligo
inserted^3
Nucleotide and amino acid sequences 
at insertion sites0
plasmid derived 
(from pUL492)
Rsal (227) (3+4) GTC CAG TAC ATC AGA TCT AAC GAC GAG pUL494ins(60)
V Q Y I R S N D E
HincII (525) (1+2) CCC GCG TCC CAG ATC TGG GCG ACG GCG pUL494ins(159)
P A S Q I W A T A
MscI (566) d+2) CTG GCC AGA TCT GGG CCC AGA AAG CTG pUL494ins(172)
L A R S G P R K L
Nael (631) (1+2) CGG GTG GCC CCA GAT CTG GGC GGC TTT pUL494ins(194)
R V A  P D L G  G F
HincII (850) (1+2) CAG GAC GTC GCC CAG ATC TGG GAC GCG pUL494ins(267)
Q D V A Q I W D A
Table 8. Sequence analysis of pUL494ins plasmids across each oligonucleotide insert. 
a The positions (in brackets) of the restriction enzyme sites at which oligonucleotides were 
inserted are shown. Positions are given relative to the 5’end of the fragment containing the 
UL49 sequences.
b The sequences of the oligonucleotides are shown in Fig. 36.
c. The nucleotides inserted into the UL49 coding sequences and the predicted changes to the 
amino acid sequence are in bold type.
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Part 1
Section 1
Construction of UL49 Insertion Mutants
For mutagenesis studies, 2 pairs of oligonucleotides of 12bp (Fig. 36) were designed 
that could be inserted into specific sites along the UL49 gene thereby creating four amino 
acid inserts in the VP22 polypeptide sequence. To enable rapid screening of plasmids for 
the presence and location of the oligonucleotides, the recognition site for Bglll was 
incorporated into the sequence of the oligonucleotides. One set of the oligonucleotides 
contained an ATG transcriptional start site which could enable the construction of N-terminal 
deletion mutants (Fig. 36, oligos 3+4) (see Chapter 9; Results, Part 2, Section 1, describing 
the construction of pUL494dell-192).
Insertion of the oligonucleotides into the UL49 coding sequences was performed by 
partially digesting pUL492, used in the construction of epitope tagged UL49 (Fig. 20a) with 
selected enzymes. Enzymes were chosen on the basis that 1) they cleaved the UL49 
sequences at no more than three sites 2) cleavage generated blunt-ended termini and 3) the 
enzymes used would give rise to a range of mutants spanning the gene. The enzymes 
which were chosen and the locations of their cleavage sites within the UL49 sequence are 
shown in Fig. 37a. Partially-digested DNA (prepared as described in Chapter 6; Methods, 
Section 3.1) was ligated with the appropriate oligonucleotide pair (Table 8) and competent 
bacteria were transformed with the ligation products.
Plasmids from up to 36 of the colonies from each transformation were analysed by 
digestion with Bglll and Xbal to screen for the presence and location of oligonucleotides. 
This screening procedure gave rise to a panel of plasmids predicted to contain 
oligonucleotides inserted at the restriction enzyme sites shown in Fig. 37b. To verify the 
location of inserted oligonucleotides and determine their orientation, the nucleotide sequence 
at insertion sites for a range of plasmids was determined. Nucleotide sequence data were 
obtained using primers derived from the plasmid sequences flanking the UL49 DNA in 
pUL492 (for insertion sites close to the 5' and 3' termini of the UL49 gene), and from 
residues 430-449 and 354-377 (for insertion sites that lay more than 300 nucleotides from 
the 3'terminus of the UL49 gene). Of the 10 sites that were initially selected (Fig. 37a),
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32KDa
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F igure  38. In vitro transcription/translation analysis of the polypeptides made by 
pUL494ins plasmids. 5}il (approximately 5 x l0 2 cpm) of the reaction sample was 
electrophoresed on a 14% polyacrylamide gel. The sizes of the reaction products 
were estimated by comparing their sizes with the sizes of the bands detected in lane 
1. The samples in each lane were as follows; lane 1: no DNA added, lane 2: 
pUL492, lane 3: pUL494ins60, lane 4: pUL494insl59, lane 5: pUL49insl72, lane 
6: pUL494insl94, lane 7: pUL494ins267 and lane 8 pUL49dell21-192.
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insertion mutants were obtained which contained oligonucleotides at 5 of the sites (Fig. 37b 
and Table 8); these plasmids were termed the pUL494ins series.
Section 2
In vitro Transcription/Translation Products of VP22 
Insertion Mutants
To verify that the insertion of oligonucletides into the UL49 ORF did not alter the 
frame in which the UL49 coding sequence was read, the ability of each of the UL49 
insertion mutants to direct translation of full-length VP22 was investigated in vitro using a 
coupled transcription/translation reticulocyte lysate system. In these experiments, 
transcription was mediated through the T3 promoter sequence present in plasmid 
pBluescript KS II, the parental construct for the pUL494ins plasmid series. As a positive 
control and size marker, plasmid pUL492, containing the unmutated UL49 ORF was used 
and no DNA was added to the negative control sample. Fig. 38 shows the results of the in 
vitro transcription/translation experiments.
In the reaction containing no plasmid DNA, only minor bands are synthesised (Fig. 
38, lane 1) which represent polypeptide species generated through the presence of 
endogenous RNA in the reticulocyte lysate extract. Addition of pUL492 to the system 
results in the synthesis of a major product, assumed to be VP22, which has a molecular 
weight of 40KDa (Fig. 38, lane 2). Major species of similar size were produced in each of 
the reactions containing the UL49 insertion mutant plasmids (Fig. 38, lanes 3-7). It was 
concluded therefore that insertion of the oligonucleotides had not prevented synthesis of 
intact VP22 protein. In addition to the major species of 40KDa, smaller, less abundant 
products also were generated. These varied in size between the different plasmids, however 
within each of the reactions containing a pUL494ins plasmid (Fig. 38, lanes 3-7), two bands 
of approximately 32KDa and 28KDa were most prominent. In the positive control sample 
containing pUL492 DNA (Fig. 38, lane 2) apart from the major 40KDa band, there was 
only one major product of approximately 38KDa, and this band was also seen in each of the 
pUL494ins samples, although it was not as intense. It was assumed that these represented 
breakdown products of full-length VP22 and their characteristics were not studied further.
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Section 3
The Construction of Viruses Containing Epitope-Tagged 
UL49 Insertion Mutants
Based on both the nucleotide sequence and the in vitro transcription/translation 
results, it was concluded that the plasmids containing the UL49 insertion mutants were 
capable of producing full-length VP22. Before inserting the UL49 insertion mutants into 
1802 viral DNA, each of the mutated ORFs was subcloned into the plasmid vector pFJ22ep, 
which contains the oligonucleotide sequence encoding the 10 amino acid epitope tag 
sequence between the HCMV IE promoter and the UL38 late polyadenylation site (Fig. 
20b). Following BamHI digestion of each of the pUL494ins plasmids, 0.97Kbp fragments 
containing the mutated UL49 ORFs were purified following agarose gel electrophoresis and 
ligated to BamHI digested pFJ22ep. The resulting plasmids were named the pUL49ins 
plasmid series. Apart from the inserted oligonucleotides, these constructs had the same 
structure as pUL49ep (Fig. 20c).
Each of the pUL49ins plasmids were digested with Xbal and the cassettes containing 
the epitope-tagged, mutated UL49 ORFs were inserted into the Xbal site present in 1802 
virus DNA (Rixon & McLauchlan, 1990). The resultant ligation products were transfected 
into BHK cells and the virus progeny were screened by Western blot analysis for the 
synthesis of polypeptides recognised by monoclonal antibody pp65. Individual plaques 
synthesising proteins of the predicted size were selected and purified to homogeneity for 
each insertion mutant. Four out of the five UL49 insertion mutants shown in Fig. 37b 
yielded virus recom binants; these were designated vUL49ins60, vUL49insl59, 
vUL49insl94 and vUL49ins267 and are collectively referred to as virus series vUL49ins 
(Fig 37c).
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Section 4
Southern Blot Analysis of vUL49ins Viral DNAs
Southern blot analyses were carried out to determine that the correct sequences had 
been inserted into the HSV-1 genome and that the insertion of a second copy of UL49 did 
not result in rearrangement of the HSV-1 genome. To ensure that the correct insertions had 
been incorporated into the recombinant virus genomes Xbal and Bglll digests were 
performed on each of the viral DNAs, and these digests were run alongside the same digests 
of each of the parental plasmid DNAs. Following electrophoresis, the DNA fragments were 
transferred to Hybond-N membrane and incubated with a 32P-radiolabelled probe consisting 
of the 1930bp Xbal fragment from pUL49ep (Fig. 20) which contained the epitope-tagged 
UL49 cassette. This probe hybridises to all of the sequences within the vUL49ins viruses 
that are derived from the epitope-tagged UL49 expression cassette, as well as the 
endogenous UL49 sequences.
Hybridisation with this probe detected a DNA fragment of 9.08Kbp in each of the 
lanes containing viral DNA (Fig. 39a, lanes 1, 3, 5 & 7) which contained the endogenous 
copy of UL49. In each of the lanes containing plasmid DNA (Fig. 39a, lanes 2, 4, 6 & 8) a 
faint band of approximately 5.1Kbp which represented undigested pUL49ep sequences was 
also detected.
The remaining bands recognised by the probe were derived from the UL49ins gene 
cassettes. A 0.75Kbp band, corresponding to the Bglll fragment containing the HCMV IE 
promoter sequence was present in each lane. The other bands were unique for each 
vUL49ins construct; maps for each of these constructs are given in Fig. 39b. Thus 
UL49ins60 virion and plasmid samples gave rise to 0.23Kbp and 1.08Kbp fragments (Fig. 
39a, lanes 3 & 4; Fig. 39b (i)) Bands of 0.78Kbp and 0.52Kbp were detected in the 
UL49insl59 DNAs (Fig. 39a, lanes 5&6; Fig 39b (ii)). UL49insl94 DNAs were predicted 
to give fragments of 0.68Kbp and 0.61Kbp (Fig 39b (iii)) which resolved as a single species 
in the blot (Fig. 39a, lanes 1 & 2). Finally, bands of 0.85Kbp and 0.46Kbp were detected in 
UL49ins267 DNAs (Fig. 39a, lanes 7&8; Fig 39b (iv)). By comparing the data in Fig. 39a 
with the predicted maps in Fig. 39b it is evident that the virus recombinants contained the 
predicted epitope-tagged UL49ins cassettes.
To orientate each of the inserted sequences in the recombinant genomes, BamHI
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F igure 39. Southern Blot analysis of vUL49ins virus DNAs. a) 0.5|ig of DNA was 
digested with B glll and Xbal and then electrophoresed on a 1.5% agarose gel followed 
by transfer to Hybond-N membrane. The membrane was then probed with a 32P- 
labelled probe consisting of the 1.9Kbp Xbal fragment from pUL49ep. The sizes of the 
major bands detected are indicated. Lane 1, vUL49insl94; lane 2, pUL49insl94; lane 3, 
vUL49ins60; lane 4, pUL49ins60; lane 5, vUL49insl59; lane 6, pUL49insl59; lane 7, 
vUL40ins267; lane 8, pUL49ins267. b) Diagramatic representation of the epitop- 
tagged UL49 expression cassettes that were used to construct the vUL49ins virus series. 
The sizes of fragments released following BamHI/Xbal digestion of the unmodified 
UL49 cassette, and of BglD/Xbal digestion of each of the UL49 insertions are indicated.
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Figure 40. Southern Blot analysis of vUL49ins virus series DNA. a) 0.5pg of DNA 
purified from of each vUL49ins virus was digested with BamHI and then 
electrophoresed on a 1% agarose gel followed by transfer to Hybond-N membrane.
The membrane was then probed with 32P-radiolabelled pUL49ep. In lane 1, 
vUL49insl94; lane 2, vUL49ins60; lane 3, pUL49insl59; lane 4, vUL49ins267; lane 
5, vUL49ep. The sizes of the major bands detected are indicated, b) Organisation of 
the genomes of the vUL49ins viruses at the U s9 /U sl0  gene locus. The orientation of
the UL49ins inserts are shown, as are the sizes of fragments obtained following 
BamHI and Xbal digestion, i) vUL49insl59 and vUL49insl94 ii) vUL49ins60 and 
vUL49ins267
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digests were performed on each of the vUL49ins viruses. BamHI digested vUL49ep was 
used as a size marker. Following electrophoresis and transfer to Hybond-N membrane, the 
membrane was incubated with 32P-radiolabelled pUL49ep which hybridises to all of the 
sequences with the viral DNAs derived from the pUL49ins plasmid series as well as the 
endogenous UL49 sequences. Hybridisation with this probe revealed that the 8.1Kb BamHI 
f fragment which contained the unmodified copy of UL49 was identical in size for each of 
the viral DNAs (Fig. 40a). This probe also detected a 0.96Kbp fragment in each of the 
vUL49ins viral DNAs and vUL49ep viral DNA which correspond to the inserted UL49ins 
ORFs. Two other bands of approximately 1.8 and 1.05Kb were detected in vUL49insl94 
and vUL49insl59 viral DNA samples (Fig. 40a, lanes 1 & 3). The unique Xbal site in 
1802 viral DNA lies within the BamHI z fragment and digestion with BamHI and Xbal 
generates two fragments of 1.1 and 0.7Kbp. Thus the 1.8Kbp fragments are derived from 
fragments containing the HCMV promoter linked to the 1.1 Kbp BamHI z fragment and the 
1.05Kbp fragments are derived from the polyadenylation sequences linked to the 0.7Kbp 
BamHI z fragment.
In lanes 2 and 4 containing vUL49ins60 and vUL49ins267 respectively, bands of 
1.8Kbp were detected which correspond to the HCMV promoter sequences linked to the
1.1 Kbp BamHI z fragments. In addition, there are bands of 4.08Kbp in each of these lanes 
which were a result of the 0.35Kbp polyadenylation sequences and the 3.03Kbp pUL49ins 
plasmid backbone sequences (equivalent to base pairs 4822-2754 in pUL49ep; Fig. 20c) 
linked to the 0.7Kbp BamHI z fragments. The plasmid backbone sequences were inserted 
because following Xbal digestion of each of the pUL49ins plasmids, prior to the insertion 
into Xbal digested viral DNA, the Xbal fragments containing the UL49 expression cassettes 
were not gel purified. From the sizes of the fragments each of the epitope-tagged UL49ins 
cassettes are transcribed in the same direction as genes US8 and Us9 (as summarised in Fig. 
40b).
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F igure  41. Polypeptides synthesised by vUL49ins viruses. 35S-radiolabelled 
extracts prepared from 35mm dishes of BHK cells infected with vUL49ins viruses 
were compared with radiolabelled extracts from HSV-1 strain 17, 1802-, RUL47A2-, 
vU L49ep- and m ock-infected cells. A liquots containing 5xlCP cpm were 
electrophoresed on a 12% polyacrylamide gel. The samples in each lane are as 
follows; lane 1: mock infected, lane 2: strain 17, lane 3: 1802, lane 4: RUL47A2, lane 
5: vUL49ep, lane 6: vUL49ins60, lane 7: vUL49insl59, lane 8: vUL49insl94 and 
lane 9: vUL49ins267. The major polypeptides are indicated ( ).
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Polypeptides Synthesised by the vUL49ins Viruses
To analyse the polypeptides synthesised by the vUL49ins series, 35S-methionine 
labelled infected cell extracts were prepared at 18 hours post infection for each of the 
vUL49ins viruses and for comparative purposes HSV-1 strain 17, 1802, RUL47A2 and 
vUL49ep. RUL47A2 is a HSV-1 deletion mutant lacking the UL47 gene, and was kindly 
supplied by Dr. J. McKnight (McKnight et al., 1992). Comparison of the profiles of the 
vUL49ins viruses with those of the control samples revealed an abundant species of 
approximately 40KDa which was present in each of the vUL49ins and vUL49ep samples 
but absent in the strain 17, RUL47A2 and 1802 samples. These polypeptides corresponded 
in size to epitope-tagged VP22 (VP22t) synthesised by vUL49ep-infected cells (previously 
described in Chapter 8; Results, Part 1, Section 4.). These species had similar mobilities to 
VP22t although in samples, vUL49insl59, vUL49insl94 and vUL49ins267 the migration 
of the additional band was slightly less than that for VP22t in the vUL49ep sample (Fig. 41, 
compare lanes 7, 8 & 9 with lane 5). These changes in mobility were thought to have been a 
result of small increases in the molecular weights of the proteins following insertion of the 4 
amino acid sequences, and also the nature of the inserted amino acids. No other significant 
alterations were apparent between the polypeptide profiles of the extracts apart from the 
intensity of VP13/14 in samples vUL49insl59, vUL49insl94 and vUL49ins267 which was 
reduced in comparison to vUL49ep and vUL49ins60 (Fig. 41, compare lanes 5 & 6 with 
lanes 7, 8 & 9) .
To confirm that the abundant 40KDa species in the vUL49ins-infected cell extracts 
corresponded to epitope-tagged VP22, Western blot analysis was performed on the infected 
cell extracts shown in Fig. 41. Following separation by electrophoresis and transfer of the 
proteins onto nitrocellulose, the membrane was then probed with monoclonal antibody 
pp65. As a positive control and to act as a size marker, the vUL49ep-infected extract was 
also run on the gel. The antibody recognised a species of approximately 40KDa in each of 
the samples that corresponded to epitope-tagged VP22 (Fig. 42, compare lanes 2-5 with lane 
1). This confirmed that the major species identified in the 35S-methionine polypeptide 
profiles corresponded to the insertion mutant form of VP22t made by each virus. In this 
blot, there is also a small but apparent increase in the size of VP22t made by vUL49ins60, 
vUL49insl59 and vUL49insl94. As described for Fig. 41, these slight changes in the 
mobility were thought to have been a result of the four amino acid insertions. The antibody
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Figure 42. Western blot analysis of 35S-methionine radiolabelled vUL49ins-
infected cell extracts. Approxim ately 6xl()4 ceu equivalents were 
electrophoresed on a 12% polyacrylamide gel and the polypeptides were 
transferred to nitrocellolose membrane. The membrane was then probed with 
monoclonal antibody pp65 (l:2000dilution). Samples were as follows: lane 
1: vU L49ep, lane 2: vUL49ins267, lane 3: vU L 49insl59, lane 4: 
vUL49insl94 and lane 5: vUL49ins60.
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Figure 43. Growth characteristics of vUL49ins virus series compared with the parent 
virus 1802. 35mm dishes containing approximately 2x10^ BHK cells were infected at 
a moi of 5 pfu per cell and harvested at various time points ranging between 0 and 36 
hours after infection. The total amount of virus present at each time point was 
determined by titration.
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also recognises a number of lower molecular weight species that correspond to C-terminal 
products of VP22 that have been generated either by cleavage of full length protein or 
internal initiation of translation.
Section 6
Growth Characteristics of vUL49ins Viruses
In order to determine whether the growth of each of the vUL49ins virus series was 
affected by the insertion of a second epitope-tagged partial copy of UL49, the growth 
characteristics of the vUL49ins viruses were compared to those of the parent, 1802. The 
gradients of the slopes during the exponential growth phase (between 6 and 24 hours) for 
each vUL49ins vims mutant suggested that the growth rates were reduced compared to 1802 
(Fig. 43). However, for each of the vUL49ins vims mutants the titre during the eclipse 
phase did not fall as significantly as did that for 1802. The final yields for each vUL49ins 
mutant were similar and were only slightly less than that for 1802. The data obtained for 
these vimses were similar to those for vUL49ep {Chapter 8; Results, Part 1, Section 5) and 
suggested that insertion of the mutant epitope-tagged copies of UL49 into 1802 did not have 
a significant effect on the growth of each vims.
Section 7
Incorporation of VP22 into vUL49ins Virions and Light 
Particles
Analysis of the polypeptides produced in cells infected with the vUL49ins vimses 
had shown that epitope-tagged VP22 was produced to similar levels as that made in 
vUL49ep-infected cells (Fig. 41). To determine whether these mutated forms of VP22 were 
incorporated into virions and light particles, Western blot analysis was performed on 
samples collected from across ficoll gradients containing the material released from infected 
cells. This material was prepared from four roller bottles of BHK cells that had been 
infected with each vims at a moi of 1 in 300 and grown at 31°C for 4 days. For comparative 
purposes, a preparation of vUL49ep was grown in parallel with the vUL49ins vimses. 
Ficoll gradients of cell-released vims were run and aliquots collected from across each
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Figure 44. Western blot analysis across gradients containing each of the 
vUL49ins virus preparations. Material was collected in 13x700jil aliquots 
from 2cm below the virion band in 13ml, ficoll gradients that were loaded 
with material from cells infected with each of the vUL49ins virus series. 
Following electrophoresis of 15jil of each sample on 12% polyacrylamide 
gels, the polypeptides were transferred to nitrocellulose membranes and each 
was incubated with pp65 monoclonal antibody. The epitope tagged VP22ins 
proteins are indicated. In lane * vUL49ep infected cell extracts were included 
as positive controls and size markers.
vUL49
1802 vUL49ep ins60 ins 159 ins 194 ins267
VP22t
Figure 45. Polypeptide profiles of vUL49ins virions. Approximately 3 x l0 9 
vUL49ins60, vUL49insl59, vUL49insl94 and vUL49ins267 ficoll purified virions 
were com pared to those of parent virus 1802 and vUL49ep. Following 
electrophoresis on a 12% polyacrylamide gel, the gel was stained with Coomassie 
Brilliant blue. The major structural polypeptides are indicated as are the bands 
corresponding to the epitope-tagged VP22 proteins (VP22t).
Virus Copy numbers of VP22 + VP22t
1802 3154
vUL49ep 12540
vUL49ins60 13185
vUL49insl59 10939
vUL49insl94 9600
vUL49ins267 12551
Table 9. The copy numbers of VP22 + VP22t were estimated following the 
excision of the VP22 bands from the Coomassie Brilliant blue stained gel shown in 
Fig. 45. The relative amount of stain in the gel slice was estimated following elution 
of the Commassie Brilliant blue stain in each band in 25% piperidine solution 
followed by spectrophotometric analysis at 605nm. The number of copies of VP22 
were calculated relative to the estimated copy number of VP16, calculated by Zhang 
& McKnight (1993).
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gradient as described in Chapter 7; Results, Part 1, Section 6. These aliquots were 
examined for the presence of epitope-tagged VP22 by Western blot analysis. Incubation of 
each of the membranes with pp65 monoclonal antibody, revealed that VP22t in each of the 
vUL49ins virus gradients was most abundant throughout the region where virions and light 
particles migrate (Fig. 44a-d). These data are indistinguishable from those obtained for non­
mutated VP22t ( Chapter 8; Results, Part 1, Section 7) and therefore it was concluded that 
the epitope-tagged VP22 made by each of the vUL49ins viruses was incorporated into 
virions and light particles (Fig. 44 a-d).
Section 8
Polypeptide profiles of purified virions and light particles
The polypeptide profiles of the vUL49ins virions purified from ficoll gradients were 
examined by polyacrylamide gel electrophoresis. This revealed that their polypeptide 
contents were similar to those for vUL49ep (Fig. 45). Indeed from visual inspection, 
vUL49ins60 and vUL49ins267 virion polypeptides were apparently indistinguishable from 
the vUL49ep virion proteins. The most noticeable difference in the polypeptide patterns was 
a decrease in the abundance of VP22t in vUL49insl94 virions. There was also a sight 
increase in the amounts of untagged VP22 present in vUL49insl94 virions.
To quantitate the VP22 protein (VP22 + VP22t) in each of the vUL49ins virions, 
bands containing the tagged and untagged VP22, and VP 16 were excised from the gel. The 
relative amounts of protein in the bands was estimated by spectrophotometric analysis of the 
stain eluted from each gel slice (Table 9). This revealed that there was approximately a 4- 
fold rise in the abundance of VP22 in vUL49ep virions as compared to 1802 virions. From 
examination of the gel the VP22 band in vUL49ep virions consisted mostly of VP22t. 
These findings are in agreement with those presented in Chapter 8; Results, Part 1, Section 
8. Analysis of vUL49ins60, vUL49insl59 and vUL49ins267 virions gave essentially 
identical results to those for vUL49ep. In vUL49insl94 virions, the amount of tagged VP22 
incorporated is less, but there remains a substantial rise (~3-fold) in the total amount of 
VP22 in these particles (Table 9). These data suggest that insertion of the oligonucleotides at 
positions 60, 159 and 267 have no discernible effect on incorporation of epitope-tagged 
VP22. The only insertion mutant which does have a noticeable effect on incorporation is 
ins 194 where there is a reduction in tagged VP22. However, even with this mutant, there is 
relatively more tagged VP22 incorporated as compared to untagged VP22.
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Figure 46. Overview  of the UL49 deletion m utants constructed, a) The UL49 ORF 
showing the restriction enzyme sites utilised in the construction of the deletion mutants, and 
their base pair positions relative to the 5 ’ term inus of the fragm ent containing UL49 
sequences. Below the ORF the numbers refer to the corresponding amino acid positions at 
which the restriction enzym es lie in the coding sequence, and are relative to the ATG 
initiation codon o f UL49. b-e) Diagramatic representations of each of the UL49 deletions 
constructed. The epitope tag sequence at the end of each ORF is shown ( | )
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Deletion Mutagenesis of Epitope-Tagged
VP22
Section 1
Plasmid Construction
Coincident with the construction of a panel of viruses containing linker insertions in 
the epitope-tagged copy of UL49, a parallel series of recombinants was produced in which 
specific regions of the tagged UL49 coding region were deleted. The construction of these 
deletion mutants was facilitated by the design of the oligonucleotides used for creating the 
insertion mutants (Chapter 9; Results, Part 1, Section 1). In total, four recombinants were 
made using epitope-tagged UL49 deletion mutants whose derivation was as follows:
1) pUL49del 120-192
As part of the strategy for constructing the plasmid series containing linker 
insertions, the enzyme Smal, which cleaves the UL49 coding sequence in three positions, 
was used to generate partially-digested pUL492 DNA (Fig. 20a). These cleavage sites lie 
within a region of 287 base pairs and thus, due to the size of pUL492, it was possible that 
DNA cleaved at more than one site would not separate on agarose gels from molecules cut 
at a single site. During the course of the screening process for plasmids containing inserted 
oligonucleotides, one construct was identified in which an oligonucleotide had inserted 
between the Smal sites located at base pair positions 407 and 623, thereby removing amino 
acids 120 to 192 from the UL49 coding region (Fig. 46c). This construct was termed 
pUL494dell20-192. As predicted from the UL49 nucleotide sequence, removal of these 
sequences and the insertion of the oligonucleotide should result in an in-frame deletion 
mutant. To verify the location of the oligonucleotide and determine its orientation, the 
nucleotide sequence of pUL494dell20-192 was obtained using a primer that annealed to 
sequences between base pairs 626 and 648 within the UL49 sequences. The nucleotide 
sequence data indicated that no frame shift mutation had occurred at the insertion site (Fig. 
47). To ensure that the plasmid encoded a polypeptide of the predicted size, the protein was
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T A P  L D L M W V A
Figure 47. Sequence analysis across the oligonucleotide insert within the 
UL49 ORF in pUL494dell20-192. The amino acid sequence across the 
oligonucleotide insert is indicated, and the Bglll site encoded within the 
oligonucleotide is underlined.
4896,0
pUL49del 120-192
(4896bp)
HCMV y ALpA
Xbal (4616bp)
Xbal (2754bp)
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UL49BamHI (3863bp) BamHI (3107bp)
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romoter LpA 
UL49
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Figure 48. Structures of UL49del plasmids a) pUL49dell20-192. b) p(JL49del 120-301. 
c) pUL49del 1-192. Following the digestion of pUL49dell20-192 with BamHI and Bglll, 
the two UL49 fragments of 341 bp and 415bp were gel purified and each fragment was then 
subcloned into BamHI digested pFJ22/ep resulting in plasmids pUL49dell-192 and 
pUL49del 120-301.
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translated in vitro from pUL494dell20-192 using the coupled reticulocyte lysate system. As 
com pared to the VP22 protein synthesised by pUL492, the product from the 
pU L494dell20-192 reaction was smaller with an apparent molecular weight of 
approximately 32KDa (Fig. 38, lane 8). This size corresponds closely to the predicted size of 
the VP22 polypeptide that should be encoded by the mutant. It was therefore assumed that 
the protein detected corresponded to the UL49del 120-192 gene product.
Prior to insertion into the virus genome, the BamHI fragment from pUL494dell20- 
192 which contained the UL49 ORF was subcloned into plasmid pFJ22ep that had been 
cleaved with BamHI (previously described in Chapter 8; Results, Part 1, Section 1, Fig. 
20b). The resultant plasmid was termed pUL49dell20-192 and contained the UL49 deletion 
mutant under the control of the HCMV IE promoter with the epitope tag sequence linked to 
the 3' end of the ORF (Fig. 48a).
2) pUL49del 120-301
It was evident from the nucleotide sequence data obtained at the insertion site in 
pUL494dell20-192, that ligation between the Bglll site in the oligonucleotide linker in this 
plasmid and the BamHI site in pFJ22ep would directly fuse the N-terminal 119 amino acids 
of VP22 to the epitope tag, thereby creating a deletion mutant in which residues 120 to 301 
had been removed. Thus, a 415bp BamHI/Bglll fragment from pUL49dell20-192 which 
contained these 5' terminal sequences was inserted into the BamHI site of pFJ22ep and the 
resultant construct was termed pUL49del 120-301 (Fig. 48b).
3) pUL49del 1-192
Due to the orientation of the oligonucleotide inserted into pUL494del 120-192, an 
ATG initiation codon within the linker sequence lies in-frame with base pair residues 623 to 
962 of the UL49 ORF (Fig. 47). To construct a plasmid which expressed these sequences, a 
341 bp Bglll/BamHI fragment from pUL49dell20-192 which contained these 3' terminal 
sequences was inserted into the BamHI site of pFJ22ep, thereby generating pUL49del 1-192 
(Fig. 48c).
4) pUL49del268-301
Introduction of the oligonucleotide at the HincII site in plasmid pUL49ins267 (Fig. 
49a) generated a Bglll site which could be ligated to the BamHI site in pFJ22ep to give an
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Figure 49. Construction of pUL49del268-301, Plasmid pUL49ins267 was 
digested with BamHI and Bglll which released a fragment of 856bp, containing the 
UL49 ORF minus the C-terminal llObp. Following gel purification the 856bp 
fragment was subcloned into BamHI digested pFJ22ep, resulting in plasmid 
pUL49de!268-301.
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in-frame fusion product between base pair residues 1 to 850 and the epitope tag sequence, 
thereby removing the C-terminal 37 amino acids of the VP22 protein. An 856bp 
BamHI/Bglll fragment from pUL49ins267 was inserted into the BamHI site of pFJ22ep, 
generating plasmid pUL49del268-301 (Fig. 49b).
Section 2
Construction of Viruses Containing the Epitope-Tagged 
UL49 Deletions
Viruses expressing the epitope-tagged UL49 deletion mutants were constructed 
using HSV-1 virus vector 1802 as the parent virus (Chapter 8; Results, Part 1, Section 2). 
Thus, the pUL49del plasmids were digested with Xbal and ligated into the Xbal site within 
the U s region of the 1802 viral genome. Following transfection of the ligation products, 
infected cells were screened by Western blot analysis using monoclonal antibody pp65 for 
the synthesis of proteins of the predicted sizes. Thereafter, 12 isolated plaques were selected 
for further screening and purification. Following 3 rounds of plaque purification, single 
isolates for each deletion mutant were selected and grown. Virus recombinants were 
designated vUL49del 1-192, vUL49dell20-192, vUL49del 120-301 and vUL49del268-301, 
collectively termed the vUL49del vims series.
Section 3
Southern Blot Analysis of vUL49del Virus Series DNAs
Southern blot analyses were carried out to determine whether the correct sequences 
had been inserted into the HSV-1 genome and to ensure that the insertion of a second copy 
of UL49 did not result in rearrangement of the vims genome. Purified DNA from each of 
the vUL49del viruses was digested with BamHI and Xbal, and compared with its parent 
pUL49del plasmid also digested with BamHI and Xbal. As controls vUL49ep and 
pUL49ep were also digested with BamHI and Xbal. Following electrophoresis, the DNA 
fragments were transferred to Hybond-N membrane, which was then incubated with 32P- 
radiolabelled probe consisting of the 1930bp Xbal fragment from pUL49ep (Fig. 20c) 
containing the epitope-tagged UL49 cassette. This probe hybridises to all of the sequences
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Figure 50. Southern Blot analysis of vUL49deletion virus series DNA. a) 0.5 |ig of DNA 
purified from of each vUL49del virus, and 0 .2pg of each parental plasmid DNA, was 
digested with BamHI and Xbal and then electrophoresed on a 1.5% agarose gel followed 
by transfer to Hybond-N membrane. The membrane was then probed with a radio-labelled 
probe consisting of the IE HCMV promoter sequence, the entire epitope tagged UL49 ORF 
and the UL38 late poly A site derived from Xbal digested pUL49ep. In lane 1, 
vUL49del 1-192; lane 2, pUL49del 1-192; lane 3, vUL49del 120-301; lane 4, pUL49dell20- 
301; lane 5, vUL49dell20-192; lane 6, pUL49dell20-192; lane 7, vUL49del268-301; lane 
8, pUL49del268-301; lane 9, vUL49ep; lane 10, pUL49ep. The sizes of the major bands 
are indicated, b) Diagramatic representation of the epitope-tagged UL49 expression 
cassettes that were used to construct the vUL49del virus series. The sizes of fragments 
released following BamHI/Xbal digestion of each of the UL49deletions are illustrated.
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within the vUL49del viruses that are derived from the epitope-tagged UL49 expression 
cassette, as well as to the endogenous UL49 sequences. Hybridisation with this probe 
detected a fragment of 8.05Kbp in each of the lanes containing virion DNA (Fig. 50a, lanes 
1, 3, 5, 7 & 9) which contained the endogenous copy of UL49.
In all except UL49dell-192 virion and plasmid samples, the HCMV IE promoter 
sequence is flanked by Xbal and BamHI sites and therefore following digestion with these 
enzymes a 0.75Kbp fragment should be released (Fig. 50b (i)-(iii)). This 0.75Kbp band 
was detected in both the virion and plasmid samples of UL49dell20-192, UL49del 120-301, 
UL49del268-301 (Fig. 50a, lanes 3 to 8). In lanes 9 and 10 containing pUL49ep and 
vUL49ep respectively, additional fragments of 0.96Kbp, and 0.35Kbp were detected. 
These fragments correspond to the full length UL49 ORF (0.96Kbp) and the UL38 late poly 
A site (0.35Kbp).
In both lanes 7 and 8 containing the UL49del268-301 plasmid and virion samples, a 
band of 1.2Kbp was detected. This band contained the UL49 ORF (minus the 3' terminal 
1 lObp) linked to the 0.35Kbp poly A site (Fig. 50b (i)). In the UL49dell20-192 plasmid 
and virion samples, two bands of 0.35Kbp and approximately 0.74Kbp were detected (Fig. 
50a, lanes 5 & 6). These bands correspond to the UL38 late poly A site and the UL49 ORF 
minus the internal 216 base pairs (Fig. 50b (ii)). TheUL49del 120-301 plasmid and virion 
DNA samples, were predicted to release a doublet of 0.75Kbp and 0.76Kbp corresponding 
to the IE HCMV promoter sequence and also the UL49 5'terminal 415bp linked to the 
0.35Kbp late poly A site (Fig. 50b (iii)). The 0.75Kbp band detected in lanes 3 and 4 
containing these plasmid and virion samples agree with this prediction (Fig. 50a). In the 
UL49dell-192 plasmid and virion DNAs bands of 1.1 Kbp and 0.35Kbp were detected (Fig. 
50a, lanes 1& 2). The larger band corresponded to the 0.75Kbp HCMV promoter sequence 
linked to the 3'terminal 341 bp of UL49, while the 0.35Kbp fragment corresponded to the 
UL38 late poly A site (Fig. 50b (iv)). This Southern blot reveals that each of the UL49 
deletion viruses contain the same epitope tagged UL49 deletions that are present in their
parent plasmids.
In order to orientate each of the inserted sequences within the vUL49del virus series
BamHI digests were performed and the restriction enzyme profiles for each of the vUL49del 
viruses were examined. BamHI digested vUL49ep was included as a size marker. 
Following electrophoresis and transfer to Hybond-N membrane, the membrane was 
incubated with 32P-radiolabelled pUL49ep which hybridises to all of the sequences within
118.
a)
1 2 3 4 5
8.1Kb
5.0Kb
2.2Kb
1.85Kbp
1.8Kb
1.45Kb
1.0Kb
0.96Kb
0.7Kb
F igure 51. Southern Blot analysis of vUL49deletion virus series DNA. a) 0.5pg of 
DNA purified from of each vUL49del virus was digested with BamHI and then 
electrophoresed on a 1 % agarose gel followed by transfer to Hybond-N membrane. 
The membrane was then probed with a radio-labelled pUL49ep. In lane 1, pUL49ep; 
lane 2, vUL49dell-192; lane 3, vUL49del 120-301; lane 4, vUL49dell20-192; lane 5, 
vUL49del268-301. The sizes of the major bands are indicated, b) Diagramatic 
representations of the genomes of the vUL49 deletion viruses. The positions of the 
inserted copies of UL49 between genes U s9  and U s 10 are shown, as are the
directions in which the UL49del sequences are transcribed. The sizes of fragments 
obtained following BamHI digestion are also indicated, (i) vUL49dell-192,(ii) 
vUL49del 120-192 and iii) vUL49del268-301.
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the viral DNAs derived from the pUL49del plasmid series as well as the endogenous UL49 
sequences. Hybridisation with this probe revealed that the 8. lKbp BamHI f fragment which 
contained the unmodified copy of UL49 was identical in size for each of the viral DNAs 
(Fig.5 la). This probe also detected a 0.96Kbp DNA fragment in the vUL49ep DNA 
sample which correspond to the UL49 ORF, and acted as a size marker.
The unique Xbal site in 1802 viral DNA lies within the BamHI z fragment and 
digestion of this fragment with BamHI and Xbal generates two products of 1.1 and 0.7Kb. 
vUL49del 1-192 contains a unique BamHI site at the junction between the epitope-tag and the 
UL49 sequence (Fig. 51b (iv)), and BamHI digestion resulted in the release of two 
fragments of 1.45Kbp and 1.8Kbp (Fig. 51a, lane 2). These were composed of the 1.1 Kbp 
BamHI z fragment linked to the 0.35Kbp late poly A site, and the 0.7Kbp BamHI z 
fragment linked to the 1.1 Kbp fragment containing the IE HCMV promoter sequence and 
the 3' terminal region of UL49 (Fig. 50b(iv)). From the sizes of these fragments the 
UL49dell-192 ORF is transcribed in the same direction as Us 10 (Fig. 51b (i)).
vUL49del 120-301 DNA contains a BamHI site between the HCMV promoter 
sequence and the UL49 ORF (Fig. 50b (iii)), which following digestion results in the release 
of a 1.8Kbp fragment (Fig. 51a, lane 3). This band may be composed of the 1.1Kb BamHI 
z fragment linked either to the 0.75Kbp IE HCMV promoter sequence, or to the 0.76Kbp 
fragment containing the UL49 sequences and the poly A sequences. It is therefore not 
possible to orientate the inserted fragment following BamHI digestion of the viral DNA. 
There is a band of 4.48Kbp which similarly may be composed of either the 0.76Kbp 5' 
terminal UL49 sequences and the poly A sequences, or the 0.75Kbp HCMV IE promoter 
sequence linked to the 3.04Kbp pUL49del 120-301 plasmid backbone sequences (equivalent 
to base pairs 4275-2754 in pUL49del 120-301; Fig. 48b) linked to the 0.7Kbp BamHI z 
fragment.
vUL49dell20-192 has BamHI sites flanking the UL49 ORF, and following 
BamHI digestion, three fragments of 1.85Kbp, l.OKbp and 0.7Kbp were released (Fig. 51a, 
lane 4). These were composed of the 1.1Kb BamHI z fragment linked to the 0.75Kbp IE 
HCMV promoter sequence, the 0.7Kbp BamHI z fragment linked to the 0.35Kbp late poly 
A site and the 0.7Kbp UL49 ORF with the internal deletion. The sizes of these fragments 
indicate that the UL49dell20-192 ORF is transcribed in the same direction as Us8 and 9 
(Fig. 51b (ii)).
vUL49del268-301 DNA possesses a BamHI site between the HCMV promoter
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F igure  52. Polypeptides synthesised by vUL49 deletions during an 18 hour infection 
of BHK cells. Aliquots containing 5 x l0 5cpm from 35S-methionine radiolabelled 
extracts prepared from vUL49del268-301-, vUL49del 120-192-, vUL49del 120-301- 
and vUL49dell-192-infected cells were compared with vUL49ep-, 1802-, RUL47A2- 
and mock-infected radiolabelled infected cell extracts. The samples in each lane are as 
follows: lane 1, mock infected; lane 2, 1802; lane 3, HSV-1 strain 17; lane 4, 
RUL47A2; lane 5, vUL49ep; lane 6, vUL49del268-301; lane 7, vUL49dell20-192; 
lane 8, vUL49del 120-301 and lane 9, vU L49dell-192. The UL49-deletion 
polypeptides are indicated ( ^ - ) .
plasmid
amino acids 
encoded
oligos
inserted
predicted size of 
VP22t protein
pUL49ep 
pUL49del268-301 
pUL49dell20-192 
pUL49del 120-301 
pUL49del 1-192
1-301 ^  
1-267 
1-119+193-301 
1-119 
193-301
d + 2 )
(3+4)
(3+4)
(3+4)
33485Da
29332Da
26053Da
13753Da
13243Da
Table 10. Details of the plasmid constructs containing the UL49 deletions. The amino acids 
from the UL49 ORF that are encoded are indicated, as are the oligonucleotides inserted into 
the UL49 sequence during the construction of these mutants. The predicted sizes of each of 
the epitope-tagged VP22 deletion mutants are indicated.
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sequence and the UL49 ORF which following digestion resulted in the release of two 
fragments of 1.45Kbp and 2.2Kbp (Fig. 51a, lane 5). These were composed of the 1.1 Kbp 
BamHI z fragment linked to a 1.1 Kbp fragment consisting of the UL49 ORF and late poly 
A sequences, and the 0.7Kbp BamHI z fragment linked to the 0.75Kbp IE HCMV 
promoter sequence. Therefore from the sizes of these fragments the UL49del268-301 ORF 
is transcribed in the same direction as Us 10 (Fig. 51b (iii)).
Section 4
Characterisation of the Polypeptides Synthesised by the 
vUL49del Viruses
To analyse the polypeptides synthesised by the vUL49del virus series, 35S- 
methionine labelled infected cell extracts were prepared for each of the vUL49del viruses. 
For comparative purposes 1802, HSV-1 strain 17, vUL49ep, and RUL47A2 (Zhang et al., 
1991, Chapter 9; Results, Part 1, Section 5) infected cell extracts were also prepared. 
Comparison of the profiles of the vUL49del viruses with those of the control samples 
revealed the presence of novel species of approximately 36KDa (in the vUL49del268-301 
sample; Fig. 52, lane 6), 32KDa (in the vUL49dell20-192 sample; Fig. 52, lane 7) and 
19.5KDa (in the vUL49del 120-301 sample; Fig. 52, lane 8). The apparent molecular 
weights of these polypeptides are significantly greater than their predicted sizes (see Table 
10) which indicates that the proteins made by the vUL49del viruses are post-translationally 
processed.
In the extract prepared from vUL49del 1-192 infected cells, no novel abundant 
species was found. A minor polypeptide which appears to be absent in other infected cell 
extracts is indicated in Fig. 52; this species may represent the tagged VP22 protein made by 
vUL49del 1-192. However, it is possible that the tagged protein co-migrates with other low 
molecular weight polypeptides and is therefore obscured.
To verify that the novel species produced by vUL49del viruses corresponded to 
epitope tagged protein, Western blot analysis was performed on the 35S-methionine labelled 
extracts used in Fig. 52. Western blot analysis was also performed on the vUL49del 1-192- 
infected cell extract to determine whether this virus produced an epitope-tagged protein. 
Following separation by electrophoresis and transfer to nitrocellulose, the membrane was 
incubated with monoclonal antibody pp65. As a positive control, and to act as a size marker,
120.
Figure 53. Western blot analysis of vUL49del infected cell extracts. Approximately 
2 x l0 4 cell equivalents were electrophoresed on a 14% polyacrylamide gel and then 
transferred to nitrocellulose membrane. The membrane was probed with pp65 
monoclonal antibody (1:2000 dilution). In lane 1, vUL49ep; lane 2, vUL49de!268- 
301; lane 3, vUL49dell20-192; lane 4,vUL49del 120-301 and lane 5, vUL49del 1-192. 
The sizes of the polypeptides detected are indicated.
Virus titre
1802
del268-301
dell-192
del 120-192
del 120-301
10 20 30 400
time (hours)
F igure  54. Growth characteristics of vUL49del virus series compared with the parent 
virus 1802. 35mm dishes containing approximately 2x10^ BHK cells were infected at 
a moi of 5 pfu per cell and harvested at various time points ranging between 0 and 36 
hours after infection. The total amount of virus present at each time point was 
determined by titration.
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the vUL49ep-infected cell extract was included on the gel. In the vUL49del268-301 and 
vUL49del 120-192-infected cell extracts, the antibody recognised abundant species of 
approximately 36KDa (Fig. 53, lane 2) and 32KDa (Fig. 53, lane 3) respectively,
A polypeptide of approximately i9.5KDa was detected in the vUL49del 120-301 sample 
(Fig. 53, lane 4) which was consistently granular in appearance in Western blot analysis. 
This species was of reduced intensity in comparison to the epitope-tagged forms of protein 
present in the other virus-infected cell extracts (Fig. 53, compare lane 4 with lanes 1, 2 & 3). 
The polypeptides detected by the antibody in the vUL49del268-301, vUL49dell20-192 and 
vUL49del 120-301 samples correspond to the sizes of the novel proteins identified in the 
profiles described in Fig.52. In the vUL49del 1-192 infected cell extract, a band of 
approximately 17KDa was detected (Fig. 53, lane 5). This band was of lower intensity than 
that present in the vUL49del 120-301 sample. From these data, it was concluded that the 
predicted epitope-tagged forms of VP22 were synthesised by the deletion mutant viruses. 
Both the polypeptide profile analysis and the Western blot data indicated that the quantity of 
epitope-tagged protein produced by vUL49del268-301 and vUL49de!120-192 were similar 
to the abundance of VP22t produced by vUL49ep. However, vUL49del 120-301 and 
vUL49del 1-192 made consistently less epitope-tagged protein compared to vUL49ep. The 
apparent decrease in the levels of epitope-tagged protein in these infected cell extracts may
have been due to a reduction in the stability of these proteins.
Section 5
Growth Characteristics of the vUL49del Virus Series
In order to determine whether the growth of each of the vUL49del virus series was 
affected by the insertion of a second epitope-tagged partial copy of UL49, the growth 
characteristics of the vUL49del viruses were compared to those of the parent, 1802. The 
gradients of the slopes during the exponential growth phase (between 6 and 24 hours) for 
each vUL49del virus mutant suggested that the growth rates were reduced compared to 1802 
(Fig. 54). However, for each of the vUL49del virus mutants the titre during the eclipse 
phase did not fall as significantly as did that for 1802. The final yields for each vUL49del 
mutant were similar and were slightly less than that for 1802. The data obtained for these 
viruses were similar to those for vUL49ep (Chapter 8; Results, Part 1, Section 5) and 
suggested that insertion of the mutant epitope-tagged copies of UL49 into virus 1802 did not 
have a significant effect on the growth of the resulting viruses.
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Figure 55. Western blot analysis across gradients containing each of the 
vUL49del virus preparations. Material was collected in 13x700fil aliquots 
from 2cm below the virion band to the top of the tube in 13ml, ficoll 
gradients that were loaded with material from cells infected with each of the 
vUL49ins virus series. Following electrophoresis of 15jil of each sample on 
14% polyacrylamide gels, the polypeptides were transferred to nitroclellulose 
membranes and each was incubated with pp65 monoclonal antibody. The 
bands indicated correspond to the epitope-tagged, mutated froms of VP22. 
In lane * vUL49ep infected cell extracts were included as positive controls 
and size markers.
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Incorporation of Epitope-Tagged UL49 Deletions into 
Virions and Light Particles
Analysis of the polypeptides produced in cells infected with the vUL49del viruses 
had shown that they synthesised tagged forms of partially deleted VP22. To determine 
whether these polypeptides were incorporated into virus particles Western blot analysis was 
performed on fractions collected from across ficoll gradients containing the material released 
from infected cells. This material was prepared from four roller bottles of BHK cells that 
had been infected with each virus at a moi of 1 in 300 and grown at 31 °C for 4 days. 
Following separation by electrophoresis, the ficoll purified virus polypeptides were 
transferred to nitrocellulose membranes. Incubation of each of the membranes with pp65 
monoclonal antibody, revealed bands in vUL49del268-301, vU L49dell20-192 and 
vUL49del 120-301 virus gradients that were distributed throughout the regions where virions 
and light particles migrate (Fig. 55a, b & c), as described for tegument proteins such as 
VP 16 (Chapter 8; Results, Part 2, Section 5). It was concluded therefore that for these 
virus mutants each of the VP22t inserts were assumed to have been incorporated into virions 
and light particles. The intensity of the bands detected across the vUL49del 120-301 gradient 
were reduced in comparison to the gradients containing vUL49del268-301 and 
vUL49dell20-192, and therefore suggested that the level of incorporation of epitope-tagged 
VP22del 120-301 was not as high as for either VP22del268-301 or VP22dell20-192.
Nothing was detected in the gradient containing vUL49del 1-192 cell released material (Fig. 55d) 
and in the absence of experiments to determine the level of sensitivity no conclusion can be made 
as to whether epitope-tagged VP22 minus amino acids 1-192 was incorporated into vUL49dell- 
192 virions and light particles.
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Figure 56. Polypeptide profiles of vUL49del virions and light particles. 
Approximately 3 x l0 9 vUL49del268-301, vUL49dell20-192, vUL49dell20- 
301 and vUL49dell-192 ficoll purified virions and light particles were 
compared to vUL49ep and 1802 virions. Following electrophoresis on a 
12% polyacrylamide gel, the gel was stained with Coomassie Brilliant Blue. 
The samples in each lane are as shown. The major structural polypeptides are 
indicated as are the bands corresponding to VP22del proteins.
VP5C
Polypeptides analysed 
gB, gC, gHc VP13/14C VP16b VP22C VP22t
predicted copy 960 1750 1846 1647 ?
numbers
(average)b
V 895 1307 1691 1647 2872
1802a
L 1828 1730 1647 4349
v 477 1177 992 1647 7745
vUL49epa
L 1462 1076 1647 8668
vUL49del V 596 1698 673 1647 1312 6113
268-301 L 2104 843 1647 2487 6289
vUL49del V 775 1795 1538 1647 2515 3787
120-192 L 1439 1705 1647 3670 4537
vUL49del v 944 2342 1531 1647 2987
1-192
L 1983 2195 1647 4167
vUL49del
120-301 V 1180 1534 1414 1647 3755
L 1305 1808 1647 2748
Table 11. The copy numbers of VP5, gB(gC, gH), VP13/14, VP22 and 
where possible VP22t were estimated following the excision of these bands 
from the Coomassie Brilliant blue stained gel shown in Fig. 56. The protein 
concentration was estimated following the elution of the Coomassie Brilliant 
blue stain in each band in 25% piperidine solution followed by 
spectrophotom etric analysis at 605nm. The copy number for each 
polypeptide was calculated assuming that the copy number of VP 16 remains 
constant in each virus..
a vUL49ep and 1802 virus particles corresponding to preparation 1 in 
Chapter 9; Results, Table 6.
b average number of copies of major structural species was taken from 
Zhang & McKnight (1993)
c number of major structural species was calculated relative to the estimated 
copy number of VP 16
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Section 7
Polypeptide Profiles of vUL49del Virus Series Virions and 
Light Particles
To further characterise the virus particles made by the vUL49del virus mutants, the 
polypeptide profiles of their virions and light particles were compared to those present in 
vUL49ep and 1802 virions (Fig. 56). Novel species of 36KDa and 32KDa were found in 
the vUL49de!268-301 and vUL49de!120-192 samples; these correspond in size to the 
tagged VP22 proteins made by these viruses. The 36KDa protein in vUL49del268-301 
virus particles was the most abundant species incorporated and appeared to be present in 
similar amounts to the VP22t protein in vUL49ep particles. By contrast, there was a marked 
reduction in abundance of the tagged protein in vUL49dell20-192 particles, however the 
protein did remain clearly visible on stained gels. The polypeptide profiles of vUL49dell- 
192 and vUL49del 120-301 particles were indistinguishable from those of 1802.
The relative abundances of the major proteins in the samples in Fig. 56 were 
examined by excising bands from the gel and measuring the amount of stain that could be 
eluted from each band (Table 11). This revealed that the levels of untagged full-length VP22 
were reduced by approximately 50% in vUL49del268-301 virus particles as compared to 
those of 1802. The amount of tagged protein as compared to full-length VP22 in these 
particles was 4.5-fold greater in virions and 2.5-fold greater in light particles. Interestingly, 
combining the estimated copy numbers of tagged and untagged proteins indicates that the 
total amount of VP22 incorporated into vUL49del268-301 particles is very similar to that for 
vUL49ep particles (Table 11). In vUL49dell20-192 particles, the amount of tagged protein 
found was reduced by about 40% as compared to the tagged protein in vUL49del268-301 
virus particles. This was mirrored by an approximately equivalent rise in the abundance of 
untagged VP22 such that vUL49dell20-192 particles contained similar levels of VP22 to 
1802 virus particles. Combining the copy numbers of tagged and untagged VP22 for 
vUL49dell20-192 suggested that the amount of protein incorporated in particles made by 
this mutant were slightly reduced as compared to vUL49ep and vUL49de!268-301 but 
markedly greater than in 1802. For both vUL49del 1-192 and vUL49del 120-301 virus 
particles the abundance of untagged VP22 protein was similar to that found in 1802 virions 
and light particles. In addition to the increase in VP22 abundance, analysis of vUL49ep 
virus particles had shown a marked decrease in the abundance of VP 13/14 (Chapter 8;
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Figure 57. The relative efficiency of epitope-tagged VP22 to enter vUL49del 120-301 
and vUL49del 1-192 virus particles was estimated by Western blot analysis. Following 
Bradford assay of the purified stock preparations of vUL49ep, vUL49del 120-301 and 
vUL49del 1-192 virions and light particles, approximately 12jig (+/-4.3jig) of viral 
protein was diluted in a total volume of 400ml of TBS + 0.1% NP40, and 3-fold dilutions 
of these samples were loaded onto nitrocellulose membrane using a slot-blot apparatus. 
The amount of protein in each slot is shown. The membrane was probed with pp65 
monoclonal antibody.
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Results, Part 1, Section 8) Comparison of the relative amounts of VP 13/14 in 
vUL49del268-301 had reduced quantities of these proteins which were similar to the 
estimates for vUL49ep, while particles made by the other 3 mutants contained quantities 
similar to those for 1802.
For vUL49del 120-301, Western blot analysis had suggested that the tegument 
protein was incorporated into virus particles (Fig. 55c) but was not detected in the 
Coomassie Brilliant blue stained gels. In addition, there was no evidence that the tagged 
protein made by vUL49del 1-192 did incorporate (Fig. 55d). To try to provide some 
estimate of the relative efficiency of the tagged proteins produced by these viruses to enter 
virus particles, 3-fold dilutions of virus particles were blotted onto nitrocellulose membranes 
and probed with pp65 monoclonal antibody. This showed that VP22t could be detected in 
0.02|ig of vUL49ep virions and light particles while epitope-tagged VP22 in vUL49dell20- 
301 virions and light particles was detected in 0.18 fig of viral protein (Fig. 57), suggesting a 
reduction of 9-fold in the level of incorporation of these proteins in comparison to vUL49ep. 
The faint detection of epitope-tagged protein in 4.8 |ig of vUL49del 1-192 virions and light 
particles (Fig. 57) may have been a result of the detection of contaminating cellular material 
migrating throught the gradient, or alternatively it could be concluded that vUL49del 1-192 
virus particles contained minimal amounts of VP22dell-192.
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plasmid
transfected
location of fluorescence
staining patternnucleus cytoplasm
pUL49ep ++ + nuclear, perinuclear & 
network
pUL49ins60 ++ + nuclear, perinuclear & 
network
pUL49insl59 ++ + nuclear, perinuclear & 
network
pUL49insl94 - +++ network & diffuse
pUL49ins267 + ++ nuclear, perinuclear & ; 
network
pUL49de!268-301 - ++++ network
pUL49del 120-192 - +++ aggregates
pUL49del 120-301 - +++ diffuse
pUL49del 1-192 - +++ diffuse
Table 12. Summary of results obtained following the tranfection of plasmid DNA 
into BHK cells and staining with pp65 monoclonal antibody.
0% of cells exhibited this patten of fluorescence 
+ 15% of cells exhibited this patten of fluorescence
++ 35% of cells exhibited this patten of fluorescence
+++ 55% of cells exhibited this patten of fluorescence
++++ 70% of cells exhibited this patten of fluorescence
Examples of staining patterns are illustrated i) edge of nucleus: Fig. 58a)
ii) network: Fig. 58b)
iii) aggregates: Fig. 60
iv) diffuse: Fig. 60 c) & d)
a)
b)
Figure 58. Immunofluorescent staining of pUL49ep transfected BHK cells using 
pp65 monoclonal antibody. BHK cells were transfected with 0.5 fig of plasmid DNA 
and were incubated at 37°C for 18 hours. Cells were stained with a 1:300 dilution of 
pp65 monoclonal antibody followed by a 1:100 dilution of FITC conjugated goat anti­
mouse antibody to detect the epitope tag sequence, a) Nuclear fluorescence , b) 
perinuclear fluorescence , c) cytoplasmic network, and the presence of VP22 in 
adjacent cells.

Figure 59. Immunofluorescent staining of pUL49insl94 transfected BHK cells using 
pp65 monoclonal antibody. BHK cells were transfected with 0.5 jig of plasmid DNA 
and were incubated at 37 °C for 18 hours. Cells were stained with a 1:300 dilution of 
pp65 monoclonal antibody followed by a 1:100 dilution of FITC conjugated goat anti­
mouse antibody to detect the epitope tag sequence. The filamentous cytoplasmic 
network is evident in the large cell on the right hand side of the photograph and a 
diffuse cytpolasmic flourescence is shown in the cell on the left.
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Part 3
Intracellular Location of the Epitope-Tagged
VP22 Mutants
To further characterise the epitope-tagged UL49 insertion and deletion mutants, the 
intracellular distribution of each of the epitope-tagged VP22 proteins was investigated by 
indirect immunofluorescence. Coverslips with sub-confluent BHK cells were infected at a 
moi of 0.1 pfu per cell with each of the vUL49ins and vUL49del virus mutants, and 
following incubation at 31°C for 3, 6, 9, 12 and 15 hours the coverslips were harvested and 
processed as described in Chapter 6; Methods, Section 4.6. Repeated attempts failed to 
produce intracellular patterns of fluorescence following virus infection. It was therefore 
decided to investigate the intracellular location of the epitope-tagged VP22 proteins following 
plasmid transfection. BHK cells grown on 13mm coverslips were transfected with plasmid 
DNA ( Chapter 6; Methods, Section 1.9) and after overnight incubation (18 hours) the 
coverslips were harvested and processed. The plasmids transfected into BHK cells were 
pUL49ep, the pUL49ins plasmid series and the pUL49del plasmid series. The results are 
summarised in Table 12.
Full length epitope-tagged VP22 synthesised in cells transfected with pUL49ep 
typically exhibited a nuclear localisation (Fig. 58a), however two distinct patterns of 
cytoplasmic fluorescence were also seen. These were a perinuclear pattern of fluorescence 
(Fig. 58b) and a distinct network pattern that had the appearance of a cytoskeletal architecture 
(Fig. 58c). In addition, a speckled pattern of fluorescence that was also detected in adjacent 
cells was also evident. This pattern of fluorescence suggested that VP22 may move between 
cells, however this property of VP22 was not further studied. The intracellular patterns of 
fluorescence for the UL49 insertion mutants synthesised in cells transfected with 
pUL49ins60, pUL49insl59 and pUL49ins268 were the same as those for full length VP22 
(data not shown).
In contrast to pUL49ep, pUL49insl94 produced exclusively cytoplasmic patterns of 
fluorescence. 70% of the fluorescing cells examined exhibited a network pattern similar to 
that seen following transfection of pUL49ep, while the remainder of the cells had a diffuse 
cytoplasmic pattern of fluorescence. Fig. 59 shows one cell exhibiting filamentous network
125.
a)
b)
Figure 60. Immunofluorescent staining of a) pUL49del268-301, b) pUL49de!120- 
192, c) pUL49del 1-192, d) pUL49del 120-301 transfected BHK cells using pp65 
monoclonal antibody. BHK cells were transfected with 0.5p,g of plasmid DNA and 
were incubated at 37 °C for 18 hours. To detect the epitope tag sequence cells were 
incubated with a 1:300 dilution of pp65 monoclonal antibody followed by a 1:100 
dilution of FTTC conjugated goat anti-mouse antibody.
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structure and another with a diffuse cytoplasmic fluorescence. The epitope-tagged versions 
of VP22 produced in cells transfected with each of the pUL49del plasmids all had 
exclusively cytoplasmic patterns of fluorescence. Interestingly, cells transfected with 
pUL49de!268-301 only formed cytoplasmic filamentous network structures (Fig. 60a). 
pUL49dell20-192 only formed cytoplasmic aggregates that were distinct from the network 
structures (Fig. 60b). The plasmids containing the large N- and C-terminal UL49 deletions 
pUL49del 1-192 and pUL49del 120-301, gave only diffuse cytoplasmic patterns of 
fluorescence (Fig. 60c & 60d).
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Figure 61. Polypeptides were selected from EHV-1, EHV-2, BHV, VZV 
and MDV that had significant levels of homology with HSV-1 VP22. From 
the sequence alignment, conservation of four out of the six residues was 
considered to be a significantly high level of homology, and the region was 
classified as being highly conserved. The highly conserved regions are 
boxed.
1 50
Ehvl MSDTWRRRRS GCNDANATEE LVYSTVRSDH RQRRPSRGTF VMRENDLYDR
Ehv4 . . . MLTPQRS SY TLQ FVTKIGKDDL L .............AEA LLCEKTNFTI
Bhvl ...........................................................
H svl ................................................................MTSRR SVKSGPREVP RDEYEDLYYT
Vzv ............................................................................................................................. ...
MDV .................................................................
51
Ehvl
Ehv4
Bhvl
Hsvl
Vzv
MDV
CSVSKENDLY ESASPNDDKV YTRRGMSTAA HYRDSEHIYE TCICJDEFYDA
F£VYLGRMIC MTVHAVTMTK FTPDKAERAA HYNPQEHIYE TCI
.......................................................................................... AAVQP AAF
F £ SGMASPDS PPDTSRRGAL QTRSRQRGEV RFVQYDESDY ALV
A £ SDGDRLCR SNAVRRKTTP SYSGQYRTAR RSVWGPPDD SDI
100
CDEFYDA 
.CRDRAAA 
CfGSSSED 
LGYITT 
. . . MGD
Ehvl
Ehv4
Bhvl
Hsvl
Vzv
MDV
101
CEYSLIGGGK 
CEYSLVGGGK 
AGTTVAAPA. 
DEHPEVPRTR 
VGADSPSPVY 
SERRKSERRR
LSTSNGRC
LSTSHGRI
. . AAPARF
RPVSGAVI
ADLYFEH
SLGYPSAY
c
£ G
T
ED
PAKAQPE
PTKTTPH
SSRASSF
PGPARAE
TPRVHQ
VS I  PARE)
FIND
ERG 
KS 
EjPR 
ijpP 
S
ST
A AAAPP. . . .
P. GVTPP___
AAADPP.. . .  
P. GSGGA. . . .  
£GSEDDFEDI 
FTQRNLNQDD
150
PRVPT..........
QRVPA..........
. . . VL..........
GRTPTTAPRA
DEWAAFREA
LSKHGPFTDH
E h v l
Ehv4
B h v l
H s v l
V zv
MDV
151
RPP
R R A
PRTQR
RLRHELVEDA
P T Q R H R S A KA
VA
V R A  
TRA  
RlPAfTRS
TK A
RA
A EC'
R A
AATSTTPR..................QQDCA
AAPSATPT..................QPDCV
SSGGAGAV.................AVG. P
PAAPAAETTR GRKSAQPESA AlLPDtA 
VYENPLSVEK PSRSFTKNAA VKPRLElE] 
VSEDVSSTTR G.............GFT NKPRTF
QR|
HR
R
J
200
EGVN SIRS 
EGVN SIRS 
EGAN AVAS 
STA PTRS 
SPR RAPP 
KGVR AVQS
KTPAQG 
SAGAIA
E h v l
Ehv4
B h v l
H s v l
V zv
MDV
LAF£ PRTE
LAF£
MARE LHF£
SGRE PRTA
FAF£
K S Q m  
RTEW^G 
EWIG 
iAE W I P
t^s£w:g 
SSIw? s
TH
TH
E
F VI
E
FI  Vi
FNFFVF
FNFFVF
YNFTIK?
AG
P£ YNF]
P.
FNFFVF 
FVF 
FNCFMF
IF
C P
C P
C
C A
VER"\ A  
\ A V  
EAV?
>av: r:
E AV F R' 
GAV?
VA? A 
RRVAA A 
LVA? E 
LAAM 
,VA?M 
TVACY
HASEAA
HASEAA
LW 
LW
YAROAAASVW
HA
*: AA
QA2FAA
250 
SA 
SA
vc
LA
LW
EAiAW
LA
E h v l
Ehv4
B h v l
H s v l
V zv
MDV
251 
£
SF
FQE
PE
P E F T N E D
PE
E M S R E R
PE
TNED
SNER
TDED
P E F  NNA
F T N E E
301
GYAAAGPNGY 
GAAAVAPIGY 
RPAARGSTSG 
QDVDAATAT. 
NRRTGDLQGG 
NENVKSRSER
LDF
LDF
LD
LNE
LDF
LDA
F
F
■Ffci
I
I
G I T  
TG AV 
SF AV
I RI
I RI
I RI
I RV
I RI
I RI
I 
I 
L 
TV 
TVH 
T
VC EG 
VC EG 
VCEG 
CEG 
EG 
IQEG
A
DRRPRTASRR FSLRCRE EAD
DRRPRLASRR FSIRCRE EAD
G..........ESRL FGERARE
. . RGRSAASR ETERPRA EAR
MGNEPMYAQV FRPRSRTETQ
TTRSERTRRG GEIEIR£ EDP
p f l  y.
EVAS 
EM AFJA1
E AAZ
QRF
Q
G
AFD
AF
A A R
EAE
ST. . . 
T. . . 
I .  . . 
EL. . . 
EADLG 
TCARR
300
. . . . MESTPD 
. . . . MERSPD 
. . . . LAARAQ 
. . . .  VNPDW 
EGASVSRRGH 
LLEESGLSQG
350
 GSHRTHNPRT PATSRRHHSS
351 361
E h v l ................................
Ehv4 ................................
B h v l ................................
H sv l ................................
Vzv R.........................
MDV ARGYRSSDSE *
ins60
ins 159
ins 194
ins267
a-helix 3a-helix 1 a-helix 2
Figure 62. Diagramatic representation of the predicted secondary structure of 
VP22. The three predicted a-helices are indicated, as are the positions of the 
oligonucleotide insertions.
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Discussion
This chapter describes the construction and characterisation of a series of HSV-1 
recombinant viruses that contained mutated versions of epitope-tagged VP22. It was hoped 
that these inserted oligonucleotides would affect the ability of VP22 to incorporate into the 
tegument which would enable the identification of regions within the protein coding 
sequence important for the incorporation of the protein into the tegument. In the following 
discussion, the effects of these alterations to the VP22 protein will be discussed in the 
context of the predicted secondary structure of VP22. The structure of VP22 was predicted 
using Homology Derived Secondary Structure of Proteins (Version 1.0 1991) which derives 
the secondary structure of proteins by a system of neural networks with an accuracy of (up 
to) 70%. The input is a multiple sequence alignment, also completed by the program (Rost 
& Sander, 1993a, 1993b; Rost & Sander, 1994). The polypeptides selected by the program 
that had significant levels of homology with HSV-1 VP22 were sequences from BHV-1, 
EHV-1, EHV-4, VZV and MDV. Examination of the predicted secondary structure of 
VP22 (Fig. 62) and the sequence alignment data (Fig. 61), show that from residues 1-200 
VP22 is predicted to consist of a random coil structure, with little conservation between 
other polypeptides selected for the sequence alignment. From residues 198 to 258, there 
are three predicted a-helical structures (Fig. 62), and this region is also highly conserved 
(Fig. 61). The largest of these a-helices, from residues 201-220, is almost entirely 
composed of hydrophobic residues, which might suggest that it may be inserted into a 
membrane, or that it forms an interface in a protein/protein interaction (Fig. 63a). Following 
an eight residue sequence with no structure, a second a-helix composed of eight residues is 
predicted. This helix is amphipathic, with polar residues located on one side of the helix and 
hydrophobic residues on the other (Fig. 63b). A short region bridges the gap between this 
second a-helix and a third. The third helix is eleven residues in length and is polar at the N- 
terminal end, and hydrophobic at the C-terminal end (Fig. 63c). Finally, the C-terminal 40 
residues have lower homology and no predicted secondary stmcture.
The characteristics of mutant viruses, vUL49ins60, vUL49insl59 and vUL49ins267 
were essentially indistinguishable from vUL49ep. They each synthesised approximately 5- 
fold higher levels of VP22 than wild type virus in infected cells, and the elevated levels of 
expression of VP22 resulted in an approximately 3-fold increase in the amount of VP22 
present in virions and light particles. These insertions were all located in regions of no 
predicted secondary structure, as shown in Fig. 62, and the results suggested that disruption 
of these sites did not affect the ability of the epitope-tagged proteins to incorporate into virus
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residues are plotted every 100° consecutively around the wheel.
The following code is used: ( ^ )  amino acids with a
hydrophobic side chain
amino acids with polar or charged 
side chains
Glycine residue
a-helix 2
D - E - D - L - N - E - L - L - G - I
a-helix 3
K - N - L - L - Q - R - A - N - E - L - V
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particles. In addition, the polypeptide profile of vUL49del268-301 showed that deletion of 
the C-terminal 34 amino acids of VP22 also had no discernible effect on the ability of the 
epitope-tagged protein to be incorporated into virus particles. Similar to the three vUL49ins 
viruses described above, the region of VP22 deleted during the construction of 
vUL49del268-301 contained no predicted secondary structure and low levels of homology.
The epitope-tagged UL49 deletion present in vUL49dell20-192 appears to be 
synthesised in infected cells to equivalent levels as the epitope-tagged VP22 protein in 
vUL49ep however, the virion and light particle polypeptide profiles of vUL49dell20-192, 
and the quantitation results, suggest that there is a reduction of approximately 4-fold in the 
level of incorporation of this protein in virus particles. The region deleted contains no 
predicted secondary structure (Fig. 62), but is in close proximity to the highly conserved 
large hydrophobic a-helix. The majority of residues within the region of no predicted 
secondary structure between positions 192-200 are capable of being components of a -  
helices, as they are each present within the a-helix between residues 200-220; therefore the 
start of the large hydrophobic a-helix may be closer to residue 192 than predicted by the 
program and this deletion may result in the removal of part of the a-helix. In addition, the 
deletion also brings the proline residue from position 119 into close proximity of the 
predicted start of this a-helix, which may provide some steric hindrance to the a-helical 
conformation. Proline is known to fit well into the first turn of an a-helix but anywhere 
further on it usually produces a significant bend in the helix thereby destabilising the 
structure. Residues 177-189, of no predicted secondary structure, are also highly conserved 
which may imply that there is a functional requirement for this length of the random coil 
structure before the start of the a-helix. Each of these explanations for the significant 
reduction in the ability of VP22dell20-192 to be incorporated into the tegument of virus 
particles suggest that the highly conserved region between residues 119-192 is important for 
the efficient incorporation of VP22 into virus particles.
The total amount of VP22 incorporated into vUL49dell20-192 virus particles was 
reduced in comparison to each of the vUL49ins viruses but was still elevated in comparison 
to virus 1802. Therefore the deletion only partially removed or partially disrupted the 
sequences required for incorporation of VP22 into the tegument. In an attempt to determine 
whether the residual VP22 incorporation sequences resided in the N- or C-terminal portions 
of VP22dell20-192, vUL49del 1-192 and vUL49del 120-301 were constructed. These 
mutant viruses were derived from the plasmid that was used to construct vUL49del 120-192, 
and contained only the N-terminal and C-terminal regions of VP22 that flanked residues 
120-192. Characterisation of these viruses showed that only VP22del 120-301 was detected
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in virions and light particles, and that the level of incorporation was reduced by 
approximately 9-fold in comparison to the amount of epitope-tagged VP22 present in 
vUL49ep virus particles. These results suggested that the region of VP22 with little 
homology and no predicted secondary structure contains sequences that enable limited 
incorporation of VP22 into the tegument, and that the highly conserved a-helical region of 
VP22 by itself is apparently not capable of directing VP22 to the tegument. These results 
may have been a result of the reduced levels of VP22del 120-301 and VP22del 1-192 
synthesised in infected cells in comparison to each of the other vUL49ins and vUL49del 
viruses. The small amounts of these proteins in infected cells may not have permitted the 
efficient recognition of sequences that enabled their incorporation into the tegument, 
therefore it cannot be concluded that the inability to detect VP22dell-192 within virus 
particles was a result of the inability of this protein to be incorporated. The reduced levels of 
synthesis of VP22del 1-192 may have been due to the introduction of a foreign ATG 
initiation codon, the context of which may not have resulted in the efficient expression of the 
gene within the infected cell. However, UL49del 120-301 contains the original VP22 
initiation codon and the reduced levels of expression of VP22del 120-301 are likely to be a 
result of reduced protein stability.
It is interesting that the only insertion (ins 194) to have altered the characteristics of 
epitope-tagged VP22 lies four amino acids upstream from the predicted a-helical region. 
Insertion at position 194 appeared to have a noticeable effect on the ability of VP22insl94 to 
be incorporated into virus particles, however the amount of epitope-tagged VP22 in 
vUL49insl94 virions remained greater than the amount of untagged VP22. In addition, 
immunofluorescent staining revealed that this mutant exhibited an exclusively cytoplasmic 
pattern of fluorescence, the distribution of which appeared similar to the subset of pUL49ep 
transfected cells exhibiting cytoplasmic fluorescence. Investigation of the residues 
introduced by the oligonucleotide insertion at position 194 show that a proline and a glycine 
residue are introduced in close proximity to the predicted first turn of the a-helix. Different 
side chains have been found to have weak but definite preferences either for or against being 
in a-helices, and both proline and glycine are very poor a-helix formers. Thus insertion of 
the oligonucleotide at this position may have disrupted the conformation of the a-helix. 
These results further support the data suggesting that the highly conserved region between 
residues 120-192 is important for the incorporation of VP22 into the tegument.
There is some evidence to show that tegument proteins are able to interact with each 
other (Smibert et al., 1994; Elliot et al., 1995, Lam et a l., submitted) and these interactions 
may influence the incorporation of proteins into the tegument. Several pieces of evidence
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suggest that VP22 is able to interact with itself. These include data from Western blot 
analysis, experiments with recombinant baculovirus and biochemical data. Firstly, Western 
blot analysis of vUL49ep virions and light particles using the pp65 antibody specific for the 
epitope-tag sequence, recognised species that were estimated to be double and three times the 
molecular weight of VP22. These were thought to be dimers and trimers of VP22, and 
because they were detected following electrophoresis on denaturing polyacrylamide gels, the 
interaction was resistant to fairly harsh denaturation (1% SDS and boiling). Far Western 
blot analysis of VP22 has since confirmed these initial results (B. Verbeek, personal 
communication). Secondly, insect cells infected with a baculovirus recombinant which 
expresses high levels of VP22 were shown to contain large irregular aggregates of the 
protein (J. McLauchlan, personal communication). Thirdly, gel filtration analysis of in vitro 
transcribed/translated VP22 showed that VP22 migrated only as a dimer and a trimer (P 
O'Hare, personal communication). In addition, increasing the salt concentration, in order to 
minimise non-specific aggregation of VP22, resulted in the migration of the protein as a 
tetramer (P O'Hare, personal communication). Fourthly, a bacterially expressed portion of 
VP22 (amino acids 159-267) appears to exist in dimer and higher molecular weight forms; 
gel filtration and preliminary NMR analysis has failed to detect monomeric protein (G. 
Hope, J. McLauchlan & P. Barlow, personal communication). The ability of VP22 to 
interact with itself is likely to influence the incorporation of the mutated epitope-tagged 
forms of VP22 into the tegument.
There is compelling evidence that VP22 also interacts with the major transcriptional 
activator, VP16 (Elliott et al., 1995). A strong interaction between VP16 and VP22 was 
first demonstrated by immunoprecipitation of both proteins from infected cells using a 
VP16-specific antibody. Transfection of VP22 and VP16 expressing plasmids into Vero 
cells resulted in the relocalisation of both proteins into novel 'doughnut' structures termed 
tegument bodies situated in the cytoplasm (Elliot et a l., 1995). The functional significance 
for this interaction is not yet known. A paper by Hensel et al. (1995) described similar 
large aggregated structures early in infection in the nucleus and latterly in the cytoplasm of 
cells infected with HCMV. These structures were identified as being composed of the 
pp l50  tegument protein and it was suggested that the acquisition of the tegument protein 
pp l50  seems to take place in these special nuclear subcompartments where nucleocapsids 
assemble. These structures are distinct from dense bodies, the formation of which is a 
characteristic feature of CMV replication (Severi et al., 1992). Dense bodies contain an 
abundance of the major tegument protein pp65, accounting for approximately 95% of their 
protein mass (Irmiere & Gibson, 1983). The remaining 5% consists of several host cell
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Mutant Location Pattern +VP16
pUL49ep most nuclear 
some cyto.
edge of nucleus 
network
0
pUL49del268-301 cytoplasmic network & diffuse 0
pUL49 del 120-192
i
cytoplasmic aggregates VP 16 also 
aggregates
pUL49del 120-301 cytoplasmic diffuse -
pUL49del 1-192 cytoplasmic diffuse -
pUL49ins60 as pUL49ep as pUL49ep 0
pUL49insl59 as pUL49ep as pUL49ep 0
PU L49insl94 cytoplasmic network & diffuse together 
form aggregates
pUL49ins267 as pUL49ep as pUL49ep 0
Table 13. Results obtained by G. Elliot following the cotransfection of a VP 16 expressing 
plasmid with pUL49ep, and each of the pUL49ins and pUL49del mutant plasmids.
Location; intracellular location of the fluorescence 
Pattern; intracellular pattern of fluorescence
+VP16; cotransfection of the mutant plasmid with a VP 16 expressing plasmid.
(O; indicates the formation of tegument bodies).
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proteins as well as DNA and RNA. The functional significance of dense bodies during the 
replicative cycle of CMV is not clear. They may be directly involved in virus 
morphogenesis , however, due to their composition, it has been suggested that they represent 
the site where surplus cellular, viral or virus induced molecules are stored before being 
eliminated from the cell (Severi et al., 1992).
Collaborative studies with G. Elliot were performed to further investigate the 
interaction between VP22 and VP 16. Cotransfection of cells using a VP 16 expressing 
plasmid and each of the pUL49ins and pUL49del mutant plasmids yielded the results 
summarised in Table 13. The VP22ins mutants encoded by pUL49ins60, pUL49insl59 
and pUL49ins267 when expressed in cells with VP 16 were all able to redistribute VP 16 into 
large aggregates at the edge of the nucleus which were indistinguishable from the tegument 
bodies formed by interaction of VP16 with full length VP22 (Table. 13). Therefore, none of 
these three insertions altered the phenotype from that exhibited by wild type VP22 
synthesised in cells transfected with pUL49ep. Both VP22insl94 and VP22dell20-192 
were unable to redistribute VP 16 into large aggregates, but these proteins were able to co- 
localise with VP 16, indicating that an interaction between VP 16 and each of these proteins 
still occured. These results imply that the ability of VP22 and VP 16 to interact is not 
sufficient for tegument body formation and that other interactions play a part. Assuming 
that no cellular proteins are involved in tegument formation, and from the results that 
suggest that VP22 can oligomerise, it is reasonable to conclude that the inablity of these 
mutants to form tegument bodies is caused by a disruption in the ability of VP22 to interact 
with itself. Such a disruption may account for the reduced levels of incorporation of 
VP22del 121-192. In the case of VP22insl94, the reduced levels of incorporation are less 
marked but there is a noticeable increase in the amount of untagged endogenous VP22 in 
vims particles; which would suggest that insertion at this position had an effect on its ability 
to compete with the endogenous form of VP22 for incorporation.
VP22del 120-301 was incorporated into vims particles, albeit to a limited extent, but 
cotransfection of the plasmid expressing this protein with a VP 16 expressing plasmid 
showed that these proteins were unable to interact. These results suggest that the 
incorporation of VP22 into the tegument in this experimental system is not dependant on an 
interaction between VP 16 and VP22. This epitope-tagged VP22 deletion mutant does not 
contain the sequences 159-267 which allow dimerisation, however it is possible that other 
sequences exist within residues 1-119 that enable VP22 to form dimers which would enable 
VP22del 120-301 to enter the tegument following an interaction with the endogenous VP22 
protein, which is in turn able to interact with VP 16. Otherwise VP22del 120-301 may be
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entering the tegument following an interaction with an as yet unspecified tegument protein 
which may or may not require an association with VP 16 for entry into the tegument. 
Alternatively, within VP22del 120-301 there may be a tegumentation signal sequence which 
enables the incorporation of this protein without the requirement for any protein/protein 
interactions. It is interesting that VP22del 1-192, which contains most of the residues (159- 
267) in the bacterially expressed VP22 protein that does dimerise is not capable of being 
incorporated into the tegument. This would suggest that residues 159-192 contribute to the 
dimerisation of VP22, however further studies are necessary to clarify the precise location of 
these sequences.
The distinctive network patterns of immunofluorescence obtained following the 
transfection of plasmids pUL49ep, each of the pUL49ins plasmid series and pUL49del268- 
301 into BHK cells suggest that epitope-tagged VP22 may be interacting with a protein that 
forms, or interacts with a cellular filamentous structure. BHK cells contain micro filaments 
composed of actin and tubulin, and intermediate filaments; the majority of which are 
composed of vimentin (Franke et al., 1979), however the major intermediate protein of 
muscle cells, desmin is also present (Frank et a l., 1982). Microfilaments are involved in the 
formation of the cellular cytoskeleton that imparts structure and elasticity to eukaryotic cells, 
while intermediate filaments appear to be responsible for anchoring the nucleus. 
Intermediate filaments may have other fuctions however these are not known. The 
possibility that VP22 is interacting with either tubulin or vimentin are thought to be unlikely 
because the patterns of flourescence exhibited by these proteins are different from the 
networks observed following transfection of the pUL49ep plasmids (G. Elliot & J. 
M cLauchlan personal communications). Alternatively epitope-tagged VP22 may be 
interacting with an antigenically related group of polypeptides, IFAP's (intermediate 
filament-associated proteins) ranging from 70 to 280KDa, which are closely associated with 
intermediate filaments (Yang et al., 1992), and appear to regulate the arrangements of 
intermediate fillaments within cells (Yang et al., 1990). The in situ localisation of some of 
these different molecular weight forms of IFAP may more closely reflect the network 
patters of fluorescence observed following transfection of the pUL49ep expressing plasmids 
into cells. The functional significance of the interaction between VP22 and these cellular 
proteins, and whether these structures are seen during normal infection of cells is not known, 
but knowledge of the nature of the cellular protein involved in this interaction may help to 
elucidate a function for VP22.
VP22 is extensively post-translationally processed. It is highly phosphorylated, 
ADP-ribosylated and has also been proposed to be nucleotidylylated. The functions of these
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modifications within VP22 are not known, but are frequently seen in proteins that regulate 
biochemical processes. Within VP22, residues 115 to 126 are proposed to be a 
nucleotidylylation site (Blaho et al., 1994). These residues are partially removed in 
VP22dell20-192, present in vUL49del 120-301 virus particles. The nucleotidylylation of 
proteins is rare and has not been extensively studied, however the functions fall into three 
categories: i) proteins where nucleotidylylation represents an intermediatory covalent 
attachment of a nucleotide to a protein during the course of an enzymatic reaction, eg. 
guanyltransferases involved in the capping of mRNA (Venkatesan & Moss, 1982), and 
DNA ligases (Weiss & Richardson, 1967). ii) Nucleotides covalently attached to viral 
genomes via stable nucleotidyl-protein linkages that function in viral nucleic acid synthesis, 
eg. adenovirus terminal protein (Desiderio & Kelley, 1981), and iii) covalent attachment of 
a nucleotide to the protein as a regulatory mechanism, eg. glutamine synthetase of E.coli 
(Shapiro et al., 1967), where the activity of the enzyme is determined by the adenylated state 
(Stadtman, 1990). The function of VP22 may be regulatory, indeed due to its association 
with VP 16, it may act to regulate the transactivating functions of VP 16. It has also been 
shown to bind to DNA, and although it is not essential for DNA replication, it may be 
involved in packaging of DNA or nucleic acid metabolism. Further characterisation of 
VP22dell20-192 in which the nucleotidylylation signal has been disrupted may help to 
elucidate the function of nucleotidylylation within VP22.
In conclusion, these results demonstrate that the incorporation of VP22 into the 
tegument is likely to involve a series of interactions between itself and/or VP 16. It is 
unlikely that these proteins form tegusome like structures as seen with HHV-6 (Roffman et 
a l., 1990), as such invaginations of the nuclear membrane are not seen during HSV-1 
infection. However, the production of light particles during HSV-1 infection, and the fact 
that the integrity of the tegument within light particles is not dependent on the presence of the 
envelope, implies that the tegument is capable of self assembly (Rixon et a l ., 1992). This 
evidence for a self-assembling tegument together with the formation of large aggregates in 
cells coexpressing VP 16 and VP22, provides several possible mechanisms for tegument 
assembly within the cell. VP 16 may function as a nucleation signal for the rest of the 
tegument proteins to build themselves around, such that VP 16 would be the only essential 
protein for the process, with VP22 and the rest of the components able to compensate for 
each other in their relative amounts. For example, it has been demonstrated that neither 
VP11/12 (encoded by UL46) or VP13/14 (encoded by UL47) is essential for virus 
assembly and that virions lacking either of these proteins appear to have increased levels of 
the other (Zhang & McKnight, 1992). Alternatively, the VP16-VP22 interaction together
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with one or more additional minor tegument proteins may form the scaffold of the 
tegument, in which case VP22 would also be essential for assembly. The argument against 
other major tegument proteins being included in a scaffold formation is provided by the 
characterisation of a HSV-1 UL46/UL47 double deletion mutant made by Zhang & 
McKnight, (1992). The polypeptide profile of this mutant virus, showed that VP 16 and 
VP22 were the only major tegument species of this virus mutant, and therefore only minor 
components of the tegument can be proposed to be candidates essential for scaffold 
formation. Recent chemical cross-linking experiments on HSV-1 virions have shown that 
the tegument proteins VP22, VP 16 and VP 13/14 can also associate with the envelope 
glycoprotein gB (Zhu & Courtney, 1994), which may suggest a possible mechanism for a 
signal in the association of the tegument with the envelope during virus assembly. The large 
aggregates of VP 16 and VP22 seen during transfection may represent an extension of the 
interactions which occur during normal tegument assembly, whereby the presence of the 
many other vims proteins within the cell and the interactions therein would affect or limit the 
size of and/or organisation of the complexes formed.
The mutational analysis of VP22, presented in this section, failed to identify a 
minimum region required for the incorporation of VP22 into the HSV-1 tegument, however 
the results presented have enabled the the preliminary identification of regions that are 
important as well as the elimination of regions of VP22 that are not involved in the 
incorporation of the protein into the tegument. With regards to the mechanism by which 
VP22 is incorporated into the tegument the results presented do not exclude the possibility 
that VP22 is incorporated into the tegument via an interaction with other proteins, and it is 
likely that by multimerising with the endogenous form of VP22 some of the mutants 
constructed were escorted into the tegument. The construction of a mutant vims that does 
not contain the endogenous copy of UL49 is therefore essential for the further analysis of the 
incorporation of VP22 into the tegument.
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Conclusions
The initial aim of this project was to devise a manipulatable experimental system that 
would enable the identification of sequences which direct proteins to the tegument of the 
HSV-1 particle. A minor tegument protein, vhs, was fused to a bacterial reporter gene, 
CAT, and the resulting fusion protein was shown to be incorporated into the recombinant 
vVHS-CAT virus particles. This was a significant result, demonstrating for the first time 
that foreign proteins could be incorporated into the tegument of HSV-1 virions and light 
particles. In the second experimental system ( Chapter 8) the tegument protein chosen, 
VP22, was a major component of the tegument, and thus easily detected on Coomassie 
Brilliant blue stained gels. In this case, the tag fused to VP22 consisted of a ten amino acid 
epitope and the expression of the fusion protein was under the control of the the strong EE 
HCMV promoter sequence. Similar to vVHS-CAT, the vUL49ep recombinant virus 
contained the epitope-tagged copy of VP22 in both virions and light particles but there was 
also a dramatic increase in the levels of VP22 in these virus particles. The mutagenesis of 
epitope-tagged UL49, described in Chapter 9, was attempted in order to identify sequences 
which direct VP22 into the tegument of virus particles. This did not identify a minimum 
region required for the incorporation of VP22 into the HSV-1 tegument, however the results 
enabled the elimination of regions of VP22 that are not involved in the incorporation of the 
protein into the tegument. Thus, this investigation has shown that tegument proteins are 
amenable to alteration without loss of ability to incorporate into virus particles. The tagging 
systems developed therefore provide the basis for further work on the sequences which 
direct proteins to the tegument and on their modes of entry.
With regard to the mechanism by which tegument proteins are incorporated into 
virus particles, the results obtained from this study and those of others suggest that proteins 
may be directed into the tegument by interaction with other structural components. Both vhs 
and VP22 have been shown to interact with VP16 (Smibert et al., 1992; Elliot et al., 1995; 
Schmelter et a l., 1996), the only tegument protein to date which is essential for virus 
assembly (Ace et al., 1988; Weinheimer et al., 1992). This implies that, at least for HSV-1, 
VP 16 plays a pivotal role in tegument formation. It is unlikely however that a mechanism 
of assembly based on interactions with VP 16 and its homologues is universal among 
herpesviruses. Firstly, VP 16 homologues are not readily identified by sequence 
comparisons in p- and y-herpesviruses. Secondly, the VZV VP 16 homologue encoded by 
ORFIO, is a tegument protein but is not essential for growth or assembly of the virus
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particle (Cohen & Seidel, 1994). While interactions with VP 16 may play a role during 
assembly, this does not preclude the possibility that other as yet unidentified interactions 
may also be occurring. For example, studies using chemical cross-linking reagents were 
performed by Zhu & Courtney, (1994) in order to determine the relationship between gB on 
the viral envelope and other virion proteins. Four virion structural proteins, likely to be 
tegument proteins were seen to be associated with gB as well as gD and gH, but not with 
gC. One of these four proteins was positively identified as being VP 16 and the others were 
predicted to be V P11/12, VP13/14 and VP22. These interactions may represent an 
extension of the interactions which occur during normal tegument assembly.
Results have shown that VP22 interacts with itself, and since VP22 is the most 
abundant tegument protein this may provide a framework for providing structural integrity 
to the tegument. Since the endogenous copy of UL49 was not deleted in any of the vUL49 
mutant viruses constructed, it is possible that the epitope-tagged copies of VP22 were able to 
incorporate into the tegument following interactions with the unmodified forms of VP22. In 
order to prevent such an interaction it would be necessary to remove the endogenous copy of 
UL49 in each of the vUL49 mutant viruses, and this could further enable the identification of 
regions within VP22 that are critical for its incorporation into the tegument. Thus far, one 
such mutant has been constructed which expresses only the VP22del268-301 polypeptide.
(Y. San & J. McLauchlan, personal communication). This protein is readily detected in virus 
particles further implying that the C-terminal domain, which is not highly conserved, is not 
necessary for incorporation. However, the virus mutant does grow significantly less well 
than the parent construct, suggesting that the C-terminal region influences the function of 
VP22.
In conjunction with the literature available, the results presented in this thesis suggest 
that it is likely that the incorporation of tegument proteins may be mediated through 
interactions between components of virus particles rather than there being a ‘tegumentation 
signal sequence’ common to all tegument proteins. It is also possible however, that 
sequences which direct proteins to a particular cellular compartment also play an important 
role, and specific cellular compartments may serve as sites for the tegumentation of capsids.
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Appendix,
The HSV-1 UL49 sequence.
ATGACCTCTCGCCGCTCCGTCAAGTCGTGTCCGCGGGAAGCGCCGCGCGGGACCCACGAG
1 i i----------------------1----------------------1----------------------1---------------------- 1- go
TACTGGAGAGCGGCGAGGCAGTTCAGCACAGGCGCCCTTCGCGGCGCGCCCTGGGTGCTC
M T S R R S V K S C P R E A P R G T H E
GAGCTGTACTATGGCCCGGTCTCCCCGGCGGACCCAGAGAGTCCGCGCGACGACTTCCGC
6 1 ---------------------+ ----------------- + ---------------------+ ------------------- + --------------------- +  + 120
CTCGACATGATACCGGGCCAGAGGGGCCGCCTGGGTCTCTCAGGCGCGCTGCTGAAGGCG
E L Y Y G P V S P A D P E S P R D D F R
CGCGGCGCTGGCCCGATGCGCGCGCGCCCGAGGGGCGAGGTTCGCTTTCTCCATTATGAC
1 2 1 ---------------------+ ----------------- + ---------------------+ ------------------- + --------------------- + -------------------- + 1 8 0
GCGCCGCGACCGGGCTACGCGCGCGCGGGCTCCCCGCTCCAAGCGAAAGAGGTAATACTG
R G A G P M R A R P R G E V R F L H Y D
GAGGCTGGGTATGCCCTCTACCGGGACTCGTCTTCGGACGACGACGAGTCCCGGGATACC
1 8 1 -------------------- + ----------------- + ---------------------+ ------------------- + --------------------- +  + 2 4 0
CTCCGACCCATACGGGAGATGGCCCTGAGCAGAAGCCTGCTGCTGCTCAGGGCCCTATGG
E A G Y A L Y R D S S S D D D E S R D T
G CG CGACCGCGTCGTTCGGCGTCCGTCGCGGGCTCTCACGGCCCCGGCCCCGCGCGCGCT
2 4 1  ------------------- + -------------------+ ---------------------+ ------------------- + --------------------- +  + 3 0 0
CGCGCTGGCGCAGCAAGCCGCAGGCAGCGCCCGAGAGTGCCGGGGCCGGGGCGCGCGCGA
A R P R R S A S V A G S H G P G P A R A
CCTCCACCCCCCGGGGGCCCCGTGGGCGCCGGCGGGCGCTCGCACGCCCCTCCCGCGCGG
3 0 1  ------------------- + -------------------+ ----------------------+ -------------------+ ---------------------+ --------------------- + 3 6 0
GGAGGTGGGGGGCCCCCGGGGCACCCGCGGCCGCCCGCGAGCGTGCGGGGAGGGCGCGCC
P P P P G G P V G A G G R S H A P P A R
ACCCCCAAAATGACGCGCGGGGCGCCTAAGGCCTCCGCGACCCCGGCGACCGACCCCGCC
3 6 1 -------------------- + ----------------- + ----------------------+ -------------------+ ---------------------+ --------------------- + 4 2 0
TGGGGGTTTTACTGCGCGCCCCGCGGATTCCGGAGGCGCTGGGGCCGCTGGCTGGGGCGG
T P K M T R  G A P K A S A T P A T D P A
CGCGGCAGGCGACCCGCCCAGGCCGACTCCGCCGTGCTCCTAGACGCCCCCGCTCCCACG
4 2 1 ______________ i----------------- 1--------------------------1--------------------1------------------------1---------------------- 1" 4 8 0
GCGCCGTCCGCTGGGCGGGTCCGGCTGAGGCGGCACGAGGATCTGCGGGGGCGAGGGTGC
R G R R P A Q A D S A V L L D A P A P T
GCCTCGGGAAGAACCAAGACACCCGCCCAGGGACTGGCCAAGAAGCTGCACTTCAGCACC
4 g l --------------------+ ----------------- + ----------------------+ -------------------+ ---------------------+ --------------------- + 5 4 0
C G G A G C C C TTC TTGG TTCTGTGGG CGGG TCCCTGA CCGGTTCTTCGA CGTGAA GTCGTGG
a s g r t k t p a q g l a k k l h f s t
GCCCCACCGAGCCCCACGGCGCCGTGGACCCCCCGGGTGGCCGGGTTCAACAAGCGCGTC
541 --------------- +-----------------+---------------+---------------- +----------------+ + 600
CGGGGTGGCTCGGGGTGCCGCGGCACCTGGGGGGCCCACCGGCCCAAGTTGTTCGCGCAG
a p p s p t a p w t p r v a g f n k r v
TTCTGCGCCGCGGTCGGGCGCCTGGCGGCCACGCACGCCCGGCTGGCGGCGGTACAGCTG
601  +---------------- +---------------+---------------- +----------------+--------------- + 660
AAGACGCGGCGCCAGCCCGCGGACCGCCGGTGCGTGCGGGCCGACCGCCGCCATGTCGAC
F C A A V G R L A A T H A R L A A V Q L
TGGGACATGTCGCGGCCGCACACCGACGAAGACCTCAACGAGCTCCTCGACCTCACCACC
661  +---------------- +----------------+----------------+----------------+----------------- + 720
ACCCTGTACAGCGCCGGCGTGTGGCTGCTTCTGGAGTTGCTCGAGGAGCTGGAGTGGTGG
W D M S R P H T D E D L N E L L D L T T
ATTCGCGTGACGGTCTGCGAGGGCAAGAACCTCCTGCAGCGCGCGAACGAGTTGGTGAAT
721 --------------- +---------------- +----------------+----------------+----------------+-----------------+ 780
TAAGCGCACTGCCAGACGCTCCCGTTCTTGGAGGACGTCGCGCGCTTGCTCAACCACTTA
I R V T V C E G K N L L Q R A N E  L V N
CCCGACGCGGCGCAGGACGTCGACGCGACCGCGGCCGCCCGGGGCCGCCCCGCGGGGCGT
781 --------------- +---------------- +----------------+----------------+----------------+----------------- + 840
GGGCTGCGCCGCGTCCTGCAGCTGCGCTGGCGCCGGCGGGCCCCGGCGGGGCGCCCCGCA
P D A A Q D V D A T A A A R G R P A G R
GCCGCCGCGACCGCACGGGCCCCCGCCCGCTCGGCTTCCCGTCCCCGCCGCCCCCTCGAG
841 --------------- +---------------- +----------------+----------------+----------------+-----------------+ 900
CGGCGGCGCTGGCGTGCCCGGGGGCGGGCGAGCCGAAGGGCAGGGGCGGCGGGGGAGCTC
A A A T A R A P A R S A S R P R R P  L E
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